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Properties of Primate Lentiviruses 
The acquired immunodeficiency syndrome (AIDS) was recognised as a new clinical 
entity in 1981, when an unusual clustering of Kaposi's sarcoma and Pncumocystis carinii 
pneumonia was observed in young homosexual males. Epidemiological studies implicated an 
infectious agent transmitted during sexual intercourse, through intravenous drug abuse, by 
blood and blood products, and vertically from mother to child (I), The first isolation from an 
AIDS patient of a retrovirus later designated human immunodeficiency virus type I (HIV -I) 
(Table I) was made in 1983 by Luc Montagnier and Barre-Sinoussi (at the Pasteur Institute 
in Paris) and confirmed by Robert Oallo (at the National Institute of Health in Bethesda, USA) 
immediately thereafter (2). In 1985, simian immunodeficiency viruses (SlV) were isolated 
from captive Asian macaques with a disease closely resembling human AIDS (3), These 
viruses include SlV from rhesus macaques (SIVmac), nemestrina macaques (SIVmne) and 
stump-tailed macaques (SIVstm), A second human immunodeficiency virus (HIV-2) was 
isolated in 1986 from mildly immunocompromised patients in West Africa; although both 
HIV-I and HIV-2 cause AIDS, individuals infected with HIV-2 exhibit a longer clinical 
latency and lower morbidity (4), Additional genetically distinct SIV strains have been isolated 
in Africa from several nonhuman primate species, including African green monkeys (SIVagm), 
sooty mangabeys (SIVsmm), mandrils (SIVmnd) and sykes (SIVsyk), In addition, a close 
relative ofHIV-I, SIVcpz, has been found in chimpanzees, These simian viruses are endemic 
to the respective African monkey species and do not appear to induce disease in their natural 
host (5), Remarkably, certain SIV strains share a high degree of sequence homology with 
several HIV-2 isolates from West Africa (6), whereas HIV-I is more similar to SIVepz (7) 
(Figure I), Although at present the origin ofHIV-1 and HIV-2 remains obscure, phylogenetic 
analyses suggest that both viruses arose from multiple zoonotic transmissions between 
nonhuman primates and humans of lentiviruses originated from a common ancestor (8), 
Classification 
HIV and SIV are members of the lentivirus genus of the Retroviridae family by virtue 
of their morphologic and biochemical characteristics, Mg2+-dependent reverse transcriptase 
activity, genomic RNA organization. and genetic homology. Lentiviruses are not oncogenic; 
rather, they cause persistent infections resulting in a variety of chronic conditions with insidious 
onset and slow progression (Latin len/us: slow), Human lentiviruses are grouped into two types, 
HIV-I and HIV-2, on the basis of serologic and genetic properties (9), Due to the extreme 
plasticity of the HIV genome, a high degree of variability exists among independent isolates. 
The greatest sequence variation, consisting in nucleotide changes, as well as small deletions and 
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Table 1. Classification of retroviruses injeclillg primates 
Subfamily 
Oncovirinae 
HTLV-I 
HTLV-II 
Spumavirinae 
Lentivirinae 
HIV-I 
HIV-2 
SIV 
Disease 
Adult T-cell leukaemia. lymphoma, tropical spastic paraparesis (humans) 
Hairy cell leukaemia (humans) 
Unapparent persistent infection (primates and other animals) 
AIDS. The virus can infect chimpanzees. 
AIDS. Less pathogenic than HIV -I. The virus can infect primates. 
Simian AIDS in Asian monkeys. No disease in natural hosts. 
HTLV: Human T-cell leukaemia virus 
insertions, is displayed by the ellv gene, which encodes the envelope glycoprotein (Env) (10), 
Classification based mostly on env sequences identifies nine genetic subtypes or clades (A 
through I) and a more divergent set of strains (the 0 group) of HIV -I, and five subtypes of 
HIV-2 (A tIuough E) (6, II), Some areas of the world harbor predominantly a single subtype, 
whereas two or more subtypes may be prevalent in other populations, reflecting different 
patterns of virus migration (12), The B subtype of HIV -I is endemic to the developed countries 
of North America and Europe, but is rarely found in those African and Asian countries where 
HIV -I infection is spreading at alarming rates (II ), Up to 25% of the amino acids encoded by 
ellv may vary in HIV-I strains from geographically separated locations (interpatient variation), 
Emergence of ellv variants also occurs in HIV-infected individuals and SlY-infected monkeys 
(intrapatient variation) to produce popUlations of closely related but distinct viral genomes 
designated quasispecies (13), Furthermore, there is evidence that a significant proportion of 
HIV -I strains are the result of recombination events between viruses of distinct SUbtypes (14), 
The high degree of variability displayed by Env is believed to be the product of at 
least two selective pressures: adaptation to infection of different cell types and escape from 
antiviral immune responses (15, 16). Amino acid differences in Env appear to have significant 
implications for certain critical functions such as CD4 binding, cell tropism. fusogenicity and 
cytopathicity (I), Evidence has been provided that while initial HIV-I infection may be limited 
to macrophage-tropic virus, usually incapable of causing syncytia in vitro (non syncytium-
inducing variants). over the course of infection subtly altered viruses emerge showing increased 
tropism for lymphocytes and syncytium-inducing ability (17), Amino acid differences in Env 
underlie many of these progressive changes in virus phenotype and tropism. whose importance 
is underscored by the finding that the appearance ofT-cell tropic variants often coincides with 
heightened virus replication rates and rapidly progressing disease (18), 
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Figure 1. Phylogenetic analysis 
of lentiviruses. Representative 
lentiviruses are compared using 
pol gene sequences. VMV: 
Vjsna~Maedi virus (sheep); 
CAEV: caprine arthritis-
encephalitis virus (goats); 
EIA V: equine infectious 
anaemia virus (horses); DIV: 
bovine inmlunodeficiency virus 
(cows); FIV: feline 
immunodeficiency virus (cats). 
The scale indicates the 
percentage of estimated 
nucleotide substitutions (9). 
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Recently, it has been shown that primary HN·I strains can be dual· tropic, as they 
can infect macrophages much more efficiently than laboratory strains adapted to growth in 
T-cell lines (19). Such dual-tropic strains may represent an intermediate between 
macrophage-tropic viruses, which arc predominant during the early stage of infection, and 
T-cell-tropic viruses, which increase just before accelerated T-cell depletion and 
progression to AIDS. 
MOI1J/IO/Ogy and structure 
HIV -I, HIV -2 and the various SIV strains share a similar morphology and 
composition. Typical virions have an overall spherical shape, are about 110 nm in diameter, 
and consist of a dense, cone-shaped icosahedral core surrounded by a membraneolls lipid 
envelope acquired during budding (Figure 2). The envelope is studded with approximately 
72 spikes, 9-10 11m long, representing tri- or tetramers of glycoprotein complexes. Each 
spike is composed by a surface subunit designated either gp 120 (HIV·I) or gp 130 (HIV·2 
and SlY) that interacts non covalently with a smaller transmembrane subunit designated 
gp41 (1).The two subunits are generated by cleavage of a common precursor, gp160, 
encoded by the env gene. Within the surface subunit, a domain recognises and binds the 
CD4 receptor on host cells. In addition, both subunits contain epitopes targeted by virus 
neutralising antibodies. The most extensive sequence heterogenicity of HIV -I Env is found 
clustered in live hypervariable regions (V I· V5) of gp 120, which are interspersed with six 
9 
Chapter 1 
conserved regions (CI-C6) (20). Sequence analyses of HlV-2 and SIV isolates supports a 
similar model for the surface subunit of these two viruses (13), The gp41 subunit shows less 
heterogenicity and is more highly conserved (20). The envelope also contains cellular 
proteins acquired during virus budding, including ICAM-I, B,-microglobulin, and the a and 
B chains of the human major histocompatibility complex (MHC) class II DR antigen (I, 21, 
22). Whether these and other cellular proteins incorporated in the virion playa role in virus 
replication or pathogenesis is currently under investigation (23). 
E1L_--'g_·g:......_-' 
pol 
o 
Figure 2. A schematic diagram of the HIV·I virion and its genomic organization. The gene length 
is expressed in kilobases. 
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The virion core contains three major structural proteins: the matrix protein, 
presumably located between the envelope and the nucleocapsid. the capsid protein, which 
forms a 5 nrn thick capsid shell, and the nucleocapsid protein, which is bound to the viral 
RNA genome (1). These proteins are derived from a common precursor encoded by the gag 
gene. Several enzymes, derived from a precursor encoded by the pol gene, are also 
packaged into virions; these are protease (PR), reverse transcriptase (RT), ribonuclease 
(RNase H), and integrase (IN), all presumably contained within the nucleocapsid. PR is 
essential for the processing of the viral polyproteins; inactivation of the enzyme leads to the 
production of immature, noninfectious viral particles (1). RT is an RNA-dependent DNA 
polymerase which synthesizes DNA from RNA as well as DNA templates. RNase H also 
functions in reverse transcription by degrading the RNA molecules of RNNDNA hybrids. 
Both enzymes are indispensable for virus replication. RT is not an accurate enzyme; its 
elTors ('misincorporations'), the lack of a proofreading system and recombination events, 
are responsible for the generation of viral genetic diversity. For the HIV -I genome, the in 
vivo error rate is estimated to be 1-3 misincorporations per replication cycle (24). Finally, 
IN is an enzyme possessing both DNA cleavage and joining activities, which mediates 
covalent linkage of viral DNA into the cell genome. 
The viral genome consists of two single-stranded RNA molecules with plus strand 
polarity of approximately 9.2 kb. Lentiviruses have a genomic structure of unique 
complexity among retroviruses (Table 2): in addition to the structural ell V, gag and pol 
genes common to all retroviruses, the RNA genome encodes the two regulatory proteins Rev 
('regulatory of viral expression') and Tat (,transcriptional transactivator'), which are essential 
for viral replication (I). The HIV-I genome also contains a number of genes encoding 
factors that are dispensable for virus growth in many in vitro systems and are therefore 
commonly called accessory genes. Nevertheless, there is increasing evidence that these 
highly conserved products fulfill crucial functions in vivo (25, 26). The accessory genes of 
the HIV-I genome are designated lief, vif, vpr, and VPIl, whereas HIV-2 and SIV encode lief, 
vif, vpx and/or vpr. 
Replication 
The life cycle of primate lentiviruses follows the general outline of other 
retroviruses. Virus replication begins with the steps of receptor binding, entry, and reverse 
transcription. This is followed by integration of the viral DNA into a chromosome of the 
infected cell, a step required for efficient replication of the retroviral genome. The second 
half of the replication cycle involves the steps of provirus transcription, mRNA processing, 
protein synthesis and processing, virus assembly, and budding. Attachment of the virion to 
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Table 2. Gelles ami proteillS o/primate lelltiviruses 
Gen 
ell\, 
gag 
pol 
rev 
tat 
vif 
vpr 
vpx 
vpu 
lief 
Protein 
gpl60 
Pr5y~g 
Pr 160g~g'I"'1 
pl9 
pl4 
p23 
pl5 
pl6 
pl6 
027 
Function and site of influence 
Envelope glycoproteins; virus attachment, entry, and release; CD4 
Matrix, capsid and nucleocapsid proteins; virus assembly 
Virion enzymes 
Regulator of viral expression 
Transcriptional transactivator 
Viral infectivity factor; early events after virus entry, before or 
Nuclear import of preintegration complex; cell cycle arrest in G2 
HIY-2 and SlY only; homologous to Ypr 
HIV-l and SIVcpz only; virus release; CD4 downregulation 
CD4 dOWIlfCfwlation; virus infectivity; T-cell function 
the host cell is mediated by a high affinity interaction between the surface subunit (gp I 20 
or gp130) of En v and the first immunoglobulin-like domain of the CD4 receptor (27-30). 
The latter is expressed on most T helper lymphocytes, on many cells of the monocytc-
macrophage lineage, and on some other cell types. A variety of cell types appear to have at 
least a limited susceptibility to HIV, including some Epstein-Barr virus (EBV)-transformed 
B cells, Langerhans' cells and other dendritic cells, follicular dendritic cells, glial cells, gut 
epithelium, and bone marrow progenitors (41). 
The inleraction of gp 120 with the CD4 receptor triggers a conformational change 
in Env which promotes fusion of viral and cellular membranes (31). Recen!ly, a number of 
chemokine receptors have been shown to cooperate with the CD4 receptor to facilitate virus 
entry through an interaction with gp 120 ( 32-34). The a-chemokine receptor fusin CXCR4 
(also known as LESTR or HUMSTR) and the B-chemokine (RANTES, MIP-I a and MIP-I 
B) receptor CCR5 serve as entry cofactors for T-cell tropic and macrophage tropic HIV-I 
strains respectively. Some macrophage-tropic and dual-tropic strains can also use other 13-
chemokine receptors such as CCRI, CCR2b and CCR3, but whether these playa major role 
in virus transmission and pathogenesis is at present unclear. Both primary and laboratory 
adapted T-cell tropic HIV -I isolates have been shown to efficen!ly employ CXCR4 as a co-
receptor in cells expressing high levels of CD4. In contrast, cooperative binding of 
macrophage-tropic HIV-I onto CCR5 and CD4 is thought to enhance infectivity for cells 
that express only traces of CD4 (34 ). The finding Ihat macrophage-tropic strains are those 
involved in sexual transmission in about 90% of documented cases, highlights the 
importance of CCR5 in HIV -I transmission. The important role played by these co-receptors 
12 
Chapter 1 
in infection and pathogenesis is reinforced by the recent finding that co-receptor gene 
mutations causing lack of protein expression 011 the cell surface, confer protection against 
HIV-I infection and disease in vivo (35-37). Like HIV -I, at least some strains of SIV have 
been shown to use CCRS as co-receptor for entry, whereas another coreceptor is thought to 
be the counterpart of CXCR4 (38). While the current model for virus entry involves 
therefore the steps of CD4 binding, interaction with CCR5 or CXCR4 (or its SIV 
counterpart), and then fusion, other factors may facilitate virus entry, including the Fe and 
complement receptors (39) and soluble CD4 (40). In addition, galactosyl ceramide on glial 
cells and colorectal cells, leukocyte function-associated antigen I, and intcgrins have been 
proposed as potential mediators of virus attachment and entry into several cell types lacking 
detectable CD4 (I, 41). 
Immediately after entry. viral particles arc ullcoated to produce a large 
nucleoprotein complex, followed by activation of RT to initiate the synthesis of a DNA 
strand of negative polarity from the genomic viral RNA template. Subsequently, RNase H 
degrades RNA in the DNAIRNA hybrid and a second strand of DNA with plus strand 
polarity is synthesised, whose integration in the host genome is mediated by IN. Although 
integration does not target specific sequences, it is not random. HIV-I for instance 
preferentially inserts into or near two classes of rcpeated DNA elements in the human 
genome, the L 1 and All! elements. These elements arc termed retroposons and share 
properties with retroviruses (42). Following initial infection, the virus may undergo a 
variable period of absent or low level replication with low or not detectable expression of 
viral genes. Although the mechanism of latency is not completely understood, provirus 
expression appears to be dependent on the combined action of multiple cellular and viral 
factors (43). Like other lentiviruses, HIV and SlY may bind to and enter quiescent cells. In 
terminally differentiated macrophages and cells arrested in the G liS or G2 phases of the cell 
cycle, virus replication can occur after proviral integration. In contrast, integration does not 
occur within lymphocytes that are in the GO phase, and until and unless the cell is activated, 
proviral integration and virus production do not occur. Paradoxically, CD4 1'-cell activation 
in the course of immune stimulation create favourable conditions for virus integration, 
replication and dissemination (44). 
Extrachromosomal replicative intermediate remain unintegrated for a limited period 
of hours or days, and may even serve as templates for the production of core and envelope 
proteins (45), although the data are controversial (46). In contrast, integrated genomes could 
potentially remain for the lifetime of the quiescent cell. In peripheral blood mononuclear 
cells (PBMC), advancing disease is characterised by a relative change in the proportion of 
cells carrying latent genomes and of those actively replicating virus. In special 
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circumstances, some integrated genomes may be defective and replication incompetent. In 
at least one instance, such defects have been associated with a prolonged asymptomatic state 
and mapped to a mutation in the lief gene (47). 
Several cellular factors, including the NF-kB family of enhancer elements (48, 49), 
NFAT, AP-I, SP-I and tat-binding proteins (50) influence viral RNA synthesis from the 
integrated DNA. Certain cytokines, such as interleukin: I or TNFa (51) can also directly or 
indirectly influence virus replication. In some cases direct transactivation of latent genomes 
can be induced by other viruses, such as human herpesvirus 6 (HHV-6) (52) and 
cytomegalovirus (CMV) (53). A unique aspect of the viral replication cycle also lies in the 
various viral-encoded factors that regulate the level of provirus expression. The regulatory 
genes tat and rev control viral gene expression at the transcriptional and posttranscriptional 
levels respectively. and are believed to playa crucial role in both viral latency and activation 
by controlling differential viral gene expression (I). The role of the Nef protein is still 
debated. The protein makes up to 80% of the early viral transcripts, although it is produced 
at all stages of viral gene expression. It was initially reported to inhibit HIV replication and 
downregulate transcriptional activity; however, subsequent reports have failed to confirm 
this negative effect (25). Recent findings indicate that in fact the protein augments virus 
replication and markedly affects T-cell function, therefore playing an essential role in 
pathogenesis in vivo (54, 55). 
The current model for regulation of viral gene expression predicts that multiple 
spliced viral mRNAs encoding Tat, Rev and Nef are produced during the early phase, 
whereas the late phase is characterised by accumulation of unspliced and singly spliced 
mRNAs encoding the precursors of the virion proteins Env, Gag and Pol. Cells harbouring 
latent HIV-I contain multiply spliced viral transcripts encoding Tat, Rev and Nef (43). Once 
initiated, the various signals leading to viral replication will drive a self-perpetuating and 
progressive loop (I), The first event in virion assembly is presumed to be an interaction 
between Gag and Gag/Pol precursors, host cell membrane and viral RNA genome. This is 
followed by processing of the polyproteins by the viral protease, final assembly and 
budding. The vif and vpu gene products appear to be essential in the late stage of virus 
maturation and release (25), 
Pathogenesis of Infection With Primate Lentiviruses 
Target organs 
Immediately after infection, high levels of cell-free and cell-associated viraemia 
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occur in peripheral blood, allowing systemic dissemination of the virus. Thereafter, the 
absolute levels of virus in blood become lower, to increase again during disease progression 
(56), The lymphoreticular. haematopoietic and nervous systems are the major targets of 
primate lentiviruses (41). The mechanisms of virus-induced damage of lymphoid and 
haematopoietic cells are probably multifactorial and may include both direct and indirect 
mechanisms (I, 41), such as perturbation of cell cycle (57), apoptosis (58), accumulation 
of unintegrated proviral DNA, increased permeability and disruption of cell membrane, cell 
t[lsion" by-stander effects induced by infected cells, autoimmunity (50), and complex host 
adaptive responses to infection (59). Critical for HIV and SIV pathogenesis is the ability of 
the viruses to induce multiple immunological abnormalities, particularly a progressive 
dysfunction and depletion of CD4+ T-cells, CD8+ T-cells, monocyte/macrophages and 
dendritic cells (41) (Table 4). Marked defects in CD4+ T helper cell function commonly 
precede substantial declines in CD4+ T-cell numbers (60). An early sign of these defects is 
the loss of proliferative responses to recall antigens, followed by a sequential loss of 
reactivity to alloantigens and mitogens. In contrast with proliferative responses, the ability 
to produce interleukin-2 (IL-2) upon antigenic stimulation is initially preserved in infected 
persons (61), although the response is eventually lost in advanced disease. 
Table 4. Major immunological abnormalities associated with HIV infectioll 
Dysfullction and depletion of CD4+ T-cells 
Decreased helper function 
Decreased B- and T-cell proliferative responses 
Impaired delayed-type hypersensitivity reactions 
Cytokine network dismption 
Polyclonal B-ceJI activation 
Polyclonal hypergammaglobulinaemia 
Increased immune complex formation 
Decreased humoral responses to immunization 
Decreased cytotoxic T-cell responses 
Decreased natural killer cell activity 
Decreased monocyte chemotaxis 
Impaired killing of intracellular pathogens 
Decreased antigen presenting function 
The mechanisms which account for the compromised T helper function in the early 
stages of infection are unclear; preferential infection and loss of certain T cell subsets (62, 
63), defective antigen presentation due to virus-induced dysfunction of dendritic cells (64), 
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and immunosuppressive effects of gp 120 (65), arc among the factors that may compromise 
T-cell responsiveness. The pathogenesis of neurological damage is also obscure (50). The 
predominant cell type that is infected within the nervous system is of monocyte-macrophage 
lineage, although other cell types such as endothelial cells, astrocytes and possibly neurons 
may infected (41). Release ofcytokines and viral proteins by infected macrophages may be 
either directly neurotoxic Of may induce further inflammatory events (66), Alternative 
mechanisms include direct or indirect (e.g. immune-mediated) destruction of glial cells or 
neurons, and co-infection with cytomegalovirus or Ie papovavirus. Recent data indicate that 
HIV-I infection may be established in the nervous system by viruses present early after 
infection. that some of these viruses are particularly tropic for the microglia and that 
adaptation to this cell type can result in the selection of a pool of predominantly neurotropic 
(microglia-tropic) viruses (67). 
Clinical features 
Primary HIV -I infection may be asymptomatic or may present as an acute an acute 
mononucleosis-like syndrome, commonly observed 1-6 weeks after exposure (68). 
Occasionally, more serious symptoms including encephalitis are observed. At present, there 
are no data to clearly indicate that the long-term prognosis in patients who experience 
symptomatic primary infection is any different from that of asymptomatic cases. 
Seroconversion to HIV antibody positivity usually occurs within 3-12 weeks. After 
seroconversion and resolution of any symptoms, an asymptomatic period generally ensues. 
Persistent generalised lymphadenopathy, which occurs in some individuals, may be the only 
clinically apparent abnormality present during this stage. After a variable period of time, 
usually measured in years (69), infected persons may begin to develop a spectrum of clinical 
conditions typically associated with a decline of CD4+ T-cells, such as skin problems, oral 
Candida, and oral hairy Jeucoplakia. Systemic upset with fever, weight loss and diarrhea may 
also become evident. As immune function declines, the occurrence of opportunistic 
infections and malignancies increases. The clinical manifestations of AIDS can include 
systemic, neurological, gastrointestinal, infectious and malignant complications (68), 
although the relative frequencies of symptoms and signs varies considerably in different 
patient groups. The spectrum of opportunistic infections, particularly, tends to reflect the 
pattern of infectious organisms present in a given geographical location. Once a patient 
develops overt disease, average survival is two years. The clinical course, however, is highly 
variable and even atter AIDS is diagnosed ,infected persons may experience long symptom-
free periods between episodes of opportunistic infections. Cohort studies among homosexual 
men and haemophiliacs in developed countries indicate that about 50% of infected persons 
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develop AIDS after 10 years. Some persons however progress relatively quickly (less than 
three years, rapid progressors), whereas others may remain asymptomatic for 16 years or 
more (long-term nonprogressors) (70, 71). 
The asymptomatic period of 'clinical latency' that intervenes between infection and 
the development of AIDS, does not imply an absence of virus replication (72). Although 
infectious virus titres and levels of p24 antigen or viral nucleic acid show a positive 
correlation with clinical stage, active virus replication persists throughout the disease course 
(73). Indeed, even when detectable virus in the periphery is at a nadir, high levels of virus 
replication and of 'trapped' extracellular virus (e.g., on follicular dendritic cells) are found 
within lymphoid organs (74, 75). Over time, changes in total body virus load are determined 
by the rate of clearance of productively infected cells, the rate of virus release from these 
cells, and the rate by which cells with latent genomes are cleared (76). Recent experiments 
studying the kinetics of virus turnover have estimated that in patients with CD4 counts of 
500 or less, 107-10' virions are produced per day, resulting in a peripheral viremia of 10'-10 ' 
RNA molecules/ml and in the destruction of approximately 2x10' CD4' T-cells/day (77, 
78). Most of the plasma virus is apparently produced within recently infected cells. On the 
basis of these studies, the possibility has been raised that the kinetics of viral and cellular 
turn over found in iatcNstage disease may persist from the outset, leading ultimately to the 
collapse of the immune system and overt disease (79). Although the hypothesis of 
'virological mayhem' (80) is attractive and may be correct, at present it remains an inference 
from observations made in late-stage disease after perturbation of the steady state with 
antiretroviral therapy. In fact, recellt analyses ofT-ceil telomere length, supposedly a marker 
for cellular replicative history, suggest that turnover in the course of HIV infection is 
increased considerably in CDS' T-cells, but not in CD4' T-cells (41). 
Infection of macaques with SlY induces an immunodeficiency syndrome closely 
resembling human AIDS. Main features of simian AIDS include CD4' T cell loss, 
constitutional symptoms, neurological disorders, opportunistic infections and neoplasias. 
The time scale of the infection is 61ster than in humans, as the average time from infection 
to disease is 1-2 years (82). As in humans, however, the course of the infection is highly 
variable in macaques: after virus inoculation, some animals rapidly progress to overt disease, 
whereas others may remain asymptomatic for more than three years, thus resembling long-
term nonprogressors with HIV-I infection. 
Can the Immune Response Control HIV Infection? 
The viral, host, or environmental factors underlying the variable rates of disease 
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progression among HIV-infected individuals or SlY-infected monkeys are currently under 
investigation. The bulk of evidence indicates that virus replication plays a major role in 
driving pathogenesis and measurement of steady-state virus load after acute infection clearly 
predicts disease progression, These observations suggest that some long-term asymptomatic 
individuals may have been infected with an attenuated virus of limited replication 
competence or pathogenicity (47, 83), However, many lon-term nonprogressors with HIV-J 
infection appear to have been infected with a virus that they have controlled (84 ). In 
addition, divergent patterns of disease progression have been observed after infection from 
the same source (85). A recent study in perinatally infected infants has also indicatcd that 
a single virus variant initiated the infection in both rapid and slow progressors (86). While 
no detinitive explanation yet exists to explain these findings, increasing evidence indicates 
that slow rates of virus replication and disease progression are intimately connected with 
host genetic factors and the normal functioning of the immune system (87). Among host-
genetic factors, defects of coreceptol' genes resulting in strong resistance to infection in 
homozygotes and to disease progression in heterozygotes arc currently attracting 
considerablc intercst (35-37). In addition, certain MHC genotypes have been found to be 
associated with the degree of resistance to infection. In particular, the B35 or the A I-B8-
DR3 haplotypes have been associated with progression, whereas other haplotypes such as 
B27-A24-DR I have been found in long-term nonprogressors (88). These data strengthen the 
case for a genetically determined ability of the immune system to control HIV infection. 
The inference that protective immune responses occur quite commonly in HIV-
infected persons may be drawn from studies indicating the difficulty in superinfecting 
primates (82). Infection of primates with attenuated viruses appears to result in a state of 
resistance against subsequent challenge with fully virulent viruses. The most striking 
example is the resistance of macaques that have been infected with SIV defective in the nel 
gene (lief-deleted SlY) to challenge with large amounts of fully virulent virus (89, 90). The 
animals contain DNA sequences of the attenuated virus, indicating the ability of the 
attenuated viruses to establish persistent infection; virus burden however is very low. The 
human counterpart can be found in persons infected with the less pathogenic HIV-2, who 
appear to have a reduced risk of infection with HIY-I despite potential exposure (91). 
Although the nature of the resistance has not been determined, it is likely to include an 
immunological component. This conclusion is supported by the finding that attenuated SlY 
viruses are fully pathogenic in immunologically noncompetent neonate macaques (92). 
However, several aspects of the apparent protection still require investigation, including the 
long time required for the resistance to develop, the nature of the potentially protective 
immune responses, and the apparent paradox of a response powerful enough to prevent 
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infection by a virulent virus but unable to fully rid the host of an infection with an attenuated 
virus. In this respect, it seems possible that an effective immune response that fails to 
eliminate existing virus, may nonetheless be effective in limiting virus replication and 
spread, particularly in cells in which virus turns over quite rapidly. By contrast, immunity 
may lack effectiveness against cellular or compartments that act as virus reservoirs, such as 
the macrophage lineage in the brain. 
Despite the devastating effects of HIV -Ion the host immune system, most infected 
individuals develop both humoral and cellular immune responses against multiple HIV 
antigens. Neutralizing antibodies are produced by most infected individuals and are 
generally directed against Env (41). Epitopic sites in Env hypervariable regions, such as the 
V3 loop, induce antibodies that are extremely type-specific, whereas those in conserved 
areas induce group-specific responses. Some investigators have observed a correlation 
between low neutralizing antibody titres and rapid disease progression, whereas other have 
not (13). Reactivity to the p24 Gag product is also detectable in infected persons, and it 
appears to mirror progression of infection. As a marker of prognosis, diminution of 
circulating anti-p24 antibodies and the appearance of p24 antigen often correlate with 
marked CD4+ T-cell loss, progression of immune dysfunction and development of AIDS 
(41). Of note is that HIV -I genetic subtypes, which are based on primary sequence analyses, 
do not usually correspond to neutralization serotypes (32). As an important target of cross-
subtype neutralization, attention is currently focused on the putative three-dimensional 
structure of gp 120, where conserved binding sites for both CD4 and CCR5 or CXCR4 must 
be located. A role for specific antibodies in mediating enhancement of virus entry and 
infection has also been suggested (93, 94 ) and is currently under investigation. 
As cellular immune responses are a critical part of the host defence against viruses, 
their role in the control of HIV infection is the focus of extensive investigation. 
Measurement ofT-ceil proliferation upon antigen stimulation is widely used to test T-helper 
cell reactivity in vitro. However, in HIV -I-infected persons measurement of cytokine release 
appears to be more sensitive and informative (61). Proliferative responses and IL-2 release 
to stimulation with synthetic pep tides spanning gpl20 have been demonstrated in 
asymptomatic HIV-I infected persons with CD4' T-cell counts >400 (61). In HIV-I infected 
humans, as also in immunised macaques (95), responses target multiple cpitopes scattered 
throughout Env. Production of JL-2 in response to in vitro PBMC stimulation with peptides 
spanning defined regions of Env have also been detected in persons exposed to HIV -I but 
lacking evidence of infection (96). Whether exposure to viral antigens, rather than 
replication-competent virus, is sufficient to prime the CD4+T-cell responses and whether 
these responses arc markers of exposure or of actual protective immunity remains currently 
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unclear. Initial reports that helper T-cells of the Th I phenotype, that is secreting 
predominantly IL-2 and IFNy on antigen stimulation, may be associated with protection 
ti"om infection or maintenance of the asymptomatic status also await confirmation (97 I 98), 
Antiviral CD8' T-cells form a primary component of the cellular immune response 
against viral infections. They may contribute to virus containment through two effector 
mechanisms. Classically, CD8' cytotoxic T lymphocytes (CTL) lyse infected cells 
displaying on their surface viral peptides in the context of MHC class I molecules. Lysis of 
target cells is induced either be the secretion of soluble lytic proteins (perforin and 
granzymcs) from specialised secretory granules, or by the engagement of the Fas molecule 
resulting in apoptosis (99). Recently, evidence is emerged that CD8' T-cells can also 
actively suppress virus replication by producing antivirallymphokines. This suppressive 
activity is not MHC restricted, although it can follow MHC-restricted T-cell stimulation, 
is mediated, at least in part by a novel CD8+ T~cell antiviral factor (CAP), and has been 
demonstrated in both HIV-infected humans and SIV-infected macaques (100). Recent data 
have demonstrated that HIV -I-specific CTL can mediate virus control by both cytolytic and 
noncytolytic mechanisms (101). The contribution ofCAF, of chemokines such as RANTES, 
MIP-I a and MIP-l B which inhibit the replication of macrophage tropic strains interacting 
with CCR5 (102), and cytokines such interleukin-16 (103) to the control of virus replication 
has recently become the subject of intense investigation. Remarkably, the detection of viral 
suppressive factors have been shown to correlate with protection of immunised macaques 
against mucosal SIV infection (104). 
Cytotoxic T lymphocytes 
The best characterized virus-speci!ic CTL are CD8' T-cells that recognize viral 
proteins processed in the cytoplasm of infected cells and displayed as peptide fragments on 
the cell surface in association with class I MHC molecules. Peptides of the appropriate 
length (mostly 8 or 9 amino acids) are generated in the cytosol following cleavage by 
proteasomes, and transferred by specialised peptide transporters to the endoplasmic 
reticulum, where assembly with MHC class I dimers (class I heavy chains associated 
noncovalently with p2-microglobulin) takes place (105). The stable trimeric complex is then 
transported through the Golgi apparatus to the cell surface and the peptide is presented to 
CTL. Chaperon molecules associated with the peptides and the class I molecules at various 
stages prior to complete assembly of the trimeric complex. MHC class II restricted CD4' 
lymphocytes may also display cytotoxic activity against a number of viruses, including HIV-
I (106). 
Specific CTL have been detected not only in peripheral blood, but also in lymph 
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nodes, spleen, bronchoalveolar lavage, genital tract and cerebrospinal fluid of individuals 
infected with HIV-I (107-111), Responses are generally multispecific, as they are directed 
against a relatively large number of epitopes both on external and internal viral proteins 
(112-115), The recognition that CTL might be important immunological correlates for 
protection against HIV infection or disease has gradually evolved, To begin with, a role for 
CD8+ MHC class I restricted CTL can be inferred from animal model systems of both acute 
and chronic viral infections. In mice, for instance, CTL playa critical role against 
lymphocytic choriomeningitis virus; in this case, as well as in murine cytomegalovirus 
infection, it is possible to protect a naive animal from virus challenge by immunization with 
a recombinant vaccinia virus expressing a single viral protein and such protection is 
mediated by CTL (116, 117), In humans, there is convincing evidence that CTL responses 
playa role in the control of a number of persistent viruses, including cytomegalovirus (118), 
In other animal and human viral infections however, evidence is less clear-cut. 
Indirect evidence for a role of CTL in the control of HIV comes from the 
observation that CTL responses against HIV antigens are present in persons exposed to the 
virus but lacking evidence of infection: these include small number of female prostitutes in 
An-iea, sexual partners of infected persons, children born to infected mothers, and healthcare 
workers exposed to infectious body fluids (96), Based upon the assllmption that the 
induction ofCTL requires endogenous synthesis of viral proteins, these findings suggest that 
transient infection and virus clearance by CTL are indeed possible. Furthermore, studies in 
both HIV-infected persons (119, 120) and SIV-infected macaques (121) have shown that 
antiviral CTL develop rapidly after infection (day 4-7 after intravenous SIV inoculation) in 
both peripheral blood and lymph nodes, and that their appearance coincides with the fall in 
viraemia that follows the initial virus burst. CTL responses against HIV-l can be unusually 
strong in comparison with other chronic viral infections. In asymptomatic HIV-l-infectcd 
adults, the frequency of circulating effector cells is sometimes high enough to allow CTL 
detection in freshly isolated lymphocytes, in the absence of in vitro restimulation (112), This 
strong response is generally maintained throughout the asymptomatic status, when is 
associated with increased numbers of circulating CD8+ T-cells expressing activation markers 
sllch as DR , but often declines with disease progression (122), At present no satisfactory 
explanation exists for such decline, although both exhaustion due to prolonged high-level 
antigen exposure (123) and progressive loss of helper function may be advocated, Continuos 
activation of memory cn, in particular, can result in low expression of Bd-2 and CD28 
that contribute to CD8' cell death (124), 
Despite extensive characterisation from the moment of virus entry to full-blown 
disease, whether the correlation between CTL responses and disease progression is an 
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indication of a role for CTL in controlling HIV infection has yet to be determined. In 
addition, the view that persons with the most benign disease course have the highest levels 
ofCTL activity, although widely accepted, is not well founded. In fact, results are divergent. 
Broad CTL responses and an inverse correlation between CTL precursor (CTLp) 
frequencies and cell-associated viraemia have been associated with long-term absence of 
progression (125-127). At the same time, either absent or very low frequencies of HIV-
specific CTL have been found in long-term nonprogressors with extremely low viral load 
(128). Similarly, no clear relationship has been found in vertically HIV -I-infected children 
between CTLp frequencies and viral load or disease progression (129). However, the small 
number of patients examined, the heterogenous composition of the study groups, and the 
different methodologies for CTL assays, limit generalization of the data reported. It is also 
likely that qualitative factors, such as affinity of target cell-effector cells interaction, playa 
crucial role in determining the effectiveness of CTL response and may in part explain ~hy 
the presence of high levels of CTL does not necessarily prevent development of disease. In 
fact, at least in some cases, high CTL frequencies may simply reflect either persistently high 
level of virus replication or a continuously diversifying genome. 
HIV -I has evolved several strategies to escape immune recognition (110). For 
instance, certain viral proteins, such as Ncr, can alter MHC expression (131). Rapid 
evolution of viral sequences is also believed to represent a major mechanism of viral escape 
(132-135). In vitro, single amino acid substitutions have been shown to abrogate CTL 
recognition by affecting either MHC binding or TCR interaction (136). Furthermore, 
mutations within epitope flanking regions may reduce presentation by affecting peptide 
processing and transport (137). Mutant viruses which are resistant to CTL have been both 
generated in vitro under selective CTL pressure and detected in vivo during infection with 
a number of viruses including HIV-I (138-141). Recent evidence suggests also that epitopes 
with mutated TCR contact sites may arise, which still interact with the TCR, but inhibit 
antiviral CTL responses by inducing T cell anergy, or by showing partial agonistic or 
antagonistic activity (142). Indeed, some Gag and RT variants have been found to induce 
antagonistic inhibition ofCTL directed against wild-type peptides. Virus variation may also 
lead to the generation of mutated sequences that stimulate the expansion of variant-specific 
CTL. Under these circumstances, the emergence of new viral variants, which transiently 
avoid recognition, would be followed by successive waves of newly induced CTL (143). 
Understanding the factors that may control virus spread is crucial to the 
development of effective therapies and vaccines against HIV. Because of the strong analogy 
with HIV infection of humans, SIV infection of macaques offers a highly valuable model for 
studying the role of CTL immunity in preventing infection after exposure of vaccinated 
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animals. In addition, this model offers the opportunity to explore crucial issues related to 
pathogenesis and disease progression, and may therefore help to clarify the complex 
interactions between primate lentiviruses and host immune system. 
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Outline of this thesis 
After an introduction to the main features of primate infections with 
immunodeficiency viruses in chapter 1, chapter 2 describes the results of two vaccine studies 
in macaques. Both studies were aimed at investigating the ability of vaccine-induced 
humoral and CTL responses to prevent infection of macaques upon intravenous challenge 
with either a molecular clone of SIYmac or a chimeric HlY-SIY virus (SHlY). Chapter 3 
outlines how the optimal conditions for CTL expansion, quantitative analyses and phenotype 
characterization were established in vitro. Additionally. the chapter describes the 
identification of a minimally defined epitope in SlY Gag recognised by antiviral CTL of an 
SlY-infected macaque. Chapter 4 contains two prospective studies conducted during the 
chronic phase ofHIY-l and SlY infection respectively. The first study analyses the kinetics 
of HIY-l and EBY-specific CTL and describes their relationship with changes in CD4' and 
CDS' cell counts over time. The second study investigates the evolution of SlY -specific 
CTL in relation to the kinetics of virus replication and virus attempts to evade immune 
surveillance. Finally, chapter 5 contains a summary and a discussion of the experiments 
presented in the framework of similar studies conducted in both humans and nonhuman 
primates. 
30 
Chapter 2 
Role of CTL immunity in preventing primate lentivirus infection 
2.1 Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect 
macaques from experimental infection with simian immunodeficiency virus 
SIVmac32H(J5). Journal of Virology (1995) 69:6289-6296. 
2,2 Immunization with envelope glycoproteins of primary human immunodeficiency 
virus type I (HIV -I) isolates does not protect macaques against homologous 
challenge. (Submitted). 

Chapter 2 
Vaccine-Induced Virus-Neutralizing Antibodies and Cytotoxic T Cells 
Do Not Protect Macaques from Experimental Infection with 
Simian Immunodeficiency Virus SIVmac32H (J5) 
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To gain further Insight into the ability of subunU ,"acclnes to proleel monkeys from experimental infecllon 
"ith simian Immunodeficlency,irus (SIV), two groups of C)nomolgus macaques were immunized "ith either 
recombinant SIVmac32H-derh"ed ennlope gl),coprolelns (Em') Incorporated inlo immune.stimulatlng com· 
plexes (lscoms) (group A) or with these SIV ED\' Iscoms In combination wilh p2rg iscoms and Ih~e Nef 
Ilpopeptides (group D). Four monkeys Immunized 'lith recombinant feline immunodeficiency ,irus En,·lscoms 
sen"ed as controls (group C). Animals were Immunized Intramuscularly at weeks 0, 4, 10, and 16. Two weeks 
aner the lasllmmunlzatioll, monkeys were challenged Inlra,"enously with 50 monkey 50% infectious doses of 
\irus derh"ed from the J5 molecular clone of SIVmac32H propagated In monkey peripheral blood mononuclear 
cells. HIgh liters of SIV.neutrallzlng anlibodies were induced In the monkeys of groups A and D. In addillon, 
p27gag-speclfic antibodies were detected In the monkeys of group B. Vaccine· Induced q"totoxlc.T.I)nlphoC)"te 
precurSors against Env, Gag, and Ncr were detected on the day of challenge in the monkeys of group B. 
Em·.speclfic C)10toxlc-T.I)1IIphoc)te precursors nere detected In one monkey from group A. In spUe of the 
obsen"ed antibody and T-cell responses, none of the monke>"s was protected Crom experimental infection. In 
addition, longitudinal determination of cell·assoclated \irus loads at weeks 2, 4, 6, 9, and 12 postchallenge 
re\"Caled no significant differences between ,"acclnated and control monkeys. These findings illustrate the need 
10 clarlry the roles of the different anns of the Immune system In conferring protection against primate 
lenth"irus Infections. 
Simian immunodeficiency \irus (SIV) has a genomic orga-
nization similar to that of human immunodeficiency virus 
(HIV) and can induce a disease in certain macaques similar to 
human AIDS. Therefore, SIV infection of macaques is widely 
used as a model for HIV vaccine research. Previous observa-
tions have provided evidence that whole inactivated SIV vac-
cines can induce protec!i\"e immunity in macaques (10. 13. 18, 
29,30,40,41). although in some of these studies the immune 
responses against cellular components of the vaccine proved to 
be at the basis of the observed protection (3. 12, 53). Immu-
nization of rhesus macaques with live attenuated SIV has pro· 
vided further evidence that the induction of protective im-
munity may be achieved by vaccination (16, 35). However, 
concerns about the overall safety of this approach may limit its 
potential for the development of HIV type 1 (HIV-I) vaccines. 
(CfL) in both HIV-infected humans and SlY-infected ma-
caques (59)" A role for CfL in controlling virus replication has 
been suggested from the observation that the clearance of 
viremia during primary infection is coincident .... ith the emer-
gence of HIV-l-specific CfL and prior 10 the development of 
detectable YN antibodies (34). Immunization of cynomolgus 
macaques with live vaccinia virus expressing Env and a subse-
quent boosler injection with recombinant Env did confer pro· 
tection against homologous challenge with SIVmne (25)" How-
e\'er, simifar immunization protocols did not induce protection 
against SIVmac infection (22, 51), although decreased virus 
loads were observed in some studies (1, 27)" 
Subunit vaccines have been proposed as a safe alternative to 
inactivated or live attenuated virus vaccines, with the advan· 
tage that only antigens relevant for the induction of protective 
immunity may be included. In this respect, much attention has 
been paid to the envelope glycoprotein (Env) as the major 
target of virus-neutralizing (VN) antibodies" Furthermore, Env 
has been shO\m to be recognized by cytotmic T lymphocytes 
• Corresponding author. Mailing address: Institute of Virology, 
Erasmus Unil"ersity Rotterdam. P.O. 8m; 1738, 3000 DR ROllerdam, 
The Netherlands. Phone: 31-10-4088066. Fax: 31-10-4365145. 
The relatively conserved Gag protein is another candidate 
for inclusion in SlY subunit vaccines. Gag is known to be a 
major target for CIL responses in both HIV-l and SIV infec-
lions (31, 59), in which Gag·specific CfL are belie\·ed 10 play 
a role in delaying the onset of disease (9). 
Regulatory proteins expressed early in viral replication are 
also interesting components of candidate SlY subunit vaccines, 
since CfL directed against these proteins may kill infected 
cells before the expression of structural proteins and before the 
release of infectious virus particles. In this respect, Nef appears 
to be of particular interest, since it is abundantly expressed 
early in infection and is able to induce CIL responses in both 
humans and macaques (14, 15, 58). In HIY-J-infected individ-
uals. several CfL epitopes have been identified in the central 
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region of Ner and shO\\n to be re~ognized in the context of a 
broad range of major histocompatibility complex (MHC) hap-
lotypes (14, 15). In SIV-infected macaques, three Nefpeptides, 
with a sequence highly homologous to that of the central re-
gion of the HIV-l Nef protein, have been shO\\TI to contain 
CfL epitopes (7). 
The system used for delivery of the selected antigens may 
playa crucial role in the generation of adequate B· and T-reH 
responses. Particular attention should be given to the induction 
of Mile class I-restricted CD8+ CfL, because it requires 
antigen processing via the endogenous route, which is usually 
not accomplished by nonreplicating antigen presentation 
forms (for a review, see reference 37). However, proteins in-
corporated into immune-stimulating complexes (iscoms), as 
wen as peptides bound to a lipid tail, have been shown to 
induce CD8+ MHC class I-restricted CIL in vitro and in vivo 
(6,17,36,39,50,55,57)_ Interestingly, previous studies have 
suggested that gp120-enriched SIVmac32H iscoms are effec-
tive in inducing protection against challenge with ceil-associ-
ated SIV (19, 23, 42). Furthermore, HIV-2 iscoms ha\'e been 
shown to induce long-lasting protective immunity against chal-
lenge with cell-free H1V-2 (43). 
In this study, two groups of monkeys were immunized with 
either recombinant SIV En\' incorporated into iscoms (group 
A) or with SIV En\' iscoms combined with p27&jg iscoms and 
three Nef Iipopeptides containing the CfL epitopes previously 
identified in the central region of Nef (amino acids 10810 123, 
155 to 169, and 164 to 178) (7) (group il). Despite the induc-
tion of VN antibody responses and CIt responses against En\', 
Gag, and 'Nef, none of the monkeys pro\'ed to be protected 
against intravenous challenge \\llh the J5 molecular clone of 
SIVmac32H. 
MATERIALS AND METfiODS 
Formu!.Uon oha<dnt prepar.lUon!. (iJ Pupar.ltlon MSIV En.' hNm!. Two 
Eo>' glycoprotein!, rdened to as S672·m and 87S9·m ..... ere produced and ill<:or· 
polrated into is(oms as pre\iOuIly deKrilxd (26). Bri~8)', p.!riphelal blood mOno-
nudear cdls (PBMC) .... ne demed from \\'00 Ihe,us ma,aque; sholll), after 
infation either with the 3211 i<olate of SIVm2c251 (Nol-emb<r 19S5 pool) 
(macaque 87&9) or .... ilh the nmc ,irus after il had undngQne an II·month in 
Inu pas,age (macaqu~ 8672) (19). ThQ SIV En\' genes .... ~r~ amplified from 
PB.\tC by PCR, and the putathe primary and ~cond.1)' cleavage ~ite~ Mre 
mutated by site-dir;xted mutagen(l;j. The\<! con,truc15 .... ere cloncd in p\;lsmid 
pSC6S (kindl)" pro-.'id(d b)' B. MO<5, Ikthe;da. Md.) under the control of a 
~)nthelk eaIlr·tate promQter. Recombinant ,,,,(dnia lirusc; (rVV,) were made 
by homologous le<:ombination .... ilh laccinia lirus (WR strain). rVVs ....-ere used 
10 infect baby hamster kidne}' cells. Twenty hQurs after inflXtion. c~l!s were 
haf\tlted, and the rW was inactr.ated ~)' paraform!!ldehyde (PFA) fi~atiQn. 
Sub<equently, the Em· glY17oploldn "ilS solubilized from the cell membrane b)' 
using ROl<!nbuch·nfl5ide (lkchem, Bub<ndorf, S .... itzerhnd). purified by kntil· 
k.:tin chromatography. an.:! eWntuall), incorporate.:! into rn:oms. The En>' pro-
Idn of feline immunodeticiency liru, (FlV) strain A.\119 (45) "'as produ<:\'d and 
in<:orporated into i>oorr.s fQtJOIling the S3.me proxedure. 
(tI) SI\'Gag isNffil. The C-terminal parI Qfpl1 and p27 of the SIVmac251 g~g 
gene....-as ncised frQm plilSmid pKA27 (kindl)' prmided b)' N. Almond and P. 
KitChin through the Medkal Rel<!ar,h CQuncil) and cloned ;ntQ the EcoRI and 
XN sites of plasmid p.\L\Lc (Ne ..... England BiQlab" Inc_, Bel'ell)" Mass.). As 
only h)"drophobk plOleins incorpotale dlkientl), into iscorru, a sequence coo-
t"ining 29 amino acids of the h}"rophobi~ part of the Iransmembrane sequence 
of HIV done 320 (2) (amino a.:-ids 633 10 111!WAGL\\'NWFSITmVLV.'YIKJ 
FIM1VGGLVG]) ",as amplified b)' PCR and cloned into the C termin\); of th~ 
p2Pg gene. Th~ resulting plilSmid, p"fAlc-Gagp27, e'pre~<es in Elcherichia c,xi 
a fUSion product of maltoli:--binding plOttin .... hich i, linked to SIV p21>""' b)' a 
foctol Xa cle3\-age ~ile. The fusion prQtein was fint Idealed from Mderi3 by 
sonication and S\lb~quentl)' purified frcom bacteri.1l proteins through affinity 
chromatQyaphy b)' aliOlloing its mlltQ~·b'nding protein pall tQ bind to an amy-
lme <:olumn. The p27<"~proteinwas released frQm the column b),in",balion....-ith 
12.5 "g of factor Xa (New England Biolab;) p.!r ml in Xa bulfer (20 mM 
TrtHIO (pH 1.41. 100",,1.1 NaG, 2 mM MgC1,) containingO_25% MEGA-HI, 10 
"g of cholesterot p.!r ml, 10 "g of phosphalid)leth.1!lQlamine per ml, and 2 I1g 
each of the o{ prQtease inhibilon aprotinin and 1eupeptin p.!r m1. The p2rg 
prouin "",1..\ finaJly<:o1!ected arul inrQrporated intQ ;s<:oms b)' a prOC<!dure similar 
to that descnlXd fQr the preparation of SIV En>' h<:orru. The amount of p2i"'g 
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pre,ent in ~ach L«om preplration .... as quantified by a commercial .1!ltigen cap-
ture enzyme-linked immunowrb<nt :l.<$.l)" (ELISA) (VironOII;l ... HlV Antigen 
Mklo.:lha S}~tem; Organon Teln",a BY, Bo~td, The Nethellands) according 
to the pr<x(dure recommended b)' the manufacturer. Recombinant p2r"J {kind· 
Iy pro\ided b)· I. JQnes, Ouord. United Kingdom) .... as used a .. a stand~rd plOlein 
for quantifi.:atiQn, 
(III) Nt! IJpo(>fptldes. Three Nd lipop.!ptides "er? ronl!ructed a('(ording to 
l<!quenc(s pre,jQusly found 10 con rain ClL epitQp.!s in SIVmac_infected ml· 
uque, {1;_ The fQI1<ming Nefp.!ptide lequences .... ere based on the 15 mQlecular 
clone of SIVmad2H (47): p.!ptide I (amino a.:-ids 103 \<) 123). LRTMSYK 
LAVD.\ISHFl; ~ptide 2 (aminQ adds ISS to 1(9), DWQD¥TSGPGlRYFK; 
p.!ptide 3 (aminQ acid, 1M to 178). GlRYPKTfGWLWKLV. The", ~p1ide, 
""-ele S}llthe,ized b)' standard Fmoc $Olid·ph~e methods (20). Itarting .... ith Rink 
amide relin. The N·tmnill~! I}~inewas coupled as Fm\X·l)~(Fmoc).After Fmoc 
deprote(tiQn, the N·termioal and the ,ide chain amino group of I}\ine "'ere 
palmito}l.lted Wilh palmitic anhrdride. T .... o serin" le;idues .... ere intwdu~ed 
b<\\'oeeo the N·termina! I)~ine and the Net p.!ptidc ,equen(e. 
Animals and ImmunlMtlon proto<ol (ue Table I). Thi, ,tud)· in.:luded mehe 
colony-bred juvenile cynomolgus macaques (.\f)(aca faiCicu./Jri5) b.:r....-e(n 1.5 
.1!ld 3.5 )ears old and "'dghing frQm 1.4 to 2.9 ~g at Ihe beginning of the ,tud}". 
All mon\..<}"5 .... ere l<!ronegatiw fQr Sl\', Iype 0 retrolirus, and ,imian T·I}m· 
pholrQpic \irus. )'lac~que> "'ere allocated 10 three group, of fQur monhj"5 each. 
including \\'00 male and \\'00 female mQnkey, and differenl MHC hlP~Ot}peS. 
Animlls .... ere immunile':! intramu'>Clllarl)" at "'eebO, 4. 10, and 16 "'ith eith« 20 
jIg of Sl\' Em· iscQm, (8672-m En" and 87S9·m En;" at JO "8 e~ch) (group A) 
or with 20 jIg ofStV Em· i>ooms and JO jIg ofp27,g ;S(0m5 in combination ",ilh 
the three Neflipop.!ptidel alll1g each (gm'Jp B)_ Four mQn\..e;slaccinaled ",ith 
reCQmbinanl FlV En,· iscorru l<!f\ed as wntrols (group C). 
SI\' challenge_ T"o w<eks after the founh immunization. monl.:e}~ "ere in· 
fccud intra>enously .... ith SO mon<ty 50<:1 infectious doses (MID~) of thc cell-
free March 1992 chl1!enge \l(xk (J5M) of SIVmu31H (pJS). a pathogenic 
mo!ewlar done demed from SIVmac3211 (Nmembu 19S5 pool) (47). The 
challenge It<xkdemed from thi, molecubr dQne had been prop'gated in Ihe,us 
macaque PB~tC and titrated in li\O b)' intraHnQ"S inocuhlion of lhelus rna· 
caques (47). On~ mon~ey (K2 (group AI! died during re(Ol'el)" frQm anelthelil 
on th~ da)' Qf challenge. 
rBMC IsolaUon_ Hepalinized blood samples "'ere <:o11e,«d al t'olo-, three-. N 
fQur· .... etl inlenall. PB~lC were isolated by demit)' gradient separation ",ilh a 
68,32 (Iol\,o!) \Clution ,omposed Qf 6~ dellran (Sigma. SI. loui" Mol,) in 
dislilled "'aIel and 32.8f< SC<!ium metrizolte (N}romed. 0,10. Nor....-ay)_ Plasm, 
samples "'ele n}opre~f\ed until ul<!d. PB"lC "ele used immediately or stored 
at -nYC unlil u,,;:d 
QUAnUtlcalloo of SlY Enhsp«ifi, !~rum aotibodlH b)' [US.\. l'inelpi~· 
"'ell phtes (CQ<tar. Cambridge. Mass.) <:oated "ilh <:oncanl,.iin A (Phamll,ia 
lKB. Upp>ala, S".den) ....-ere inrubated "ith 50 "I of !()(}.ng,'mllenti!·k(\in-
purified En~ derhed from SIVmad2H·infecled C8166 cdls (19) in phosphlte· 
buffered saline (PBS) conUinjng I~ Triton X·loo. Virus-derhed S1Vmld2H 
"'a, u>ed as immobilized antigen to confirm that Ihe Env·'p.!cific .1!ltit>..lditl 
dele,ted due immunizati<m .... ith vaccinia \irus·pr~xluced En\" gly.:oprotein r(c, 
ognized the natilt proleio_ Quantifi;:atiQn Qf SIV Em' .... a' perfolmed as pre'i-
Qu!l)' deKnlXd (16), Uninfected C8166 cells ....-er~ "",d as the negative (onlm!. 
After 16 h of incubation at rOOm temp.!ralu!( (RT), wells were bloch.:! "'ith PBS 
<:ontaining 0.1% T....-cen 20 and 10< bmine ~rum albumin (f'TB) lupplemented 
"'ith IW fela! calf '>I:rum (fCS) and 0.5'1- nonfat dry milk. SU~l<!quentiy. plate, 
\lere incubated for 2 h at RT .... irh 50 III Qf ",of old dilutiQns of plalma;n PTB 
wntaining 4<;"< FCS. After being ",.,hed. oound antLbod)"....-a, d(te,ted by uling 
a biQtin-conjugated go,t anti-human immunoglobulin preparation (Amershlm) 
and subsequentl)· incubated....- ith horseradish p.!ro';dase-conjugated wept'l idin 
(Amershlm). For subst .. t? reactions, 3,3',5,S'-letramHh)I·b.:rujdine ....-as uled 
(5). Endpoint titen "'ere cakulated b)'using a rutolf,alue three time> abol-e the 
re,pective dilution Qf the preimmune l<!rum at .1!l optkJI de",it)" at 450 lun. 
One-"a)" anal)~is of "ali.nce (Minitab, Inc_. State College, Pa.)....-as u~eJ to 
<:ompare anliliody titers bet"ecn groups. The I ... e\ of significance Ins P < 0_05. 
Quantititatlon of SlY Gag·sptdfit strum antibo<!its by Inhlbltlon EllS,.\.. 
Gag"pedfi~ antibody liters were measured in inhiliition EliSAs ....-ith biotin)"· 
hted poll)-donal antL<erum frQm an SIVm~c_infe~led monke}·. Ninet}··!i~·wdt 
plates (Costar) ,,~re (<}lted .... ilh 100 Ilt of a 1:200 dilution in PBS of sonicatcd 
bacterial culture of pMAl.c·Gagp27 containing aboul 10 j.lg of p27<" p.!r mt. 
After incubation 31 RT for 16 b. wells \\tIe in,ubated fQr 30 min ....-ith Pro 
<:ontaining 10% fCS and then (Qr60 min al RT "'ith 100 j.ll ofty,ofold d~utiom 
Qf mQnle)' plalma. Fifty micrQliters ""-:l.~ discalded frQm each" ell befQIC 50 jIl Qf 
biotin}'laled poll}donall<!rum in PTB containing 4~ FCS .... as added. This poly-
clonal scrum was deml!d from ~n StVmacBKl&.infected rhelus macaque (lindl)' 
prmidcd by J. Heeney, mo, Rijl\lijk, The Netherlands) and .... as sho .... n to haye 
a high liter Qf Gag,sp.!dfic antibodies b)' immunoblNting.lt ",as diluted to gile 
an abwrbance al an Qptical demity at 450 nm equal to 60% Qf th~ ma.-.:imum 
ab$Orblnce in a dire.:t SIV ELISA. After incubation {or 2 h at RT, ....-ells .... ere 
"'a,htd and incubated ",jth hOr<eradish p.!/O,jdas<:~njugated S\!cpt3lidin. For 
Substrate reactions, 3,3·'s's'·ttllameth)1--benzidincwa, used (5). Inhibition titers 
"'-ere defined a~ Ihe dilutiof15 Qf monkey plasma inhibiting 50':1 of the ablQr~ance 
at an optka! deruit)' at 450 om .... ithout the addition of plasma. 
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SI\' otulrnllzatf"o assay. The SIV D;:utralization "->';3Y us<:d in there experi-
ments "'as p.:rfmrned as prt"oiQl.lI1y d~scrib.:d ",ilb SIVrnad2H (19). Dri~Hy, 10 
III of S<'rial dilotiom of heal·inacm-ated S<'ra ... ere ilKUbmd in four lepl;';'at;: 
well; .... jlh 10 pi of SIVrnad2H diM.:d \0 gne 10 infe,tiou; particle, per 10 VI. 
After a 3O-min ilKUhat;on 31 37'C, 200 iiI of medium containing 2 x 10' CSIM 
~ells"asadded \0 each",;:IL Plates"'I" iocub3ted for 1 daysa! 37'C, after v.hkh 
the ,dl; from ;:a,h "dl .... 'I( Iramferred to polr·l-·I)~in;:-c<)aled Hal-bottom 
microliter pbte~ /ited in methanol, and e\.mined for the preS<I!(<: of SIVmac-
infected C\!lls b)' an SIV-,pedfic immunopuoxidMe may. Wells ronlaining 00 
infected celts "ere scored as positr.';:, aud Ih" numbu of poolln;: "dl> was u.<ed 
to rle(ennine the 50% neutralizing do,e endpoint for the rdatil'l! serum. Ea,b 
lime point was te,ted twke. The dilIer~n~> in titer> among th~ dilIerent groups 
at ea,h time point '..ere enJuated by Slud~nfs I telt. Tb~ thremold of ,ignlH· 
cane.: was P < 0,05. 
DitumlnaUon of frequeodts for CJL pr«unon (CfLp). (1) Pf~paraUon or 
antlgen·pRleDtloJ!: tdb. L)mphoblalloid B-ceillines (B·LCL) wu~ eltabli>h~d 
by th~ imubatioo of PB~{C wilh ""I"'rnatant from the 55'» ~1l1in~ producing 
herpe5'lirus papio (44) (kindly pM'ided by R. Bontrop, Rij"'Ul:, The Nether· 
lands). Aulok'go(l'l B·LCL \lere Infected for 18 h \I ith rVY e_'pre!.>;ng either Env (,un·m and ,S7S9·m) (26), pS5- (SIVrnac32H) (kindly prO\ided by A. Me· 
Mkhd, Oxford, United Kingdom), Or Nd (SIVmac32H done pIS) (47a) at a 
mu!tiplkity of infection of 10 and then fi~ed in 1.5% PFA. 
(ll) Um[lIng.dllut[oo ml<f1x\I[!ore,. Cryoprelerwd PBMC coHeeted on the 
do)' of challenge and at lIeek 9 or 12 pos({hlilenge Were tha"ed and !-eeded in 
parallel in serial dilutions ranging from4 x 10' to I x 11)3 in RPMll640(GlIxo, 
G3lthersburg, Md.) containing 100 IU of ""okillin per mI, 100 [.I.g of stlepto-
mycin ""r ml, 2 roM L·g1utamine,and 2 x 10-' M ~-mercaptoxth.ool (refe""d 
t(l as complete m~djum) ,upplemented "jth 10% h~at·inacti>-aled fetal bo;ine 
serum (Hydont" Laboratories, Logan, Utah)(referred to as R·IO). CU!IUles lIefe 
set up in 24 replicate wdll of !}6.",ell round-bouom plates in a final '-olume of 
100 [.1.1 per "'-ell. Autologous irradiated (2,500 I~ds) fuder PB!-lCwere added al 
10' ""r wei!' Responder celli were stimulated on days 0 and 7 of culture "llh 
autologoul IVV·lnfected B·LCL npreillng the approplille SIV protein at 10' 
I"'r well Recombin3nt interleukin·2 at 10 Ulml wal added to mkrocultul(S on 
d3Ys), 7, and 10. On day 14,cells fromu(h",ell "ere re>U\l"'nded and l\\-O 1(1.[.1.1 
aliquoll lI~re sneened for 01010-o..ity in splil·"ell CfL as.\3)"$ "ilh dther rV\' 
eWre\$ing one of Ihe SIV protd"., or control ",ild·t)p¢ , .. ;;cinh ,iruses (Copen. 
h'gen strain). 
The phenot)pe of the npande<l ceIl population "'<1.1 assessed on day 15 of 
rulture bj' 00\\' 010metry (fluoltlC<:ru:e·a,tr. .. ted ce!lwrler WACS] anal)~is) 
\'ollh Ouoreseein i50thiOC)anate-«lnjugated anti·Cm (Okt4: onho Diagnollics, 
Raritan, NJ.) and ph)"OOel)lhlin-conjugaled anti·CDS (1.<:u 2~: Be.:ton Dickio· 
ron, Etten·Uur, The Netherlands). 
(IU) C)toto\ldtJ- assay, C)10to";dty 1Ii11 measured in stand,rd S·h sodium 
chromate ("Cr) release assai"S. Autologo(l'l B-LCL infe(ud for 16 h at a mul· 
liplkityof infection of 10 lIith dther rW e'prelsing Olle of the SIV proteiM or 
control "i!d·type , .. ",in;3 \'iru~s (Copenhai:<o strain) lI~re u~d as tari:et cells. 
These ",ere labelled f(}r I h lIith 100 flCi of"Cr al37'Cio 5% CO2, wash~d thr~e times in complete medium, resuspend;:d in R·!O at lo5/mi, and added to 
eff«tol celli in 50 "I (5.00J cells po;:r lIell) in !}6.lIdl round·bottom plates 
(Cmlar). Aller a S·h incubation at 37'C in 5~ COl. sUl"'matanl> were han'(sted 
"jlh a Skaaon hane,!er {Shtron, ();lo, Norway), and the rdule of 'ICr was 
measured in a gamma counler. Matimum "Cr rd~ale wal di:termined by de· 
lergent (S<;t Triton X·lOO) I)~is of !argel c.:1I1. Sponlani'QtlS release \las deter· 
min~d by tbe \ru:ubation of target cells In R·!O alone. Mllimum "er re!ease and 
<ponlanWtlS re!ease ·,\tre 5o!1 up in 18 replkate well';. SpontaneOus release lIal 
<25~ of mallinum "Cr release in all as5a)"S. 
(hJ Cakulalton of CUp frequendu. fndr.idual 1Ie1ls \'oere ooo.lidered po>i· 
tr.-e "heo the uperimenlal release of spo;:d& I3rgell but conICol targm e~· 
ceeded spontaneous release by ) standard de,iatio"'l_ CI1.p frequencies wece 
estimated by Ibe m<thod described by Strijbosch (t al. (54). Frequeru:ics "ere 
normalized to the number of CI1.p per 10" plated cells. 
QUJoUfication of nl1·as,odat«l lirul load. Serial fivefold dilutions offre,hly 
iwlaled PBMC in R·l11laoging from I x 10" 10 1.6 x 11)3 "ere seeded in 
dupti>'ate wells in loe prese~e of) flg of oollcana,alin A pcl ml. PB!>IC wece 
cocuitured lIith the human T-ceJlline CSI66 at 105 c.:111 per mL Recombinant 
interkukin·2 was added on day 3 at !O Uim!. Cells were cultured for 6 "eel! at 
37'C in a humidified 5% COl inrubator. CUltures "ere refreshed fIIice a lIeek. 
SUl"'malants lIere assayed regularly for p27""'< by anligeo capture ELISA (Or· 
ganon Teknika). The number of Infected cdls lidS cakulated from the highe>t 
positive dIlution and (_~pres.sed as the number of infected c.:lls per 10" PBMC. 
The diff~reJl(es in the mean Hlue! ohirus load among th~ different groups al 
ea~h time point were evaluated by Studen!"s t test. The threshold of lignifi,aru:e 
11"-\ p < 0.05. 
RESULTS 
Antibody responses Induced by the candidate SIV subunll 
,·accines, (I) SIV En\"-Speclfic serum antibodies, Monkeys were 
immunized intramuscularly with the different vaccine prepara· 
tions at weeks 0, 4, 10, and 16 as outlined in Table I. The first 
TABLE l. Immllnization schedule for qnomolglls macaques 
Group Monkt)'S TmmunogenS"' [.I.g..'dole 
A 769, K70, K81, K2 SlY Env isoom 8672-m 10 
SlY Env iscom 8789·m 10 
B K77, K80, K83, K88 SlY Env isoom 8672-m 10 
SlY Env iscom 8789·m 10 
SlY p27"E iscoms 10 
Ncr lipopeptide 108-123 1.0 
(LRTMSYKlA VDMSH) 
Ncf lipopeptide 155-169 1.0 
(DWQDYTSGPGIRYPK) 
Nef lipopeptide 16--t-178 1.0 
(GlRYPKTGWLWKLV) 
C K66, K7I, K73, K79 FlY Env iscoms 10 
UMonke}"l lIere immuniud intramuscularly at \le~k5 0, 4, 10, and 16 30d 
<halJenged intravenously at "'ak 18 \'oilh 50 MID!<) of the 15 molecular clooe of 
SIVmad2H. 
immunization induced Env.specific antibodies in three mono 
keys from group A and two monkeys from group B (Fig. IA). 
The responses in all monkeys increased after the second and 
third immunizations but declined rapidly after each booster 
injection. After the fourth immunization, antibody titers re-
turned to approximately the same levels as those reached after 
the third immunization, that is, at levels similar to those found 
after experimental infection. Em'·specific antibody titers did 
not differ significantly between monkeys from groups A and B. 
No SlY Env-specific antibodies were found in the monkeys 
from control group C before challenge. 
(II) SIV Gag·specil1c serum antibodies, p27"~g·specific anti· 
body levels were measured in Mo monkeys from group B after 
the first immunization and in all monkeys from group B after 
the second immunization (Fig. lB). Titers increased after the 
second and third immunizations but declined rapidly after each 
booster injection. Mter the fourth immunization, antibody ti· 
ters reached levels similar to those measured after the third 
immunization. No p27""g'specific serum antibodies were found 
before challenge in monkeys from groups A and C. 
(ill) VN serum antibodies, All monkeys from groups A and 
B developed VN antibodies to SIYmac32H upon immuniza-
tion (Fig. IC). These VN antibody titers were similar to or 
exceeded those observed after experimental SIVmac infection. 
VN antibody titers did not differ significantly bern·een monkeys 
from groups A and B. In monkeys from control group C, no 
VN antibodies were found before challenge, 
CfLp frequencies on the day of challenge, The abilities of 
candidate SlY subunit vaccines to induce SlY-specific CfLp 
were studied by limiting·dilution analyses of PBMC collected 
on the day of challenge (Table 2). The CfLp frequencies of 
replicate experiments fell consistently within the same range, 
"'ith largely overlapping 95% confidence intervals. More spe· 
cifically, the coefficient of variation for 12 replicate experi· 
ments of both En\,- and Gag-specific CTL responses showed a 
mean of 8.1%, Relatively high levels of CfLp specific for Env, 
Gag, and Nef were detected in PBMC from group B monkeys 
K80 and K83, ranging from 7 to 105J10~ PBMC. The highest 
CfLp frequencies were found for Env (105 and 25/10" PBMC, 
respectively). These responses were dearly vaccine induced 
since no specific CfLp .... -ere detected in PBMC collected from 
these monkeys before immunization. The other tv .. o monkeys 
in group B, K77 and K88, showed CTLp against tv.'o of the 
three proteins (K77, Gag· and Nef-specific CfLp; macaque 
K88, Env- and Gag·specific Cfip), albeit at lower b'els (2 to 
15/10" PBMC), In the monkeys from group A, only macaque 
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group A (anv) group B (anv/gag/nef) group C (control) 
S 
§lQ24 
c. 
6 12 18 24 30 36 42 0 6 12 18 24 30 36 42 o 6 12 18 24 30 36 42 
weeks post primary immunization 
frO. 1. Pre· and postchaHenge SIV-~]X-dfi, antibody relpooscs in group A, B, and C mQnl«)~. (A) SlY EnNpcdfic $erum antibodies, a~ determined b)' indire~t 
ELISA ..-jlh SIVmac)2!1-<krhed Env as imrnOOlliud antigen. (B) SlY Gag·s~i~c antibodies, as d~twnined by inhibition EUSA. Bacterial p2r<-'g w3..I Uled as 
immobilized antigen. BiOlin)1ated poO'donal serum of an SIVmac-infeded monkq was U\.ed (Of inhibition. (C) SIVmac32H VN antiOOdy f¢\pon~l. Serial dilutions 
of monkey plasma w~r~ in(Ubated ",ilh SIVmac.3211 and added 10 C8IM c.:lls. The nUffiNfof negatr'-e 'ilellswas u\.ed \0 dtlermine the 50% neutraUzingdos.e endjXIinl 
titer for the rdalke phsma. The wed.:, of tmmunilatk'nl ale indkated by small allo""s. The day of cha1i(nge i$ indicated by a large am"'·. Group A monkeYI (Env 
immuniud): +,169; 0, K70; +, K81; x, Kl. Group B monkep (En ... ·G.g·Nd immunized): 6., K17; V, K8O; T, K8J;"", K&3. Group C mon\;:e}"S (conllol): O. K66; B. 
K7I;., K73; D, K79. Monkey Kl (group A) died during reco,-e'Y from anmhc,ia on the oJlY of chalknge. 
769 exhibited low levels of Env-specific CTLp (IIHf' PBMC), 
To investigate whether the CTL responses found were MIlC 
restricted, cells expanded by Envospecific stimulation of PBMC 
from monkey K80 were tested against autologous and MHC 
class I-mismatched rW Env-infected larget cells. Lysis of the 
autologous target cells but not of the MHC class {-mismatched 
target cells was detected, indicating that the CTL responses 
induced were indeed predominantly MHC class I restricted 
(data not sho'.'.TI). In addition, with cells from the same mon-
key, FACS ana~'Sis was performed on day 15 with cultures 
exhibiting Env-specific CTLp activity. The majority of ex-
panded cells proved to be of the CD8+ phenotype (CD8+, 
69%; CD4+, 17%). 
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SIV-speclfic serum antibodies after challenge. Env-specific 
antibody titers decreased during the first 2 weeks after chal-
lenge in the monkers from groups A and B but showed an 
anamnestic response that peaked at week 4 or 6 postchallenge 
(Fig. tAl. Env-specific antibodies were also detected in the 
monke)'S from control group C, starting at week 4 or 6 after 
infection and increasing gradually afterwards. In all three 
groups of monkeys, Env-specific antibody titers eventually 
reached a plateau at about the same level. VN antibody de-
velopment in the monkers from groups A and B also showed 
an anamnestic response (Fig. IC)_ In the monkeys from group 
C, VN antibodies were induced following infection. With the 
exception of monkey K88, in all of the monkeys from group B, 
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TABLE 2 Pre- and post~hallenge En .. -, Gag-, and Ncf-specific Cllp rrequencieS" 
FI~qucfl,.l' (Cflp/W" PB!>lq' 
Group Macaque Day of challenge WI; 9 or 11 PQ\tchJlIenge 
Env G.g Nef Em' G., Nd 
A 769 1(0--3) NO NO 8 (4-12) 2 (0--3) 0 
K70 0 NO NO 3 (1-5) 1(1-2) 0 
"'I 0 NO NO i3 (8-17) 10(6-14) 0 
D K77 0 2 (0--5) 4 (0--10) 8 (0--16) 5 (0-10) \7(\0--24) 
KSO 105 (80--130) 10 (5-15) 7 (3--11) 110 (96-1S1) IS (9-20) 63 (49-76) 
K83 25 (16--34) 13 (4-22) 11 (5-17) 8 (4--12) 11 (6-16) 10 (4--16) 
K8S 15 (4-26) 3 (0--8) 0 95 (74-116) \9(1-30) 2 (0--6) 
"Effe;;tor ,.;IIi "ere obtain:d by sp<.'cific stimulation "jlh PFA·lhed autologous B·leL infected \'oilh IV\, e>prelling the respect;".:: SIV protein in Ihe presen,;: of 
reoombimnt interleukin_2. SpliH,ell.lJCr releaS<' a~\a)~ "'ere p<.'rfonned On day 14 of <:uhure. Specific l)tNo'l1cily "as "s"'jed \\ilb autologous IJ.LCL infected "ilb 
dther rVV e'pre»iog Inc SIV protein UDder inw\tigatiO;ln or wild_l)pe eontro! ncc;oia ~iru\_ Dlla lrum limiting.<JilutiM a.\\3)'S "ere aD~lyzed" iln ma~imum liJ.:dihood 
and minimum ch.j·lqulre method.<. 
b Em·., Gag., and Nef·specific Cflp frequencies were also me'llUred in Ihe PB~fC of K80, K83, and K8S (Env onl)) Nfore immunization, and no CUp "ere 
dete.:ted. The 95% ronfidence inter..-als are in r3lenlneses. /'.'0, nOI done. 
p2r:ag-specific plasma antibody titers declined 2 weeks after 
challenge but showed an anamneslic response that peaked at 
week 4 poslchallenge (Fig. IB). p27'"as_specific antibody reo 
sponses were also induced afler challenge in the monkeys from 
groups A and C. 
SIV-speclfic CH.p frequencies after challenge. The frequen-
cies of CfLp spccific for Env, Gag, and Nefwere measured at 
week 9 or 12 postchallenge in PBMC from group A and B 
monkeys (Table 2). Postchallenge CfLp measurements were 
carried out in parallel with those of prechallenge CfLp under 
identical culture and assay conditions. In monkey K80 (group 
B), the frequencies of En\,- and Gag-specific CfLp were sim-
ilar to those detected on the day of challenge, whereas the 
frequency of Nef-specific CfLp showed a marked increase_ In 
monkey K83 (group B), the frequencies of Gag- and Ner-
specific CfLp were similar to those measured on the day of 
challenge, whereas the frequency of Em'-specific CfLp 
showed a slight decrease_ Monkey K88 (group B) showed an 
increase in bolh En\,· and Gag-specific CfLp after challenge 
and the induction of relatively low le\'els of Nef-specific Cflp. 
In monkey K77 (group B), Env-specific CfLp were induced 
after challenge. in the same monkey, Gag- and Nef'specific 
CfLp were detected, wilh a marked increase in the latter. 
A 
, R~ II 
, 
• • " " • 
Env-specific CfLp were detected in all of the monkeys from 
group A after challenge, In the same group, Gag-specific crLp 
were detected at relatively low (monkeys 769 and K70) or high 
(monkey K8l) frequencies. No Nef-specific CfLp were dem-
onstrated in any monkey from group A. 
Ceil-associated ,·irus loads, After challenge \\ith 50 MIDsO] 
of the J5 molecular clone of SIVmac32H, all animals became 
infected, as illustrated by repeated isolalion of SIV from their 
PBMC (Fig. 2). SIV was isolated from all monkeys at week 2 
postehallenge. Longitudinal evaluation of cell-associated virus 
loads showed that the number of SIV-infected cells in circula-
tion fluctuated over time, with a peak at 2 or 4 weeks after 
challenge_ FUrthermore, \irus loads differed considerably 
\\1thin and among the groups. The mean value of '1ruS load for 
the monkeys from conlrol group C was consistently higher than 
that for the vaccinated groups, with Ihe exception of the values 
at week 12_ However, Ihe differences in virus loads did not 
reach statistical significance. 
DISCUSSION 
In this paper, we ha,-e shown that SIV subunit vaccines 
consisting of En\' glycoproteins incorporated into iscoms either 
, 
B C 
, 
, 
J 
········rrffi· 
, 
" 
• 
" " 
, 
• " " wo;(!k$ post chai!enge weeks postchaHenge weeks post challenge 
FIG. 2. CeU·assodated ,iru,loadi in the PB!.ICofSIV·'-acdnated (groupiA [A] and B JB]) and control (groupCICj) monke}'S during a 12·WNk foU(l";\··up period. 
Scrl.1.l fivefold dtlul10lls of PBMC rMging from 10' to %0 for wuk 2 poitchillenge and f10m I(}' to 1,600 for aU other lime points "-ere incub~ted "'ith <:8166 cells 
(016 weeb. The num""r ofinf;xted ulls per 10' PBMCwa.\ c.1.lcuhted from Ihe hjghe~1 dilution that ""liS po>ith-e in a p2i<'~ antigen caplure EliSA. Group A (Em) 
monk~'S: _. 769; «», Kll}, 12:::2\ KSI. Group B (Env·Glg·Nd) monk~'S: [;2], K77; _, K80; c:::J. K83; .... KB8. Group C (control) monke)"s:tzJ, K66;CXJ, 
K71; ~ K13; E'3, K79. 
37 
Chapter 2 
alone or in combination with p2-,s~g iscoms and Ner Jipopep-
tides failed to generate protection against intravenous SIVmac 
challenge. despite the induction of VN antibodies and CfL 
responses. 
The two Env glycoproteins used for immunization, S789'm 
and 8672-m, shared 98.6 and 97.0% amino acid sequence ho-
mology, respectively, with the En\' protein of the J5 molecular 
done of SIVrnac32H used for challenge (26). Because most of 
the VN antibodies detected in sera from infected monkeys 
recognize conformational epitapes (28), it is considered im-
porlant that recombinant Env proteins arc presented to the 
immune system in a form that most closety resembles the 
native conformation. In fact, using a panel of 15 monoclonal 
antibodies recognizing both conformational and linear 
epitopes, we have recently ShO ..... 11 that the antigenicity of the 
recombinant Env proteins used in this study is similar to that of 
virus·deri\·ed Env protein (26). Furthermore, we found here 
that the VN antibody titers induced by the hvo recombinant 
Env proteins incorporatcd into iscoms in group A and B mon-
keys were similar to or exceeded those found afler experimen-
tal SIYmac infection. 
VN antibodies were measured v.ith the 32H strain of SlY· 
mac cultured in CBi66 cells. It has previously been shown that 
antibodies which neutralize SIYm-ac32H also efficiently neu· 
tralize the 15 molecular done derh'ed from this virus (Ha). 
The YN antibody titers on the day of challenge did not show 
inverse correlations with the le\'els of virus load measured after 
challenge. This is in agreement with pre\ious studies carried 
out with the SlY macaque model, which failed to demonstrate 
a correlation between VN antibody titers and resistance to 
experimental SIV infection (13, 18, 24, 40). It should be 
pointed out, however, that in all of these studies, VN assays 
were based on the neutralization of virus propagated in T-cel! 
lines. There are clear indications that the neutralization of 
HIV and FIV propagated in susceptible cell lines is more easily 
accomplished than neutralization of virus propagated on pri· 
mary l}mphocyte cultures (4, 48, 52). In light of these obser-
vations, one may speculate that the biological significance of 
the VN antibodies measured in our vaccinated monkeys is 
limited. The development of YN assays with monkey PBMC 
and non·cell·line.adapted SIV might help to demonstrate bi-
ologically more significant antibodies. 
The method we used for the determination of CfLp fre-
quencies was established in studies carried out \\ith HIV-I-
infected individuals (21, 33, 56) as well as SIVmac-infected 
monkeys (20a). The frequencies of SIV Env·, Gag-, and Nef· 
specific CTLp were measured in parallel assays of PBMC from 
the day of challenge and from week 9 or 12 postchallenge. 
Replicate experiments showed good reproducibility of crLp 
frequency estimates. 
The use of both iscoms and lipopeptides proved to be effec· 
tive in inducing SlY-specific CfL responses in the monkeys 
hom group B. As can be expected for analysis of an outbred 
population of monkeys, the frequencies of SIV-specific crlp 
differed considerably among similarly immunized monkeys. 
The highest crLp frequencies were those for the Env protein 
and appeared to be similar to those previously observed for 
SIVmac251-infected macaques (58). The vaccine·induced 
Gag- and Nef·specific CfLp frequencies were lower but com· 
parable to those found by Yasutomi et al. in both vaccinated 
and SIVmac-infected macaques (60). 
To achieve in vitro ex-pansion of SIV·specific CfLp, autol· 
ogous B·lCL infected with rVV expressing the respectiw SIV 
proteins and fixed in PFA were used for specific antigen stim· 
ulation. This protocol has previously been shown to selectively 
expand MHC class I-restricted CDS"" crL against the Gag 
38 
protein of HIY-I (56). The same approach has now also 
proyed to selectively ex-pand MHC cla~s I·restricted CD8+ 
crL against SIV antigens (20a). In agreement with previous 
findings, the Env-specific cytotoxic response of monkey K80, 
which showed the highest frequency after vaccination, ap· 
peared to be predominantly directed against autologous tar· 
gets but not MIlC class I·mismatched targets, suggesting that 
the killing was mediated by MHC class I·restricted crL rather 
than by NK cells (46). In addition, in the same monkey the 
majority of cells expanded by Em'·specific antigen stimulation 
showed a CDS+ phenol)pe. To our knowledge, this is the first 
demonstration of the induction of crl responses in primates 
with antigens incorporated into iscoms. 
In the monkeys from group A (immunized \\ith Env iscoms 
alone), only one showed low· level Em',specific crLp reo 
sponses on the day of challenge. Howeyer, the ability of these 
monkeys to mount a crL response against the Env protein was 
demonstrated by the detection of Env·specific CTLp after 
challenge. Although the number of monkeys in group A is too 
small to allow dra\\ing any further conclusions, it may be spec-
ulated that in the monkeys from group B, simultaneous immu· 
nization \\ith different SIV antigens may haye improved the 
induction of Em··specific en., for example, by a mechanism of 
increased virus-specific T-helper·cell activity (49). 
After challenge, an increase in SlY-specific crlp was ob· 
served in some cases. This variability is in line with observa· 
tions that the frequencies and kinetics vary considerably 
among infected monkeys (20a). This observation, also made 
for HIV-l-infected individuals (33), may reflect various de· 
grees of homogeneity of crL populations induced by \·accina· 
tion or infection (11, 32, 38), 
Upon immunization with the three Nef lipopeptides, Nef· 
specific CTLp were found in three of four monkeys. These 
monkeys had not been selected on the basis of their MHC 
haplotypes. Similarly, Bourgault et al. (6) noted that 6 of 12 
unselected macaques showed crL responses after immuniza· 
tion .... ith a set of peptides also derived from the central region 
of Nef. This indicates that this region, like the corresponding 
region of mV·l Nef (14, IS), is recognizcd by crL in the 
context of a range of different MHC class I haplotypes, stress· 
ing its potential for vaccine de\'elopment purposes. 
Nef has previously been shown to be an efficient crL target 
in SIV-infected macaques; 8 of 12 monkeys displayed Nef-
specific crL responses (58). In our study, a similar number 
(four ofse\'en monkeys) was found to display Nef-specific crL 
acth'ily afler infection, Interestingly, no Nef·specific CfLp 
were detected at 12 weeks postchallenge in the monkeys from 
group A, whereas in the monkeys from group B (which had 
been immunized v.ith the Nef lipopeptides), Nef·specific crlp 
frequencies were either highly increased (K77 and KSO), main· 
tained (K83), or induced (K88) followJ'ng infection. This find-
ing allows speculation of a priming effect exerted by immuni· 
zation with the three Nef Jipopeptides in the monkeys from 
group B. 
In SIV·infected monkeys, the presence of SIV-specific crL 
has been shown to correlate with a better clinical outcome of 
infection, suggesting that vaccine· induced crl contribute tll 
protecti\'e immunity (8, 5S). In one of our previous vaccine 
studies, four of eight monkeys appeared to be protected from 
challenge with cell·associated SIVmac (19). MHC class I·as-
sociated protection was obselyed; all of the animals protected 
against cell·associated virus challenge shared the MHC class I 
allele Mamu-A26 with the monkey cells used for challenge 
(24). This suggested that virus·specific CfLdirectly recognized 
the SIY·infected donor cells in an ~mC-restricted manner, In 
this light, it is interesting that SlY-vaccinated Mamu·A26·pos· 
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Hive monkeys, like the monkeys in this study, were nol pro-
tected from challenge with cell· free, monkey-cell-gro\\n SIV-
mac. In agreement .... ilh our observations, Yasutomi et al. have 
recently shown that a vaccine-elicited crL response specific 
for a single viral epilope does not protect macaques from 
SIVmne challenge (60). They proposed the presence of crL 
.... ith only one specificity and the absence of VN antibodies as 
an explanation for the lack of protection. In this study, how-
ever, vaccine-induced VN antibodies and CfLp specific for 
one regulatory and 1"'.0 structural proteins apparently did not 
protect monkeys from ex-perimental SIVmac infection. If CfL 
responses do playa significant role in mediating protection 
against SlY infection, it may be argued Ihal CfLp frequencies 
should reach very high le\'els to exert a protective effect. On 
the other hand, CTL responses may have a beneficial effect on 
the course of infection despite their inability to clear SIV 
infection. In fact. although all monkeys were still clinically 
heahhy I year after challenge. preliminary data suggest that 
the absence of CfLp early in infection may indeed correlate 
v.ilh a more rapid decrease in total CD4 counts later in infec· 
tion. 
An evaluation of the kinetics of cell·associated virus loads 
showed no significant differences among the respecth'e groups 
of monkeys during a 12·week follow·up period. Indeed, we 
found Ihalthe virus loads fluctuated considerably O\'er time. In 
fact. a higher mean virus load was measured in the pnMC of 
control monkeys than in those of the monkeys from groups A 
and B, especially at week 6 postchallenge. However. the op· 
posite was true at week 12 postchallenge. This indicates that 
kinetic studies rather than measurements at one time point are 
required when virus loads are considered as a parameter for 
protection. 
Taken together, our resuhs show that candidate SIV subunit 
vaccines based on iscoms and lipopeptides efficiently induced 
specific VN antibodies and CfLp. However, the presence of 
VN antibodies and CfLp specific for multiple SlY proteins on 
the day of challenge proved to be insufficient to protect mono 
keys from intravenous SIVmac challenge. These findings indio 
cate that the type of immunity needed to prevent infection may 
be quite different from that thought to control persistent in· 
feclion with primate lentiviruses. 
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SUMMARY 
Chimeric simian-human immunodeficiency viruses (SHIVs) used as challenge viruses 
in macaques provide a new tool for testing the protective potential of candidate HIV-l 
vaccines. Here, four cynomolgus macaques were immunized with iscoms containing recombi-
nant envelope glycoproteins (En\') derived from either a syncytium inducing or a 11011-
syncytium inducing HIV-l primary isolate from the same patient. After four immunizations, 
the vaccinated animals and two control monkeys were challenged intravenously with 
SHIV"" ... l' carrying an HIV-I Env also derived from this patient. On the day of challenge, 
HIV-I V3-loop and CD4 binding domain specific antibodies were detected. In addition, 
SHIV :WI3.1 neutralizing antibodies and HIV -1 Env specific cytotoxic T lymphocyte precursors 
(CTLp) were demonstrated in all immunized monkeys. After SHIV"" ... , challenge, levels of 
virus replication were low, as virus could be recovered from only one of the two control 
monkeys during 13 weeks of follow up. Nevertheless, both control monkeys developed 
SHIV,:no,J.l specific antibodies and CTLp. Absence of SHIV nO.3.l specific antibody responses 
and of both culturable and PCR detectable virus suggested that three of the four vaccinated 
macaques were protected from challenge. However, the demonstration of CTLp against 
multiple SHIV.u(u.l antigens, including the non-structural proteins Rev and Tat, indicated that 
also in these three animals replication of the challenge virus had not been prevented. Although 
HIV-l Env-based vaccination strategies may be effective in limiting virus replication, they 
appear to be unable to induce sterile immunity against intravenous infection. 
INTRODUCTION 
One of the major obstacles in the development of a vaccine against HIV-l has been 
the lack ofa suitable animal model for HIV-I infection that would allow the screening of the 
protective potential of candidate HIV-I vaccines. Although chimpanzees, gibbons, pig tailed 
macaques and human-mouse chimeric animals have all been infected successfully with HIV -I, 
the use of these models is hampered by major drawbacks including limited availability, ethical 
concerns, and limited HIV-I pathogenicity (for review see Heeney, 1996). The construction 
of SHIVs, which carry HIV-I Env and replicate in macaques, offers the unique opportunity 
to test the potential of HIV-I Env-based vaccines in macaques (Li et aI., 1995; Dunn et aI., 
1996; Joag et aI., 1996; Luciw et aI., 1995; Reimann et aI., 1996; Igarashi et aI., 1994; Ranjbar 
et aI., 1997). 
Virtually all HIV-I Env-based vaccine formulations tested so far used envelope 
glycoproteins derived from T celi line adapted HIV-I isolates (Johnston, 1996). These are 
known to differ in primary sequence, structure and biological properties from viruses isolated 
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directly from peripheral blood mononuclear cells (PBMC) (McKeating, 1996). With respect 
to vaccine development, the most significant difference is probably the relative resistance of 
primary HlV-1 isolates to antibody-mediated virus neutralization (VN) (Moore ef al., 1995; 
Poignard ef al., 1996). Based on their replication characteristics and cellular host range, 
primary HIV -I isolates can be divided into non syncytium inducing (NSI) - usually 
macrophage tropic - variants, and syncytium inducing (SI) - usually T cell line tropic -
variants. NSI and SI strains have been shown to differ in cellular co~receptor usage, sequences 
of the VN inducing variable regions V2 and V3, and the level of conservation within V3 
(D'Souza & Harden, 1996; Groenink ef al., 1993; Bosch ef al., 1994; De Jong ef al., 1992b; 
Fouchier ef al., 1992; De Jong ef al., 1992a; Simmonds ef al., 1991; Kuiken ef aI., 1992; 
Groenink ef al., 1991; Chesebro ef al., 1992). Furthermore, NSI strains have been found to 
predominate in the asymptomatic stage of infection, whereas a predominance of SI strains is 
observed in about 50% of HIV -I infected individuals progressing to AIDS (Koot ef al., 1992; 
Zhu ef al., 1993; Zhang ef al., 1993). These progressive changes in phenotype and tropism 
indicate the existence of structural differences in antigenic determinants and mechanisms of 
escape from VN antibodies, which -may have major implications for vaccine development. 
In a previous study we tested the ability of SIV-Env vaccines to protect macaques 
against intravenous SIVm" challenge (Hulskotte ef al., 1995a). Although no protection was 
observed, the view that SIV specific CIL immunity may have contributed to the rapid control 
of virus replication in at least some of the animals studied remains an attractive and plausible 
hypothesis (Hulskotte ef al., 1995a; A.M. Geretti 1997, unpublished). As SlY-En v differs in 
several structural, biological, and immunologic properties from HIV-I Env (Burns & 
Desrosiers, 1994). we designed a study in which cynomolgus macaques were immunized with 
different HIV-I Bnvs before challenge with SHIV. To investigate potential differences in the 
immunogenicity of SI and NSI derived envelope glycoproteins, two groups of monkeys were 
immunized with Bnvs derived from either an NSI or an SI HIV-I biological clone, both 
originated from PBMC of the same seropositive individual. The antigens were presented in 
iscollls to allow efficient induction of both VN antibody and Cli responses (Rimmelzwaan 
& Osterhaus, 1995). The macaques were subsequently challenged with a molecularly cloned 
SHIV (Ranjbar ef al., 1997), carrying the envelope glycoprotein of an HIV -I molecular clone 
derived from the same seropositive individual. 
MATERIALS AND METHODS 
Generation and characterization of HIV -1 Env iscoms. (i) Construction of recombinant 
vaccinia viruses (rVV). Env genes of two HIV -I biological clones 320.2a5 and 320.2a6, isolated 
directly from PBMC of an asymptomatic HIV -I infected individual (#320) from the Amsterdam cohort 
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or homosexual men (de wolr cf al., 1987) were used as starting material (Andeweg ef al., 1992). The 
two Env display 86.1% amino acid sequence identity. 320.2a5 but not 320.2a.6 displays syncytium-
inducing (SI) capacity (Groenink ef al., 1991; Andeweg ef al., 1992); they are rurther rererred to as 
320.S1 and 320.NSI, respectively. To facilitate incorporation of the hydrophillic outcrmembrane gp 120 
part into iscoms (Rimmelzwaan et al., 1994), amino acid substitutions were introduced into the cleavage 
site by site-directed mutagenesis (5J8K-N. 520R-T, S27R-S), RVV expressing the cleavage site mutated 
Env were designated v320.S1 and v320.NSI respectively. Expression of full-length Env precursor was 
verified by western blot analysis. 
(ii) Preparation ofHIY-l Env iscoms, HlY-1 320.S[-Env and 320.NSI-Env, derived rrom 
rVV v320.S1 and v320.NSI respectively. and control Env of feline inununodeficiency virus (FIV) strain 
AMI9 (Rimmel.zwaan e/ al., 1994), were produced and incorporated into iscoms using a method 
described previously (Hulskotte el af., 1995b) with minor modifications. Brieny. 22 h after rVV 
infection of BHK21 cells, cells were harvested and inactivated in 1.5% para formaldehyde (PFA) for 15 
min (Hulskotte et at., 1997). Env proteins were solubilized from the cell membrane using 4% n-Octyl-P-
d-glycopyranoside (Sigma, Zwijndrecht, The Netherlands). purified by lentil-lectin chromatography, and 
incorporated into iscoms consisting of purified Quil-A components (lscoprcp 703R; Iscotec, LuJea. 
Sweden). Formation of iscom particles was confirmed by electron microscopy. 
(iii) Quantification of HIV~l Env in iscoms. Quantification of HIV -Env was carried out by 
an ELISA based on a previously described protocol (HuJskotte el at., J995b). Recombinant HIV - J IIIB 
gp 160 (rgpI60; Cat.No. 24001 ABT, USA) was uscd as a standard. 
(iv) Characterization of HIV~l Env preparations by ELISA. Antibodies and envelope 
giycoproteills. The human monoclonal antibodies (HuMabs) used included: CD4bd specific HuMabs 
GP68 (Schutten ef al., 1993) and [gGI-B[2 (Burton ef al., 1994), HlY-1 V3 specinc HuMabs 257-D 
(Gorny ef al., 1993) and 391195D (Gorny ef al., [993), IAM-2G [2 which recognizes a conformational 
sensitive gp 120 epitope unrelated to the V I, V2, or V3 loop or to the CD4-binding site (Trkola et at., 
1996), and IAM-2F5 which is specific for a relatively conserved epitope on gp41 (ELDKWAS) (Muster 
et al., 1993). ELISA The procedures followed the protocol described above using 300 ng/ml of the HIV-
I Bnv under investigation or a control lysate of BHK21 cells infected with wild-type vaccinia virus in 
PBS containing 0.1 % n-Octyl-P-d-glycopyranoside and serial two-fold dilutions of the HuMabs. The 
HuMab concentration giving 50% of the maximum optical density at 450 nm (OD.un) obtained for that 
HuMoab was taken as a relative measure for affinity. Differences obtained with the same monoclanal 
antibody (Mab) on different HIV -I Env preparations were considered significant if more than 3 times 
difference in relative affinity was observed. 
Animals and immunization procedure. This study included six colony-bred juvenile 
cynomolgus macaques (Macacafasicularis) seronegative for SIV, type 0 retrovirus, and simian T-
Iymphotropic virus. Macaques were allocated randomly to three groups of two monkeys each. Animals 
were immunized intramuscularly at weeks 0 and 4 with 10 J.lg and at weeks 10 and 18 with 20 ~Ig of 
HIV-I Env iscoms (320.NS[-Env; monkeys K9 and #135, 320.S[-Env; monkeys #K84 and #[44) or 
control FIV Env iscom preparations (monkeys #127 and #106). 
SHIY,wu,l. challenge. Two weeks after the fourth immunization, the monkeys were infected 
intravenously with 1500 TCIDs(J of the cell-free 2/95 pool of SHI~20.~.1 (kindly supplied by Drs. N. 
Almond and S. Jones, Potters Bar, United Kingdom), which is constructed and referred to as SHIV,,61O 
by Ranjbar ef al. (1997). The challenge stock had been propagated on CEMXI74 cells. The HIY-I 
envelope used to generate this SHIV was derived from another clone (320.3.1) of the same HIV-l 
seropositive individual #320 from whom the Env used for immunization were derived (Groenink et al., 
1991). The SHIVnll.3,l-Env displays 81.7% and 97.5% amino acid sequence identity with the outer 
membrane part of the 320.NSI- and 320.SJ-Env used for inmmnization, respectively. HIV-l;uu.l.l exhibits 
an SI phenotype and tropism for both macrophages and T cell lines (Groen ink e/ at., 1991). 
Serology. (i) Binding of monkey sera to different HIY·l Envs. Serum reactivity with 
different HIV-I-Envs was assayed using an ELISA based on an assay developed by Moore & Jarrett 
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(1988). Wells coated with capttJre antibody D7324 (Aaito BioReagents, Dublin, Ireland) were blocked 
for 45 min with 0.1 M Tris pH 7.5/0.1 M Nael containing 0.1% Tween~20, 0. I % Triton X-100, 2% 
normal sheep serum, 2% FBS (referred to as E-buffcr) supplemented with 10% sonicated lysate of 
monkey herpes virus papio transformed B-ccll lines (4.107 cells/rnl; HP-Iysate), and subsequently 
incubated with 300 nglml of HIV-Env or a control lysate of BHK21 cells infected with wild-type 
vaccinia virus in E-buffer containing 4% HP-Iysate for 2 h at 37°c' RVV expressing the following HIV-
I Env were used: 320.NSI and 320.S1 (derived of biological clone 320.2a.6 and 320.2a.5 respectively 
(Andeweg el al., 1992)), 168.NSI and 168.S1 (kindly provided by Dr. O. Rinmlelzwaan, Rotterdam, The 
Netherlands; derived from NSI and SI virus isolates, respectively, obtained from HIY·J infected 
individual # 168 (De long el al" 1992b; Tersmette el a/" 1989)) and HIV -I III' (vSC25, kind gilt of B. 
l'o'Joss and C. Chakrabarti, Bethesda, USA). Monkey scra at a solution of 1:25 were pre-incubated in a 
sonicated lysate ofBHK21 cells (4.107 cells/ml; BHK-Iysate) for I h at 37°C. Plates were washed ami 
incubated with serial two-fold serum dilutions starting at I :50 in E-buffer supplemented with 2% of 
BHK-Iysate for 1.5 h at RT, followed by an I h incubation with amnity isolated goat F(ab')2 anti human 
IgG gamma chain peroxidase conjugate (Biosource, Camarillo, USA) for I h at RT. The substrate 
reaction was carried out with 3,3',5,5'-tetramethyl-benzidine (TMB; Sigma). Endpoint titers were 
calculated using a cut-off value threefold above background values. The same protocol was used to 
detennine the kinetics of SHIVmJ.1·Env specific serum antibodies. As SHIV 3211.3.1 was grown Oil 
CEMX 174 cells, here BHK-Iysate was replaced by CEMXI74-lysate. 
(ii) Serum reactivity with HIV·1 V3loop pep tides. Reactivity of monkey sera and pooled 
sera of HIV -1 seropositive individuals (HIY -1 pool) to V3 was measured by using an inhibition ELISA 
using V3-peptides as described before (2). As viral sequences within the gpl20 V3 region arc associated 
with SI or NSf viral phenotypes, different V3-mixotypes consisting of peptides based on NSI, NSI-
intermediate, SI-intenTIediate or SI V3 consensus sequences were used (8,9,13,20,33,54): NSl, 
CTRPNNNTRKSI- HIPrrIN-IOPORAPYTTO-ElD/Q-llODIRQAHC; NSI-intermediate, 
CTRPNNNTRKOIHIOPORA-P/I-YTJ'G-FiNIDIQ-llODlRQAHC; SI-intennediate, CTRPNNNTRK-
O/S-I-HIRIY-IOPORA-INIP-YN/H/L-TT-FiOIR-KlR-llODlRQAHC;SI,CTRPNNNTRKRI-HrrIRlY-
IOPORA-P/Y -Y N IH-TT-OIKlR-Q/KIR-llODIRQAHC. 
(iii) Inhibition of IgG1.n12 binding. RVV expressed 320.2a.6 HIV -I Env was adsorbed onto 
07324 coated 96-well microtiter plates as described above. Subsequently, wells were incubated with I 
to 50 dilutions of monkey sera pre-incubated in BHK-Iysate for J h at RT. Fifty f.11 were discarded from 
each well before adding 50 f.11 of biotinylated IgG I-B 12. After incubation for 1.5 h at RT, wells were 
washed and incubated with HRPO-conjugated streptavidin. TMB was used for substrate reactions. 
Inhibition percentages were calculated on the basis of the formula: % inhibition = [(OD~5U IgG I-B 12 -
OO~5U background) - (OO'UII test serum - OO.f50 background)] : (0045U IgGI-BI2 - 004511 background) 
x 100 %. Inhibition of>15% was considered significant. 
(iv) Neutralization of HIV~1 infectivity. Neutralization was evaluated in an infectivity 
reduction assay measuring the effect of serum on the virus endpoint titer, expressed as tissue culture 
infectious dose (TCIOso). This method was adapted from Hogervorst et af. (1995) and Mascola et lIf. 
(1996). Phytohemagglutinin-stimulated peripheral blood lymphocytes (PH A-blasts) or CEMXI74 cells 
(105) were used as target cells. One to 20 dilutions of sera and serial 3-fold dilutions of virus stock in 
R-J 0 containing 20 IV/ml recombinant intcrleukin-2 (rIl·2) (20 J.l1 serum dilution and 20 ,.tI virus) were 
pre-incubated in quadruplicate wells. After 30 min at 37°C, target cells in 40 f.11 R-lO containing 20 
IV/ml rll-2 were added to each well and incubated for 20 h at 3rCl5% CO2, SubsequentlY, cells were 
washed 3 times and maintained in 200 ~I R-IO containing 20 iU/ml rll-2. Por HIV-I"" (MRC AIDS 
directed programme), at day 7 cultures were harvested and tested for the presence of p24 core antigen 
by an anti-p24 capture ELISA (McKeating el al" 1991) using as conjugate the p24 specific Mah 
1404EII (Janvier et af., 1990). For SHIV32o.3.I' half of the supernatant was exchanged with fresh 
medium at day 4. At day 10 cultures were harvested and tested for the presence of HIV -I Env using the 
D7324 capture ELISA described above. Background values were set by calculating the mean OD45(J of 
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the negative control wells (containing cells without vims and serum) plus three times the standard 
deviation (SD). TCIDso were calculated using the method of Spearman-Karber. TCIDsu reduction was 
defined as the ratio of the TeIDS(} in the presence of nannal monkey serum to the TCID!>(J in the presence 
of test serum, 
(v) Serum reactivity with SIV·Gag. A Gag specific inhibition assay was used as described 
previously (Hulskotte et al., 1995a). Inhibition of binding of a biotinylated polyclonal serum, I YO, of 
a SlY infected monkey to Gag-p27 by a tenfold dilution of the respective monkey sera Was measured. 
Inhibition percentages were calculated on the basis orthe formula: % inhibition::: (OD4~() I YO - OD45(1 
background) - (OD'50 test serum - OD"o background)] : (OD"o IYO - aD"" background) x 100 %. 
Determination of CTL precursor (CTLp) frequencies. CTLp frequencies were determined 
as described (Geretti et al" 1997; Hulskotte et al., 1995a). Briefly: 
(i) Preparation of Antigen Presenting Cells (APC). Autologous 8-cell lines (B-LCL) 
infected with rVV expressing either HIVMl Env (v320M NSI or v320-SI as indicated), HIV-lfiluTat 
(TG3196; Transgene, Strasbourg, France), HIY-I"," Rev (TG4113; Transgene), SIYmac32H p55'" 
(kindly provided by Prof. A. McMichel, Oxford, United Kingdom), or SIYmac32H(J5) Nef (kindly 
provided by Drs. B.W. Rud and M. Mackett) and fixed in 1.5% PFA were used as APC. 
(ii) Limiting*dilution microcultures. Freshly isolated or cryopreserved lymphocytes were 
seeded in R-J 0 in at least five dilutions of24 replicate wells from 4x IO~ to 4x I 03 cells/well. Cells were 
cultured with autologous irradiated (2,500 rads) feeder PBMC (lO'/well, day 0), APC expressing the 
protein under investigation (I04/well, day 0 and 7), and rIL2 from day 3. 
(iii) Cytotoxicity assay. On day 14, aliquots from each well were screened for cytotoxicity 
in spliHvell5 h 5lCr-release assays. Autologous B-LCL infected with rVV expressing the viral protein 
under investigation or control wild-type vaccinia virus (vSC65, Rimmelzwaan et af., 1994) or I 86poly 
(Transgene» were used as targets. Maximum release was determined by detergent lysis (5% Triton X-
100) of target cells. Spontaneous release was determined by incubation of target cells in R-IO alone. 
Spontaneous release was less than 30% of maximum release. 
(iv) Calculation of CTLp frequencies. Individual wells were considered positive when the 
experimental release exceeded spontaneous release of specific targets but control targets by three 
standard deviations. CTLp frequencies were estimated by the maximum likelihood method using a 
statistical software (Strijbosch et al., 1988), that included a X2 goodness-of fit test statistics. Frequencies 
were normalized to the number of CfLp per 106 cells. Limiting dilution assays of PBMC isolated from 
the monkeys before exposure to either HIV or SIV antigens showed CTLp frequency estimates 
consistently <2/10' PBMC. 
Virus detection. (i) Virus isolation. Virus isolation was perfonned by cocultivation of freshly 
isolated PBMC, their CDS-depleted fractions, lymph node mononuclear cells (LNMC), spleen 
mononuclear cells (SPMC) ,or thymocyte,s with I o-~ml CEMX 174 cells in 3 J.lg/ml ConA. Recombinant 
11-2 was added on day 3 at 10 IV/ml. Cultures were refreshed twice a week and kept for 6 weeks. 
Alternatively, virus isolation was performed by cocultivation ofPBMC with mitogen stimulated PBMC 
using a viral load assay. A total of2.1 06 freshly isolated PBMC were seeded at I o-~ and 3.3x I O~ cells per 
well in fifteen replicates in 96-well nat-bottomed plates in the presence of 3 l1g/ml ConA, 50 lV/ml rll-2 
Dnd 2x I O~ human PHA·blasts. At day 3, 100 J.l1 medium was removed Dnd 150 III R-I 0 containing 50 
IU/ml rll-2 was added. At days 7, 14, 21 and 35 cultures were fed by replacing part of the old cells by 
fresh human PH A-blasts. Supematants were assayed regularly by antigen capture ELISA for the presence 
of HIY-I Env or SlY Gag p27 (Y5-p24 antigen kit, Organon Teknika, Boxtel, The Netherlands, or 
Coulter SIV core antigen assay, Coulter Electronics, Mijdrecht, The Netherlands, respectively). 
(ii) Nested~Gag PCR. To investigate the presence of SHIV.no.3. 1 DNA, a nested PCR 
amplifying a 500 bp fragment of SIV Gag p27 followed by hybridization with a radioactive labelled Gag 
specific probe was used as described (Geretti et al., 1997). 
(iii) Plasma p27 antigen detection. SIV p27 core antigen in plasma was quantif1cd by antigen-
capture ELISA (Coulter Electronics, Mijdrecht, The Netherlands). 
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TABLE 1. Relative affinities of HuMabs for HIV-I 320.N51 and 320.51 Env 
CD4bd v, gpl20 
Envelope protein GP68 IgGJ-BI2 257·D 391/950 2G12 
320.NSI 6:50' 1I4 25 157 118 
320.NSI cm~ 700 JJ6 12 t47 175 
320.NSI em PFN 1000 200 
" 
200 262 
320.SI 400 342 25 60 198 
320.s1 em " 45 126 250 
320.S1 em PFA 70 115 85 
~ Concentrations of monoclonal antibody (ng/ml) giving 50% of maximal binding. 
h em, after cleavage site mutation 
" PFA, after PFA fixation 
J OD.t51l values barely above background levels at the concentrations tested. 
RESULTS 
gp41 
2F5 
3500 
2425 
3575 
]275 
2450 
1375 
Antigenicity of recombinant HIV-l Env preparations, The antigenicity of the 
320.NSI and SI recombinant HIV-I Env was studied by determining the relative affinities of 
a panel of HuMabs selected for their ability to neutralize primary HIV-I isolates (Burton ef 
al., 1994; Schutten ef al., 1995; Trkola ef al., 1995; Schutten ef al., 1997)(Table I). Both Env 
preparations reacted with antibodies against the CD4bd (Mabs GP68 and IgGI-B 12), the V3 
loop (Mabs 257-D and 391195D), a conformational epitope on gpl20 (Mab IAM-2G 12), and 
a linear epitope on gp41 (Mab IAM-2F5). Cleavage site mutation abolished the reactivity of 
CD4bd specific HuMabs with the 320.SI-Env but not with the 320.NSI-Env. PFA fixation did 
not significantly affect the relative affinities of any of the antibodies. 
Vaccine-induced HIV-l Env specific serum antibody responses. (i) Kinetics of 
HIV -Env specific serum antibody response, After the second immunization, all four HIV-I 
Env immunized monkeys developed serum antibodies that recognized the SHIV",,-,.I Env (Fig. 
O. Antibody titers increased after the third immunization, decreased subsequently, to increase 
again after the fourth immunization. The monkeys vaccinated with 320.SI-Env developed 
higher antibody titers and showed more pronounced booster responses than the animals 
vaccinated with 320.NSI-Env (Fig. I). No HIV-I Env specific antibodies were found in the 
control monkeys (not shown). 
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FIG. 1. Prc- and post-challnge SHIV 3:!03.I-Env specific antibodies. Small arrows indicate immunisalions; 
the large arrow indicates the day of challenge. 
(i1) Reactivity of sera with different primary and T-cell line adapted HIV-l Env 
preparations. Sera collected on Ihe day of challenge were tested for Iheir ability to bind 10 
primary and T-cell line adapled HIV - I Env preparalions (Fig.2A). All monkeys developed Ihe 
highest antibody liters against Ihe Env used for immunizalion. Sera from the 320.NSI-Env 
immunized monkeys, but not sera from 320.SI-Env inununized monkeys, recognized the T cell 
line adapted HIV-III,,-Env. Bolh groups of monkeys showed serum reactivity with 168.NSI 
and 168.S1 Env, derived from an NSI and an SI inducing primary HIV-I isolale respeclively. 
The overall binding of Ihe sera was lower than Ihat observed wilh Ihe respeclive #320 Env 
used for immunization. The sera from 320.NSI-Env immunized monkeys generally bound 
better to the NSI Env than to their SI counterparts. However, this was not the case for the 
binding of the sera from Ihe 320.SI-Env immunized monkeys 10 Ihe 168.S1 protein. 
(iii) SeruIII reactivity with the HIV-l V3loop. Serum reaclivity with Ihe HIV-I V3 
loop was sludied on Ihe day of challenge by a V3 peptide inhibilion assay (Fig. 2B). The 
peptides used were V3 mixotypes representing NSI, SI and intermediate phenotype consensus 
sequences (De Jong et al., 1992b; Fouchier et al., 1992; De Jong et al., 1992a; Groenink et 
al., 199 I; Simmonds et al., 1991; Kuiken et al., 1992). All monkeys developed V3 specific 
antibodies. However, neither immunization with NSI-Env nor immunization with SI-Env 
preferentially induced serum reactivity with the concordant consensus V3 sequences. In 
contrast, reactivity of pooled sera from HIV-I seropositive individuals was preferentially 
inhibiled by the NSI V3 consensus peptide. 
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FIG. 2. Env specific antibody 
responses of sera collected either on 
the day of challenge Of prior to 
vaccination, and of pooled sera of 
HIV -1 serOpositive individuals 
(H[V-[ pool). (A) Env specific 
antibody responses against different 
HlY-I Env. 320.NS[- and 320.S[-
were primary isolates of seropositive 
individual #320 and their Env were 
identical to those used for 
immunization (Andeweg e/ al., 
1992; Groenink el al., 1991); 
I 68 .. NSI and 168.S1 were primary 
isolates of seropositive individual 
# 168 (de long el al., 1992b; 
Tersmette et al., 1989); HIV -I Hla is 
T-cell line adapted. (8) V3 specific 
antibodies, determined by inhibition 
ELISA. Inhibition of binding of a 
I: I 00 serum dilution HIV -I Eny by 
different V3 mixotypes consisting of 
NSI, NSI-intermediate, SI-
intermediate, or SI V3 consensus 
sequences is indicated. Pre· sera and 
serum of control monkeys were not 
able to bind to I·IIY ·Env and 
therefore no reactivity is shown. (C) 
CD4bd specific antibodies, 
determined by inhibition of binding 
of the CD4bd specific HuMab [gGl-
B 12 to HIV-l Env by 50-fold 
diluted serum samples. TIle standard 
error of the mean of three 
experiments is presented as a 
vertical line. 
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(iv) Inhibition of HIY-! CD4bd specific HuMab binding. On the day of 
challenge, reactivity' with the CD4bd of HIV-l was studied by testing the serum ability to 
inhibit binding of HuMab IgG I-B 12 to HIY-l Env (Fig. 2C). Pre-immunization sera and sera 
!i'om control monkeys did not signilicantly inhibit IgG I-B 12 binding. Sera from the 320.NSI-
Env immunized monkeys exhibited high inhibition levels, similar to those found in the pooled 
sera ofHIY·1 seropositive individuals. In contrast, the monkeys immunized with the 320.SI-
Env showed no (#144) or low (#K84) inhibition. This may have been due to the loss of 
CD4bd antigenicity in the 320.SI-Env used for immunization (Table 1). 
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(v) Virus neutralizing antibodies. The development of antibodies showing 
neutralizing activity towards SHIVJ2o.J.1 and T cell line adapted HIV-1uIB was analyzed with 
an HIV-I reduction neutralization assay (Fig. 3). By the day of challenge. all HIV-I Env 
vaccinated animals had developed VN antibodies to the SHIVJ2oJ., challenge virus. 
Neutralization levels in 320.SI-Env vaccinated monkeys exceeded those found in 320.NSI-Env 
immunized monkeys. In contrast, no significant neutralizing activity had developed against the 
T cell line adapted HIV -1mB when measured on cither primary human PHA-blasts or on a T-
cell line (CEMXI74). The serum pool from HIV-I seropositive individuals neutralized both 
SHIV J2()J,1 and HIV -IIIIB' 
Vaccine-induced HIV-l Env specific CTLp. By the day of challenge, no clear 
differences in CTLp induction had emerged between the 320.SI- and 320.NSI-Env immunized 
monkeys (Table 2). Relatively high CTLp frequencies were detected in one animal of each 
group (36 and 13/10" PBMC, respectively). Although the other two animals showed relatively 
low CTLp frequencies (5 and 3/10° PBMC, respectively), these responses were vaccine 
induced since no specific CTLp «2/1 0") were detected in naive PBMC collected either from 
the same monkeys before immunization or from the control monkeys of group C (not shown). 
virus titer reduction (%) 
0 90 >98 0 90 >98 
, , , 
i<> K9 I A (N81) i<> 0 III 135 
~ III 0 K84 I B (81) 144 
<) 0 106 I c (control) 
< 0 127 
A ,<: B ,C HIV-1 pool , , ; 
<> SHIV"o.3., CEMX174 III HIV,". PHA-btast 
0 HtV,". CEMX174 
FIG. 3. VN-antibody responses against SHIVno.3.1 (A) and HIV-\HB (8) measured by a virus 
neutralization reduction assay. For HIV-I I!IB reduction in virus titer on CEMX 174 cells and PH A-blasts 
was measured. As a consequence of low-level replication in human PHA-blasts, for SHIV 32113.1 reduction 
was only measured in CEMX 174 cells. 
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TABLE 2. SHIV specific CTLp frequencies (CTLpIlO'cells) on day of challenge and week 13 
postchallenge (pcy .. 
Group Monkey Sample day of week 13 pc 
challense 
HIV Env SlY Gag HlVEnv SIV Nef HlVTat HIV Rev 
A K9 PBMC 36 (19-52) 4 (1-7) 19 (12-27) 
NSt LN 21 (14-29) 
spleen 39 (25·53) 20 (9-30) 15 (4-26) IO (3·17) 
135 PBMC 5 (2-8) 5 (2-8) 32 (18·45) 0 5 (1-10) 0 
LN 3 (1-6) 
spleen 12 (5-18) 
8 K84 PBMC 13 (7-20) 14 (4.24) 2 (0·4) 0 8 (3-13) 20(11-29)' 
St LN 5(1·9) 
spleen 8 (4·12) 
144 PBMC } (1-5) 5 (2-9) 10(3.6) 0 15 (4·26) 0 
LN 5 (1-9) 
spleen 0 
C t27 PBMC ,d I (0·2) 7 (3-lI) 4(0·9) 14 (2-26) 0 
LN 5 (1·9) 
spleen 4 (2-7)' 
106 LN ,d 0 
spleen 0 10(6·15) 0 0 0 
~Effector cells were obtained by specific stimulation with PFA rtxed autologous 8-LCL infected with 
rVV expressing the protein under investigation (in case of En v; 320.SI-Env for macaques K84, 144 and 
127, 320.NSI-Env for macaques K9, 135 and 106) in the presence of rn·2. Split·well "Cr release assays 
were performed on day 14 of culture. Specific cytotoxicity was assayed with autologous 8-LeL infected 
with either rVV expressing the HIV -1 env protein under investigation or wild-type control vaccinia 
virus. Data from limiting-dilution assays were analyzed with the maximum likelihood method. 95% 
confidence intervals are given in parentheses. The cut-off value for CfL was determined at < 2/101'> (not 
shown). For all frequency calculations X2 goodness-of-tIt values were always <7. except for the two 
samples indicated by *, which goodness-of-tlt was poor and were analyzed by the minimum chi square 
methond, not done. 
SHIV,,"_,., specific CTLp frequencies after challenge. We studied the development 
of virus specillc CTL upon SHIV'2<'-'.1 challenge. The frequencies of CTLp specillc for HIV-I 
Env, Tat, Rev, and for SIV Gag and Ner were measured at week 13 post challenge in PBMC, 
LNMC or SPMC (Table 2). Pre- and post-challenge CTLp measurements were c"Tied out in 
parallel using identical culture and assay conditions. CTLp in naive PBMC were always below 
211 0" cells (not shown). Consistent with the serological data, CTLp specific for multiple 
SHIV"".,.I antigens were found in both control monkeys and in the 320.NSI-Env vaccinated 
monkey #135 (Table 2). Surprisingly, the three other immunized monkeys also developed 
CTLp against mUltiple SHIV antigens, whihc were indicative of low-level virus replication. 
At week 13 post challenge, all monkeys showed CTLp (>2110") specific for one or more SHIV 
proteins (Table 2). HIV -I Env specific CTLp were induced in both control monkeys. CTL 
against HIV -I Tat and Rev were detected in five out of six and two out of six animals 
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respectively, whereas CTL against SIV Gag and Nef were detected in five out of six and two 
out of six monkeys respectively. CTLp frequencies in most cases ranged between 5 and 15/10r., 
The highest CTLp frequency was 32110'. After challenge, the frequencies of Env specific 
CTLp increased in HIV-Env vaccinated monkeys #144 and #135, but decreased in monkeys 
#K84 and #K9 (Tables 3 and 4). 
To study the effect of SHIV310J., challenge on CTLp induction in different lymphoid 
compartments, SlY Gag specific CTLp were determined in parallel limiting dilution analyses 
ofPBMC, LNMC and SPMC. SIV Gag specific CTLp were detected in all three compartments 
in monkeys #K9, #135, and #K84. Monkey #144 showed relatively low SIV Gag specific 
CTLp in PBMC and LNMC but not in SPMC. Monkey # 127 showed relatively low SIV Gag 
specific CTLp in LNMC and SPMC but not in PBMC. 
40 
c 
o 30 
:;:; 
:0 
.£; 
c 
.g 20 
'0 
Q) 
0. 
(f) 
, 
0> 
cu 10 (9 
Kg 
D pre 
IY'i.i!.iH wk 13 pc 
135 K84 144 106 127 
A (N81) B (81) C (control) 
FIG. 4. Gag specific antibodies, determined by inhibition ELISA. Bacterial p27-gag was used as 
immobilized antigen. The percentage inhibition ofa biotinylated polyclonal serum of a SIVrnac-infected 
monkey by a tenfold dilution of monkey sera collected at 13 weeks post challenge (wk 13 pc) or prior 
to vaccination (pre) is shown, 
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TABLE 3. Longitudinal evaluation of the presence of SHIV in PBMC of HIV -Env vaccinated (groups 
A and B) and control monkeys (group C) in the first 13 weeks post challenge (pc) 
Macaques 
Time pc A (NSI) 8(51) C (control) 
K. 135 K84 144 127 106 
day J 
day 6 
day 10 
week 2 
week J + - +-
weekS 
week 7 +nd - nd - nd - nd - nd 
week 9 - nd + nd - nd +nd - nd 
week 13 ++ + -
'Virus detection by peR and virus isolation respectively. The presence of SHIVn1u,1 DNA in PBMe 
was assayed by a nested peR. + indicates virus detection; - indicates lack of virus detection; nd, not 
done. 
Virus detection after challenge. After challenge. SHIV;no.3.1 was recovere from 
PBMC (Table 3) and lymphoid tissues (Table 4) of the 320.NSI-Env vaccinated monkey #135 
and control monkey #127. In monkey #135, proviral DNA could be detected in PBMC at 
weeks 3, 7, 9 and 13 after challenge. Virus was detected by virus isolation and PCR in the 
lymph node biopsy obtained at week 7 post challenge and in samples of lymphoid tissues 
(LNMC, SPMC, thymus-, bone-marrow cells) obtained at week 13 after challenge. The virus 
burden appeared to be less pronounced in monkey #127: proviral DNA could repeatedly be 
detected in PBMC and in cells derived from the axillary and mesenteric lymph nodes obtained 
at weeks 7 and 13 post challenge respectively, but not in cells of the axillary and inguinal 
lymph node, spleen, thymus and bone-marrow obtained at week 13 post challenge. In addition, 
virus could be isolated from LNMCax taken at week 7, but not from PBMC or from lymphoid 
tissue samples obtained at week 13 after challenge. In the other monkeys, repeated attempts 
failed to isolate virus from PBMC, their CD8-depleted fractions, LNMC, SPMC or 
thymocytes, or to detect SIV p27 core antigen in plasma (not shown). In addition, no proviral 
DNA could be detected at any time point in their PBMC, LNMC, SPMC, thymocytes or 
bone-marrow cells. 
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TABLE 4. Virus detection by peR and virus isolation techniques in lymphoid tissues of HIV-Env 
vaccinated (groups A and B) and control (group C) monkeys at week 7 and 13 post challenge 
Monkeys 
Weeks. pc Tissue 
A (NSI! B(51) C (control) 
K9 135 K84 144 127 106 
7 LN,,-, 
, 
++ ++ 
I3 LN:lu!1I . ,d Hd . ,d . ,d . ,d . ,d 
I3 LNn~ ++ +. 
I3 spleen ++ 
I3 thymus ++ 
Il BM • ,d Hd . ,d . ,d . ,d - nd 
'Vims detection by peR and vims isolation respectively. LN: lymph node; ax: axillary, in: inguinal; 
mes: mesenteral; BM: bone-marrow. + indicates virus detection; - indicates lack of virus detection; nd, 
not done. 
DISCUSSION 
In the present paper, we have studied the efficacy of subunit HIV -I vaccines based 
on SI or NSI envelope proteins incorporated into iscoms. Upon challenge with SHIVJ2(U.l' one 
NSI-Env immunized monkeys became productively infected. In contrast, one other NSI- and 
the two SI-Env immunized monkeys were apparently protected from infection, as indicated by 
the absence of SHIV31OJ.!·specific antibody responses and the inability to detect SHIV.'lo.).! by 
virus isolation and PCR. However, the pattern of SHIV-"oJrspecific CTLp development in the 
apparently protected animals indicated that also in these animals virus replication had not been 
prevented completely. In both control monkeys, SHIV)2().3.1 infection induced specific 
antibodies and CTLp. However, levels of virus replication were low, as during the 13 weeks 
of follow up, SHIV",,,.! could only be detected in one of the two control monkeys. The 
observation that even after challenge with such a poorly replicating virus no complete 
protection could be obtained, extends our previous findings in the SIV-macaque model 
(Hulskotte ef al., I 995a): in this model we showed that immunization with SIVmac Env iscoms 
or preparations containing SIVmac Env iscoms, Gag iscoms and Nef lipopeptides also induced 
VN antibodies and CTLp, but failed to induce protection against a pathogenic SIVmac 
challenge. 
Most vaccine development strategies have used HIV-I envelope glycoproteins ofT-
cell line adapted viruses, which generally induce poor VN activity against primary HIV-I 
isolates (Johnston, 1996). For our study we have chosen envelope glycoproteins from primary 
viruses, which were selected from NSI and SI clones of one HIV-I infected individual. The 
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procedures we have used to generate and purify the envelope glycoproteins have previously 
been shown to result in oligomeric proteins of HlV-IIIIB (Earl el aI., 1990). lscoms 
incorporating the NSI- and 81- Envs produced in this way were shown to induce neutralizing 
antibodies against SHIV.:no.3.[. which carries an HIV-l envelope derived from the same 
individual from whom also the Sl and NSl Envs originated. As it may be expected from the 
higher degree of amiTlo acid sequence homology between the 320.SI-Env and SHIV.u() . .:u-
Env(97.5%) than between the 320.NSl-Env and SHlV"" .. u-Env (81.7%), SHlV"".J.l-Env 
specific as weB as VN antibody responses were higher in the monkeys immunized with the 
former protein. It is interesting to note that the only vaccinated animal that became 
productively infected had been vaccinated with the NSl-Env and had developed the lowest 
SHIV.nu.J,I-antibody responses. 
In contrast to the neutralizing activity detected against SHIV:uu.J.1, no neutralizing 
activity against HIV-lmB was observed in the sera of the vaccinated monkeys (Fig. 3). This 
may be due to the high amino acid sequence difference between the HIV-lulB-Env and the 
immunizing Envs (Myers el al., 1993). However, HlV-1 nIB was effectively neutralized by 
pooled sera from seropositive individuals infected with viruses probably as distant from HIV-
luIS as the viruses of individual #320 (Fig. 3). Therefore, quantitative and qualitative 
differences in antibody induction upon natural infection and immunization should also be 
considered to explain this observation. 
The sera from the immunized monkeys were also tested for their antibody reactivity 
against major VN inducing sites. All monkeys developed antibodies against the V3 loop. 
Although differences in V3 are associated with an NSl and Sl phenotype (De Jong el al .. 
1992b; Pouchier el al., 1992; De Jong el al .. 1992a; Groenink el al., 1991; Simmonds el al .. 
1991; Kuiken ef al .. 1992), sera of monkeys immunized with Envs containing either NSl or 
Sl V3 loop sequences did not show a clear difference in their recognition of the consensus NSI 
or Sl V3 loop sequences (Fig. 2B). Sera of HIV-I infected asymptomatic individuals, which 
can be expected to harbour mainly NSl virus strains (Schuitemaker el al.. 1992), did 
preferentially recognize the consensus NSl V3 loop sequences. Therefore, it may be speculated 
that maturation of the antibody response or long term exposure is necessary to develop a more 
specific V3 response. CD4bd reactive antibody responses appeared to be higher in the NSI-
Env immunized monkeys, which is not unexpected considering the loss of the corresponding 
antigenic site in the Sl-Env preparation due to cleavage site mutation (Table I). 
Besides the development of virus specific antibodies, we also studied the 
development of specific CfL responses after vaccination and challenge. HIV -I specific CTL 
have often been demonstrated in HlV-1 infected humans in the absence of ill vilro 
restimulation (Cease & Berzofsky, 1994). In contrast, the frequencies of circulating CTLp in 
SlY-infected or vaccinated macaques is usually too low to allow detection in the absence of 
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ill vifro expansion (Geretti ef a/., 1997; Venet ef a/., 1992). In previous studies we have 
investigated the optimal conditions for the measurement of CTL in cynomolgus macaques 
(Geretti ef a/., 1997). Limiting dilution analyses of cells expanded by antigenic stimulation was 
shown to allow reproducible detection of SIV specific CTLp also in monkeys lacking 
significant responses in standard bulk CTL assays. Therefore, this approach was chosen to 
study the potential of the candidate HIV -I Env iscom vaccines to induce HIV -I Env specific 
CTLp in monkeys. 
As expected from our previous experiments (Hulskotte el a/., 1995a), the use of 
iscoms proved to be effective in inducing HIV-I Env specific CTLp in all the immunized 
cynomolgus macaques, at frequencies ranging from 3 to 36/10' PBMC. Although lower than 
those generally found in HIY-I infected individuals (Geretti el a/., 1995; Klein el a/., 1995), 
these frequencies are similar to those measured in SIVmac infected macaques (Gallimore e/ 
a/., 1995; Venet ef a/., 1992; Geretti el a/., 1997). In particular, in our previous study of 
SIYmac32H(J5) infected cynomolgus macaques, CTLp measurement by the same method gave 
SlY Env specific CTLp frequencies of less than 30/10' in S out of 10 monkeys tested (A.M. 
Geretti, unpublished results). 
Although only the two control monkeys and one NSI-Env vaccinated monkey (i.e. 
#135) showed evidence of productive SHIV"".3.1 infection by virus detection or antibody 
induction, after challenge all monkeys developed CTLp against one or more of the SHIV 
proteins Env, Gag, Nef, Tat, and Rev. It is unlikely that these were induced by the mere 
presence of antigen in the challenge material, as the stimulation protocol we used has been 
shown to preferentially expand major histocompatibility complex class I restricted CDS' CTL 
ill vifro (Geretti el a/., 1997), which generally require de 1I0VO synthesis of viral antigen for 
their priming (Rock, 1996). Furthermore, most animals also developed CTL against Rev or 
Tat, which are not present in the virion. Taken together. these findings indicate that SHIV 3211 .. U 
had indeed replicated in the animals after challenge. In addition, they suggest that CTLp 
determination is a more sensitive technique to demonstrate virus replication than virus 
isolation, PCR and antibody measurements. It may be speculated that the SHIV -specific CTLp 
contributed to protection against productive infection. However in this small group of animals 
no correlation was found between either protein specificity or CTLp frequency and the 
outcome of challenge. 
One of the major problems of using first generation SHIVs, as we did in these 
experiments, is their relatively poor replicative capacity ill vivo. Although in monkey # 127 
SHIV"",.! could be demonstrated by virus isolation and PCR, for monkey #\06 only indirect 
proof of virus replication was obtained, by showing the induction of antibody and CTLp. 
Where and how long the challenge virus actively replicated in this animal, can only be 
speculated from our data. Most likely virus replication occurred in lymphoid tissues for a 
56 
Chapter 2 
limited period of time, since the virus could neither be demonstrated in PBMC nor in the 
lymphoid tissues examined at the time of euthanasia. Clearly. transfer of larger segments of 
HIV -I into an SlY backbone, or additional rapid passages of SHIV in macaques, may have 
led to viruses with a higher replicative capacity in macaques (Li et al., 1995; Luciw et al., 
1995; Reimann ef al., 1996; Joag ef al., 1996; Mooij ef al., 1997). However, a drawback of 
the latter approach is the possible divergence of the envelope of the challenge virus from the 
original HN -1 envelope. Still, the levels of protection achieved in our study proved to be more 
liInited than those induced by Env-bascd vaccination protocols followed by homologous 
challenge with a SHN that had indeed been serially passaged in monkeys (Mooij et ai., 1997). 
Differences in immunization schedules, vaccine formulation, challenge doses and animal 
species may all have been at the basis of the different degrees of protection achieved. 
In evaluating the protective capacity of the HIV-I Env based vaccination strategy 
used here, it should be born in mind that natural HIV -1 infection in humans usually occurs via 
the mucosal route which is not very efficient (Jones and Curran, 1994). Moreover, low virus 
load is associated with reduced probability of the virus being transmitted from one individual 
to another (Cao ef al., 1997). These considerations implicate that even a limited degree of 
protection induced by vaccination, may be important to control virus replication and thus 
spread of HIV -1 in humans. 
ACKNOWLEDGMENTS 
We thank Drs. S. Zolla-Pazner and M.K. Gorny for supplying the HuMabs 257-0 and 
391/95D, H. Katinger for IAM-2F5 and IAM-2G12, in part through the MRC AIDS directed 
programme, and D. Burton for IgGI-BI2, . Furthermore, we thank N. Almond and S. Jones for 
supplying the challenge virus, F. Mallet for the Y3-mixotypes, R. van Binnendijk and M. Paden for 
the autologous B-celliines, 1. Karlas for preparing the FlY Env iscoms. P. Boers for help in PCR, J. 
Habova for electron microscopy and N. Schmidt for biotechnical assistance. Drs. M. Schutten, C. 
Guillon and J. Groen are acknowledged for helpful discussions and Ms. C. Kruyssen for secretarial 
assistance. Recombinant vaccinia viruses expressing the different HIY-I envelope proteins were 
generated in the framework of the joined RIYM/AMC/EUR project on HIY -I vaccine development. 
which like the rest of the presented study, was supported by the Dutch AIDS Foundation and the 
Praevelltiefonds (grants 90.052 and 28-2369, respectively). 
REFERENCES 
Alldeweg, A.C., Gl'oenink, f\.'1., Leeflallg, P., et aI. (1992). Genetic and functional analysis of a set of 
HIY-I Envelope genes obtained from biological clones with varying syncitium inducing capacities. 
AIDS Res.Hum.Retroviruses 8, 1803-1813. 
Bosch, IV1.L., Andeweg, A.C., Schipper, et ai. (1994). Insertion of N-Iinked glycosylation sites in the 
57 
Chapter 2 
variable regions of the human immunodel1ciency vims type I surface glycoprotein through AAT triplet 
reiteration. 1. Viral. 68,7566-7569. 
Cao Y., Krogstad, P., Korber, n.T. et al. (1997) Maternal HIV-J viral load and vertical transmission 
of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat. Ivied. 
3,549-542. 
Burton, D.R., PyaH, J., Koduri, R., et al. (1994). Efficient neutralization of primary isolates of HIV-I 
by a recombinant human monoclonal antibody. Science 266, 1024-1027. 
Burns, D.P., Desrosiers, R.C. (1994). Envelope sequence variation. neutralizing antibodies, and 
primate Icntivirus persistence. Cllrr. Top. Microbiol.lmmwlOl. 188, 185-219. 
Cease, K.Bo, Berzofsky, J.A. (1994). Toward a vaccine for AIDS: the emergence of 
immullohiology-hased vaccine development. AI/fl. Rev. 111111111110/. 12,923-989. 
Chesebro, n., 'Vehrly, K., Nishio, J., et al. (1992). Macrophage-tropic human immunodeficiency virus 
isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with 
T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. l. \'iral. 66,6547-6554. 
D'Souza, iVI.P., Harden, V.A. (1996). Chemokines and HIV-I second receptors. Contluel1l:e of two 
fields generates optimism in AIDS research. Nat. Med. 2, 1293-1300. 
D~ Jong, J., De Ronde, A., Keulen, 'V., et al. (1992a). Minimal requirements for the human 
immunodeficiency virus type I V3 domain to support the syncytium-inducing phenotype: analyses by 
single amino acid substitution. l. \'im/. 66,6777-6780. 
De Jong, J., Goudsmit, J., Keulen, 'V., et al. (1992b). Human immunodet1cicncy virus type I clones 
chimeric for the envelope V3 domain differ in syncytium formation and rcplication capacity. l. Vim/. 
66,757-765. 
Dc 'Voir, F., Goudsmif, J., Paul, D.A., ct al. (1987). Risk of AIDS related complex and AIDS in 
homosexual men with persistent HIV antigenaemia. B. M. l. (Clill. Res. hi/). 295,569-572. 
Dunn, C.S., Beyer, C., Kieny, M.P., et al. (1996). High viralloacl and CD41ymphopenia in rheslls and 
cynomolgus macaques infected by a chimeric primate lentivirus constru.cted using the env. rev, tat, and 
vpu genes from HIV -I Lai. Virology 223, 351-361. 
Earl, P.L., Doms, R.'V., Moss, B. (1990). Oligomeric structure of the human immunodeficiency virus 
type I envelope glycoprotein. P. N. A. S. USA 87, 648-652. 
Fouchiel', R.A.M., Groen ink, M., Kootstra, N.A., et al. (1992). Phenotype-associated sequence 
variation in the third variable domain of the HIV-I gpl20 molecule. J. Viml. 66, 3183-3187. 
Gallimore, A., Cranage, M., Cook, N., et al. (1995). Early suppression of SIV replication by CD8+ 
nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1, 1167 .. 1173. 
GCl'etti, A.M., Dings, M.E.M., Van Els, C.A.C.M., et al. (1996). Human immunodelkiency virus type-
I (HIV-I) - and Epstein-Barr Virus - specific cytotoxic T Iymphocytc precursors exhihit different 
kinetics in HIV-I infected persons. l.llI/. Dis. 174,24-45 
Gerctfi, A.IV!., Hulskottc, E.G.J., Dings, M.E.M., et al. (1997). Simian immunodel1ciency virus 
(SIV)-specific CD8+ cytotoxic T lymphocyte responses of naive and vaccinated cynomolgus mm:aques 
inlected with SIYmac32H(J5): quantitative analysis by in vitro antigenic stimulation. Vaccille 15: J 269-
1275. 
58 
Chapter 2 
Gorny, M.K., Xu, J.Y., Karwowska, S., et aI. (1993). Repertoire of neutralizing human monoclonal 
antibodies specific for the V3 domain of HIV- I gp120. J. Immww!, 150,635-643. 
Groenink, 1\'1., Fouchier, R.A.M., De Goede, R.E.Y" et al. (1991). Phenotypic heterogeneity in a panel 
of infectious molecular human immunodeficiency virus type 1 clones derived form a single inidvidual. 
J. Vim/. 65, 1968·197S. 
Groenink, M., Fouchier, R.A., Bl'oersen, S., et aI. (1993). Relation of phenotype evolution of HIV-I 
to envelope V2 configuration. Science 260, 1513-1516. 
Heeney, J,L. (1996), Primate models for AIDS vaccine development. AIDS 10, S IIS·S 122. 
Hogcrvorst, E., de jong, J., van 'Vijk, A., et al. (1995). Insertion of primary syncytium-inducing (SI) 
and nOI1-SI envelope V3 loops in human immunodeficiency virus type I (HIV-l) LAI reduces 
neutralization sensitivity to autologous, but not heterologous, HIV -I antibodies. 1. Viro!. 69, 6342-6351. 
Hulskotte, E.G.J., Geretti, A.M., Siebeliuk, K.H.J., et al. (1995a). Vaccine-induced virus neutralizing 
antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian 
immunodeficiency virus SIVmac32H(JS). J. Virol. 69,6289·6296. 
Hulskotte, E.G.J., Rimmelzwaan, G.F., Does, J., et al. (1995b). Antigenicity and immunogenicity of 
recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories. Vaccifle 
13,1187·1197. 
Hulskotte, E.G.J., Dings, M.E.M., Norley, S.G., et al. (1997). Chemical inactivation of recombinant 
vaccinia viruses and the effects on antigenicity and immunogenicity of recombinant simian 
immunodeficiency virus envelope glycoproteins. Vaccine, in press. 
Igarashi, T., Shibata, R., Hasebe, F., et al. (1994). Persistent infection with SIVmac chimeric virus 
having tat, rev, vpu, env and nef of HI V type 1 in macaque monkeys. AIDS Res. Hum. Retroviruses 10, 
1021·1029. 
Janvier, B., Al'chinard, P., Mandrand, B., et al. (1990). Linear B-cell epitopes of the major core 
protein of human immunodeficiency virus types 1 and 2. 1. Vim!. 64,4258-4263. 
Joag, S.V., Li, Z., Foresman, L., et al. (1996). Chimeric simian/human immunodeficiency virus that 
causes progressive loss ofCD4+ T cells and AIDS in pig~tailed macaques. 1. Vim!. 70, 3189-3197. 
Johnston, M.1. (1996). HIV I AIDS vaccine development: challenges, progress and future directions. 
Rev. Med. Virol. 6,123·140. 
Jones, \V.K., Curran, J.\V. (1994). Epidemiology of AIDS and HIV infection in industrialized 
countries. In Textbook of AIDS medicine, pp. 91-108. Edited by S. Broder, T.C.J. Merigan, and D. 
Bolognesi: Williams Wilkins. 
Klein, M.R., Van Baalen, C.A., Howerda, A.M., et al. (1995). Kinetics of Gag-specific CfL responses 
during the clinical course of HIV -I intection: A longitudinal analysis of rapid progressors and long-term 
asymptomatics. 1. E\p. Med. 181, 136S·1372. 
Koot, M., Vos, A.H., Keet, R.P., de. Goede, R.E., et al. (1992). HIV-I biological phenotype in 
long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6, 49·54. 
Kuiken, C.L., de Jong, J.J., Baan, E., et al. (1992). Evolution of the V3 envelope domain in proviral 
sequences and isolates of human immunodeticiency virus type I during transition of the viral biological 
phenotype. J. Vim/. 66,4622·4627. 
59 
Chapter 2 
Li, J.T., Halloran, M., Lord, C.I., ct al. (1995). Persistent infection of macaques with simian· human 
immunodeficiency viruses. J. Virol. 69, 7061·7067. 
Luciw, P.A., Pratt-Lowe, K, Shaw, K.E., et ai. (1995). Persistent infection of rhesus macaques with 
T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). 
P. N. A. S. USA 92, 7490·7494. 
Mascola, J.R., Snyder, S.\V., \Veislow, O,S., et al. (1996). Immunization with envelope subunit 
vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of 
human immunodeficiency virus type I. 'nlC National Institute of Allergy and Infectious Diseases AIDS 
Vaccine Evaluation Group. J. Illfecl. Dis. 173,340-348. 
McKeating, J.A., McKnight, A., IVloore, J.P. (1991). Differential loss of envelope glycoprotein gp 120 
from virions of human immunodeficiency vims type 1 isolates: effects on infectivity and neutralization. 
J. Viral. 65, 852·860. 
l\:lcKeating, J.A. (1996). Biological consequences of human immunodeficiency virus type I envelope 
polymorphism: does variation matter? 1995 Fleming Lecture. 1. Gell. Viral. 77, 2905·2919. 
Mooij, P., Van der Kolk, M., Groenestein, R, et al. (1997). HIV-I vaccine protection from 
homologous SHIV-Env challenge. EC-CA workshop 011 FIV, SIV alld SHIV Wlccillatioll, abstract, 73 
Moore, J.P., Cao, Y., Qing, L., et al. (1995). Primary isolates of human immunodeficiency virus type 
I are relatively resistant to neutralization by monoclonal antibodies to gp 120, and their neutralization 
is not predicted by studies with monomeric gp120. 1. Viral. 69, 101-109. 
1\'lool'e, J.P., Jarrell, RF. (1988). Sensitive ELISA for the gpl20 and gp160 surface glycoproteins of 
HIV-l. AIDS Res. Hum.Retroviruses 4, 369-380. 
Muster, T., Steindl, F., Purtscher, M., et al. (1993). A conserved neutralizing epitope on gp41 of 
human immunodeficiency virus type 1.1. Vim!. 67,6642-6647. 
l\:lyers, G., Rabson, A.B., Berzofsky, J.A., et aI. (1993). Human retrovinlses and AIDS. A compilation 
and analysis of Huceic acid and amino acid sequences. Theol'. Biol.Biophysics, Los Alamos 
Poignard, P., Klassc, P.J., Sattentau, Q.J. (1996). Antibody neutralization of HIV -I. ImmllllOl. Today 
17,239·246. 
Ranjbar, S., Jones, S., Stott, E.J., et aI. (1997). TIle constmction and evaluation of SIV/HIY chimeras 
that express the envelope of European HIV Type I isolates. AIDS Res. Hum.Retroviruses 13, 797-800. 
Reimann, K.A., Li, J:I'., Veazey, R, et al. (1996). A chimeric simian/human immunodeficiency virus 
expressing a primary patient human immunodeficiency virus type) isolate env causes an AIDS-like 
disease after in vivo passage in rhesus monkeys. 1. Virol. 70, 6922-6928. 
Rimmelzwaan, G.F., SiebeJink, K.H,J., Huisman, R.C., et al. (1994), Removal of the cleavage site 
of recombinant FlY envelope protein facilitates incorporation of the surface glycoprotein in immune 
stimulating complexes. 1. Gell. Viral.7S, 2097-2102. 
Rinunelzwaan, G.F., Osterhaus, A.n.M.E. (1995). A novel generation of viral vaccines based on the 
iscom matrix. Edited by M.F. Powell and M.1. Newman, New York Plenum Press, pp. 543-588. 
Rock, K.L. (1996). A new foreign policy: MHC class I molecules monitor the outside world. 
1lIIlIIlIIwl.Today 17,131·137. 
Schuitemaker, H., Koot, M., Koolstra, N.A., et al. (1992). Biological phenotype of human 
60 
Chapfer 2 
immunodeficiency virus type I clones at different stages of infection: progression of disease is associated 
with a shift from rnonocytotropic to T-ceH-tropic virus population. 1. Viral. 66, 1354-1360. 
Schutten, M., McKnight, A., Huisman, R.C., et al. (1993). Further characterization of an antigenic 
site of HIV -I gp 120 recognized by virus neutralizing human monoclonal antibodies. AIDS 7, 919-923. 
Schutten, rvl., Andeweg, A.C., Bosch, M.L., et aI. (1995). Enhancement of infectivity of a 
non-syncytium inducing HIV-J by sCD4 and by human antibodies that neutralize syncytium inducing 
HIV-l. Scatld. J. 111Imr11l01. 41, 18-22. 
Schutten, M., Andeweg, A.C., Rimmelzwaan, G.F., et al. (1997). Modulation of primary human 
immunodeficiency virus type I envelope glycoprotein-mediated entry by human antibodies. J. Gell. 
Viral. 78, 999-1006. 
Simmonds, P., Zhang, L.Q., McOmish, F., ct al. (1991). Discontinuous sequence change of human 
inulllmodeficiency virus (HIV) type I env sequences in plasma viral and lymphocyte-associated proviral 
populations in vivo: implications for models of HIV pathogenesis. J. Viral. 65, 6266-6276. 
Strijbosch, L.'V.G., Does, RJ.M.M., Buurman, 'V.A. (1988). Computer aided design and evaluation 
of limiting and serial dilution experiments. Jill. 1. Biomed. Computer 23,279-290. 
Tersmette, M., Gruters, RA., de 'Volf, F., et al. (1989). Evidence for a role of vindent human 
immunodeficiency virus (HIV)variants in the pathogenesis of acquired immunodeficiency syndrome: 
studies on sequential HIV isolates . . J. Firal. 63, 2118-2125. 
Trkola, A., Pomales, A.B., Yuan, H., et al. (1995). Cross-clade neutralization of primary isolates of 
human immunodeficiency virus type I by human monoclonal antibodies and tetrameric CD4-IgG. 1. 
Viral. 69,6609-6617. 
TrkoJa, A., Purtscher, M., Muster, T., et al. (1996). Human monoclonal antibody 2012 defines a 
distinctive neutralization epitope on the gp 120 glycoprotein of human immunodeficiency virus type I. 
J. Viral. 70, 1100-1108. 
Venet, A., Bourgault, I., Aubertin, A., et al. (1992). Cytotoxic T Lymphocyte response against 
multiple simian immunodeficiency virus (SIV) proteins in SIV-infected macaques. 1. Immullol. 148, 
2899-2908. 
Zhang, L.Q., MacKenzie, P., Cleland, A., et al. (1993). Selection for specific sequences in the external 
envelope protein of human immunodeficiency virus type I upon primary infection. 1. Viral. 67, 
3345-3356. 
Zhu, T., Mo, H., 'Yang, N., et al. (1993). Genotypic and phenotypic characterization of HIV-I in 
patients with primary infection. Science 261, 1179-1181. 
61 

Chapter 3 
Characterization of CTL t'esponses against primate lentiviruses 
3.1 Preservation of phenotype and function of positively selected virus-specific CD8+ T 
lymphocytes following anti-Fab detachment from immunomagnetic beads. Journal 
of IlIIlIIunological Methods (1993)161: 1 29-1 33. 
3.2 Simian immunodeficiency virus (SIV)-specific CD8+ cytotoxic T lymphocyte 
responses of naive and vaccinated cynomolgus macaques infected with SIVmac32H-
J5: quantitative analysis by in vitro antigenic stimulation. Vaccine (1997) J 5: 1269-
1275. 
3.2 CD8+ cytotoxic T lymphocytes of a cynomolgus macaque infected with simian 
immunodeficiency virus (SIV)mac32H-J5 recognize a nine amino acid epitope in 
SIV Gag p26. Journal afGeneral Virology (1997) 78:821-824. 

Chapter 3 
Short communication 
Preservation of phenotype and function of positively selected 
virus-specific CD8+ T lymphocytes following anti-Fab 
detachment from immunomagnetic beads 
A.M. Geretti, C.A.C.M. Van Els, CA. Van Baalen, M.C.M. Poe len and A,D.M.E. Osterhaus 
Laboralory of ImmllllObiofogy, National "mill/Ie of Pliblic Heallh alld Ellrirollmental Pm/ectioll, 3720 BA Bill/wren, Netherlands 
(Received 26 October 1992, revised received 9 December 1992, accepted 8 January 1993) 
Comparison of anti-Fab with overnight detachment of measles virus- or HIV-specific CD8+ T 
lymphocytes, positively selected with immunomagnctic beads, showed that the anti-Fab detachment 
procedure is a more rapid, efficient and reproducible method, which avoids downregulation of the 
targeted surface marker. 
Key words: CDS+ T cell, human; Immunomagnetic separation; Detachment; Cellular immune response: Measles virus; HIV 
Introduction 
In recent years, the cell fractionation proce-
dure with antibody-coated magnetic beads devel-
oped by Ugelstad (Ugeistad et aI., 1980) has been 
widely applied to both positive and negative sepa-
ration of T lymphocyte subsets for use in func-
tional studies, Previous reports (Funderud et ai., 
1990) suggested that overnight incubation of 
rosetted cells is an efficient method for cell-bead 
detachment following positive selection. Re-
cently, an alternative method of detachment has 
Correspondence to: A.M. Gerclli, Laboratory of Immuno· 
biology, National Institute of Public Health and Environmen-
tal Protection, P,O. Box I, 3720 BA Bilthoven, Netherlands. 
Tel.: 31-30·742219; Fax: 31·30·25~93. 
Abbrerialiolls: MV, measles virus; lIIV, human immunod· 
eficiency \lrus; B·LCL, D I)'mphoblastoid cell lines; CTL, 
cytotoxic T I)mphocyte; rVV, recombinant \'accinia \lrus; ER, 
experimental release; SR, spontaneous release; MR, maximal 
release; E:T, effector-to· target cell ratio; FMF, fluorescence 
mediated flow c)'tometf)'; mAb, monoclonal antibody. 
been proposed, based on the competitive action 
of a goat anti-mouse Fab antiserum on the cell-
bead interaction. This method proved succcssful 
for the isolation of B lymphocytes with preserva-
tion of both phenotype and function (Rasmussen 
et aI., 1992)_ We have applied the anti-Fab de-
tachment procedure to the isolation of CD8+ 
cytotoxic T lymphocytes (crL) with specificity for 
MV or HIV. The method was evaluated for both 
freshly isolated and cultured T cells and proved 
to be a rapid, efficient, and reproducible proce-
dure yielding highly pure and functionally intact 
T lymphocyte sUbpopulations. 
Materials and methods 
PBMC were obtained by Ficoll·Hypaque gra-
dient centrifugation of blood from healthy indi-
viduals, from patient lP suffering from acute 
measles infection, and from five asymtomatic HIV 
seropositive individuals. Magnetic beads coated 
with anti-CD8 mAb (Dynabeads 1\'{·450, Dynal, 
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Oslo, Norway) were used at various target cell· 
to-bead ratios to fractionate lymphocytes into 
CDS-enriched and CDS·depleted T cell subpapu-
lations, according to the manufacturer's instruc-
tions. For spontaneous cell-bead detachment, 
roscttcd cells were resuspended in RPMI 1640 
containing penicillin (100 U/mn, streptomycin 
(l00 M/ml), 10-5 M 2·ME and 2 mM L·gluta· 
mine (referred to as complete medium) and incu-
bated overnight at 37°C (Funderud et aI., 1990). 
For anti-Fab induced detachment, roscttcd cells 
were resuspended in 200 ,ttl of completc medium 
and incubated for 60 min in the presence of 
10-15 I.d of anti-mouse Pab polyclonal antiserum 
(DETACHaBEAD, DyoaO. Detached cells were 
harvested on a magnetic separation device (MPC· 
6, Dynal). 
Cytolytic activity was determined in standard 
sodium chromate (Sler) release assays, Briefly, 
fractionated and unfractionated effector cells 
were incubated with infected or control sler_ 
labeled target cells at various E: T ratios in du-
plicate wells (experimental release, ER). Sponta-
neous sier release (SR) (target cells plus medium) 
and maximal ster release (MR) (target cells plus 
5% Triton X-lOO) were determined in quadrupli-
cate wells. Supernatants were harvested after a 4 
h incubation at 3rC and analysed in a gamma 
counter. The percentage of specific lysis was cal-
culated according to the formula: (ER-SR/MR-
SR)' 100. SR never exeeded 25% MR. 
Resulls and discussion 
Yields and purity of T cell subsels 
We fractionated PBMC from five healthy indio 
viduals with anti·CD8 coated beads using a 10: 1 
bead to target cell ratio. Yields by 3!1ti·Fab de· 
tachment consistently exceeded 55% of the tar· 
geted cells. In contrast to previous reports 
(Rasmussen et aI., 1992), yields obtained after 
detachment by overnight incubation were more 
variable and less efficient, ranging from 20% to 
45%. With both detachment procedures, posi· 
tively selected subpopulations consisted of over 
99% T cells as assessed by FMF, whereas can· 
tamination of the negative fraction by targeted 
cells was always below 3%. Cell viability for both 
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enriched and depleted fractions consistently ex-
ceeded 95% as determined by dye exclusion 
counting. 
Cell surface expression of CD3 alld CDS markers 
The overnight detachment procedure led to 
decreased surface expression of the marker tar-
geted for fractionation, as we observed with both 
positively selected CD8+ (Fig. 1) and CD4 + (not 
shown) T lymphocytes. A similar observation has 
been reported previously with positively selected 
B lymphocytes (Funderud et aI., 1990; Rasmussen 
et aI., 1992). This may be due to cross-linking and 
downregulation of the surface marker as a conse-
quence of prolonged physical interaction with the 
immunomagnetic beads. In contrast, the surface 
expression of the CD8 marker was found to be 
unaffected on the cells detached with the anti-Fab 
procedure. Neither procedure affected the ex-
pression of the CD3 marker. Two representative 
examples are shown in Fig. 1. 
FUllctional studies 
We compared the lytic activity of MV-specific 
CDS+ crL detached by either the anti-Fab or 
the overnight incubation procedure. Bulk PBMC 
were obtained from patient JP 3 weeks after the 
onset of clinical symptoms of acute measles, and 
expanded in vitro by two cycles of stimulation 
with autologous MV infected B-LCL, as previ-
ously described (Van Binnendijk et aI., 19S9, 
1990). As shown by FMF, the stimulated bulk 
PBMC consisted of predominantly CD3 + T Iym· 
phoC)'tes (87%). The percentages of the 
CDS+CD4-, CDS-CD4-, and CDS-CD4+ sub-
sets were 56%, 26% and 5%, respectively. Cells 
were fractionated with anti-CDS coated beads, 
detached by either the anti·Fab or the overnight 
incubation procedure, and tested for their lytic 
activity against autologous MV-infected B·LCL. 
As illustrated in Fig. 2A, the MV·specific cyto-
toxic activity detected in the bulk PBMC was 
preserved in the CDS+ subset and no significant 
difference in activity between cells detached by 
the anti·Fab and or by the overnight incubation 
procedure was detected. Similar results were ob-
served with the CD8+ MV-specific crL clone JP, 
obtained from the same donor (Van Binnendijk 
et ai., 19S9, 1990). This clone was used because of 
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Fig. I. Expression of surface CD3 and CDS markers on T celts isolated with anti-COS-coated magnetic beads and detached by 
either the anti-Fab or the overnight incubation procedure. Cells were stained .... ith anti·CD3 fluorescein (FITC) conjugate and 
anti·CDS ph~'roerythrin (PE) ronjugate. Samples were analrsed by two-colour C}1ofluorimetry shortly after isolation. A,B: cells 
isolated from PDMC and detached by either anti-Fab (A) or overnight incubation (B). C,D: cells isolated from a CDS+ 
MY-specific CfL clone and detached by either anti-Fab (C) or o\-ernight incubation (D). 
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Fig. 2. A: cytotoxic activity of T cells isolated from bulk 
PBMe (patient JP), 3 weeks after the onset of symptoms of 
measles, stimulated with autologous htv-infecled B-LeL, and 
fractionated with anti·CDS-coated magnetic beads. Positively 
selected cells were detached from the beads b)' either the 
anli·Fah or the Q\'ernight incubation procedUre. Cells were 
tested against autologous MV-infected B·LeL Effector to 
target cell ratios (E:T) ranged from 1.25 to 20. Legend: 0, 
I~,is by unfr3ttionated PBMe; .0 I)~is by anti·Fab detached 
CDS+ fraction; 0, I)'sis by overnight detached CDS+ frac-
lion; e, I).is by CD8- fraction. B: cytotoxic activity of a 
CDS+ MV.specific crL clone (JP) before and after positi\'e 
seiel;tion with anti·CD8-l;oated magnetic beads, followed by 
the anti·Pab or the overnight detal;hment procedure. Cells 
were tested against autologous MV·infected B·LCL at effec· 
tor·to·larget l;cll ratios (E: T) ranging [rom 0.9 to 7.5. Results 
of one of two representative experiments are given. Legend: 
0, lysis by non·treated cells; +, lysis by anti·Fab detached 
cells; 0, lysis by overnighl detached cells. 
its well defined MV-specific MHC class I re-
stricted lytic activity. In two independent experi-
ments, positively selected clonal CDS+ T cells 
showed MV-specifie cytolytic activity similar to 
that of the untreated clone and no functional 
difference was detected between cells detached 
by either procedure (Fig. 2B). One explanation 
for the preservation of the functional activity in 
the cells with decreased CDS expression is that 
the downregulation of the targeted surface marker 
is only temporary and followed by rapid recovery. 
On the other hand, the loss might only have been 
partial, with retention of sufficient residual sur-
face molecules for the isolated cells to exert their 
function. 
Use of the anti-Fab detachmellt procedure to inves-
tigate cellular immune responses against HIV 
We evaluated the applicability of the immuno-
magnetic bead separation with anti-Fab detach-
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ment to the fractionation and analysis of HIV-
specific cytolytic activity of PBMC from HIV 
seropositive individuals. The procedure resulted 
in similar yields, viability, and purity of positive 
and negative cell fractions as obtained with PBMC 
from healthy individuals (data not shown). Func-
tional studies were performed with PBMC from 
HIV infected individuals, which were specifically 
stimulated in vitro with rVV-HIV gag infected 
autologous B-LCL (Van Baalen et ai., submitted). 
Stimulated PBMC were then tested for specific 
cytotoxic activity against a panel of a\1tologous 
and mismatched B-LCL expressing either gag or 
a control antigen. The unfractionated PBMC 
showed significant cytotoxic activity against autol-
ogous gag-expressing targets (26.7% at an E: T 
of 45: n. Comparison of the cytolytic activity of 
the anti-Fab detached CD8+ fraction and the 
CD8- fraction indicated that the gag-specific 
CfL activity predominantly resided in the CDS+ 
lymphocyte subset, with a percentage of specific 
lysis of 3S.9% compared to 3.5% of the CD8-
fraction (percentages of lysis of control targets 
have been subtracted from those of gag-infected 
targets). 
We conclude that the anti-Fab detachment 
procedure is a more rapid, efficient and repro-
ducible method of obtaining highly pure T cell 
fractions than the overnight detachment proce-
dure, and is a valuable adjunct to studying cellu-
lar immune responses to virus infections at the 
subset level. 
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Simian immunodeficiency virus 
(SIV)-specific CDS+ cytotoxic T 
lymphocyte responses of naive and 
vaccinated cynomolgus macaques 
infected with SIVmac32H(J5): 
quantitative analysis by in vitro 
antigenic stimulation 
Anna-Maria Geretti\ t. Ellen OJ. Hulskotte*, MarHnda E.M. Dings*, 
Carel A. van Baalcn*, Geert van Amerongen* and Albert D.M.E. 
Osterhaus*§ 
Detailed analyses of simiall immullodeficiency vims (SIV).specijic cytotoxic T lympho-
cyte (CTL) responses if! mecilln/cd alld illfeefed macaques may help to clarify the role 
of CTL immunity ill protecfion agailfSt lentMmses. Here, the optimal conditions for 
the measurement of SW Gag-specific CTL were irll'estigated by bulk and Iimitillg 
dilution assays of peripheral blood IllOlIOllltcfear cells (PBMC) from naive and vacci-
nated cynomolgus macaques (Macaca fascicularis) illfecred with SWmac32H(J5). In 
vitro resrimulatioll was generally required for CTL deleelioll. Seteclfl'e aelit'atioll of 
CD8+ alld MHC.restricted SlV Gag-specific CTL was illduced by stimulation with 
autologous para-fonnaldehyde-fixed B-Iymphoblastoid cell lines infected with a recom-
binant t'accillia vims eJ.pressillg SIV Gag. Applied to limitillg dUutioll assays, antigellic 
stimulation reproducibly demonstrated SlV Gag-specific CTL preCllrsors (CTLp) ill 
PBMe of all animals studied, illc/uding those lacking sigllijicafll responses ill standard 
bulk CTL assays. © 1997 Elsevier Science Ltd. 
Ke)llOrds: animal models, proleclive immunity. recombinant antigellS 
Even though cytotoxic T lymphocytes (crL) are 
believcd to contribute to the control of human and 
animal viral infcctions, their role in the host defense 
against lentiviruses has not bcen firmly established l • 
Infection of macaques with several strains or clones of 
simian immunodeficiency virus (SIY)mac shows 
remarkable similarities with human immunodeficiency 
virus (my) infection of humans!. Following SlY 
inoculation, a burst of virus replication is observed, 
which rapidly subsides in coincidence with the develop-
ment of antiviral immune responsesJ• The subsequent 
course of the infection varies considerably among 
macaques: some animals rapidly develop an AIDS·like 
disease and die within few weeks or months. whereas 
others may remain asymptomatic for > 3 years. This 
individual variability, combined with the opportunity to 
define parameters of infection such as strain, dose and 
route of virus inoculation, may prove valuable for clari-
fying the role of crL immunity in the control of lenti-
viral infections. 
·'nslilute of Virology, Erasmus University, P.O. Box 1738, 
3000 DR Rotterdam, The Netherlands. tPresenl address: 
Department of Virology, Division of Pathology and 
Communicable Diseases, Rowland Hill Street, london 
NW3 2PF, UK. tCentral Animal laboratory, National Insti-
tute of Pub!!c Health and Environmental Protection. 
P.O.Box 1, 3720 BA BiJlhoven, The Netherlands. §Author to 
whom all correspondence should be addressed. (Received 
21 October 1996; revised version received 2 January 1997; 
accepted 13 Janauary 1997) 
We4 and others5.6 have reported recently that 
vaccine-induced SlY Env-, Gag-. or Nef-specific crL 
failed to protect macaques upon challenge with cell-
free SIYmac. In the same model. however, Gallimore 
et al.7 found an inverse correlation beh .... een the 
frequency of vaccine-induced SlY Nef-specific crL 
precursors (crLp) and peak virus load measured after 
challenge. These findings indicate that crL may not be 
able to prevent or control HIY or SlY infection, unless 
stringent qualitative and quantitative requirements are 
mel. Detailed analyses of crL responses in both vacci-
nated and infected macaques may help to clarify these 
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requirements, thereby facilitating the design of 
immunotherapeutic intervcnlions8• However, initial 
reports have indicated that CTLp frequencies of 
immunized and naive rhcsus6.~ or cynomolgus4•7.11l 
macaques infected with SIVrnac may he relatively low 
by comparison with those often measured in HIV-l 
infected humans II, implying that sensitive and repro-
ducible methods are required to evaluate CTL 
responses in macaques. Extending observations 
previously made in HIV-l infected humans1W, we 
report here that ill ~'ilro expansion of effector cells 
under limiting dilution conditions by stimulation with 
SlY Gag recombinant vaccinia virus (rVV)-infcctcd 
and para-formaldehyde (pfa)-fixed B-Iymphoblastoid 
cell lines (B-LCL), significantly enhances CfL detec-
tion in both immunized and naive cynomolgus 
macaques infected with SIVmac32H(J5). 
MATERIALS AND METHODS 
Animals 
The study included eight colony-bred juvenile 
(1.5-3.5 years) cynomolgus macaques seronegative for 
SIV, Iype D simian retrovirus (SRV) and simian T cell 
leukaemia virus·1 (STLV-I). Four monkeys (designated 
K77*, KSO·, K83* and KSS*) were immunized with an 
SIV Env-Iscoms. Gag-Iscoms and Nef-Iipopeptides 
subunit vaccine, as described l • The other four monkeys 
(K73, K79, K66 and K71) were naive at the time of 
SIV infection. Animals were inoculated intravenously 
with 50 monkey median infectious doses of cell-free 
SIVmacJ5, a pathogenic molecular clone derived from 
SIVmae32H and grown on rhesus peripheral blood 
mononuclear cells (PBMqU, Infection was confirmed 
by virus isolation4, antibody detection in ELISA' and 
nested.Gag PCRu. 
POMe preparation 
Blood samples were drawn from the femoral vein 
into tubes containing heparin. PBMC were separated 
by density gradient centrifugation\ washed three times 
in complete RPM I 1640 medium (containing 
100 U ml-r penicillin, 100 Jig ml- 1 streptomycin, 
10-5 M p·mercapto ethanol and 2 mM L-glutamine), 
and either used immediately or cryopreserved. Cell 
viability (as assessed by Trypan Blue exclusion) 
exceeded 95% after thawing. Cell-associated virus load 
was determined in serial dilutions of freshly isolated 
PBMC co-cultured with the human T cell line C8166; 
the lowest dilution contained 106 PBMC'. Herpes 
papio·transformed B-LCL were established by incuba-
tion of PDMC with cell-free supernatant from the 
Herpes papio-producing ceUline S594, and maintained 
in complete medium containing 10% foetal calf serum 
(FCS; R-W). Serological MHC typing was performed 
by Dr R. Dontrop (BPRC, Rijswijk. The Netherlands). 
SIV p26 core antigen in plasma was assayed by 
antigen-capture ELISA (Coulter SIV Core Antigen 
Assay, Coulter Electronics, Mijdrecht, The 
Netherlands). 
Immunomagnetlc cell fractionation 
PBMe in complete medium with 2% FCS were 
mixed with magnetic beads coated with anti-CDS 
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monoclonal antibodies (mAb) (Dynabeads M-450, 
Dynal, Oslo, Norway) at a 1:10 target cell-to-bead 
ratio16• After incubation for 60 min at 4°C, fractions 
were separated on a magnetic separation device 
(MPC-6, Dynal). Positively selected CD8+ cells were 
detached from magnetic beads using a goat anti-
mouse-Fab polyclonal antiserum (DETACHaBEAD, 
Dynal). This separation procedure yields highly pure 
cell popUlations, without interfering with either CDS 
expression or cytotoxic function of effcctor cells(~. By 
immunofluorescence analysis positively selected 
fractions typically consisted of > 99% CD8+ cells, 
whcreas CD8+ contamination of depleted fractions was 
consistently <2% (data not shown). 
Immunofluorescence analysis 
Cell samples in PBS with 0.1% BSA were incubated 
for 30 min at room temperature with anti-CD2 
(Leu-5b-fluorescein isothiocyanate, Becton Dickinson, 
Mountan View, CAl and anti-CD8 (Leu-2a-phycoery· 
thrin, Becton Dickinson) or anti-CD4 (OKT4-FITC, 
Ortho Diagnostic System. Raritan, NJ) mAb. Samples 
were washed twice with PBS, fixed in 1.5% pfa and 
analysed with a FACScan (Becton Dickinson). 
Preparation of antigen presenting cells (APC) 
Autologous B-LCL were infected overnight with 
rVV (lOm.o.i.) expressing either the Gag p56 gene of 
SIVmac32H (kindly provided by Professor A. 
Md ... lichel, Institute of Molecular Medicine, O.xford, 
UK) or the Tat gene of SIVmac251 (TG4174, kindly 
provided by Dr M.P. Kieny, Transgene, Strasbourg, 
France), and subsequently fixed in 1.5% pfa. as 
described r2. Autologous irradiated (8500 rad) SIV Gag 
rVV-infccted D-LCL were used as APC in a limited 
number of experiments. Cultures stimulated with these 
APC showed no signs of vaccinia virus-induced 
cytopathic effects. Antigen expression in SlY Gag APC 
was confirmed by immunofluorescence analysis using a 
polyclonal bovine anti-vaccinia serum (RIVM, Dill-
hoven, The Netherlands) and the murine anti-Gag 
mAb CLBl4 (CLB, Amsterdam, The Netherlands). 
Bulk culture conditions 
Bulk assays were done with either unstimulated or 
restimulated PBMC. For antigenic stimulation, PDMC 
(2.5 x 104 per well) in R-1O were cultured for 14 days in 
96·well round-bottomed plates with SIV Gag or Tat 
APC (WI per well) and autologous irradiated 
(2500 rad) feeder PBMC (104 per well). Cultures were 
supplemented with 10 U ml- 1 recombinant interleukin 
(IL)-2 (rIL-2) from day 3, and restimulated with 101 
per well APC on day 7. During the second cycle of 
stimulation the culture medium was enriched with 10% 
supernatant from concanavalin A (ConA)-stimulated 
blasts. In some experiments, PBMe (106 ml- I) were 
cultured for 10-14 days with autologous irradiated 
PHA·blasts infected with SIVmac32H(J5) (lOS ml- I), 
as described by Gotch et al.n. For mitogenic stimula-
tion, PBMC (lOG ml-1) were cultured for 3 days with 
ConA (5/1g ml- 1), washed, and expanded with r1L·2 
(20 U ml- I ) for 4-11 days. Effector cells were assayed 
for cytotoxicity in duplicate or triplicate wells at 
indicated effector-to-target cell (E:1) ratios. 
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Limiting dilution cuUure conditions 
Limiting dilution assays were done with either unsti· 
mulated or restimulated PBMe, to estimate crL(~ and 
CfLp frequencies rcspccth'ely. POMe restimulation 
was performed as described for bulk assays. The 
optimal limiting dilution assay parameters, including 
numbers and ranges of dilutions, and numbers of repli-
cate wells, were predetermined for each monkey in a 
pilot experiment. All assays included at least four and 
up to eight PBMC dilutions, and each dilution included 
al least 24 and up to 48 replicale wells of 96-well 
round·bottomed plates. Three or four aliquo\s from 
each well were tested in split-well cytotoxicity assays. 
Cytotoxicity assay 
Cytotoxicity was measured in standard Ster-release 
assays against autologous and allogenic MHC class I 
mismatched B-LCL infected overnight with 10 m_o,i. of 
SIV Gag or Tat rVV, Autologous B-LCL either 
infected with 186-poly rVV (containing a polycloning 
site without insert and kindly provided by Dr M.P. 
Kieny, Transgene) or incubated with medium alone 
served as control. Targets were labelled for I h with 
100 I!Ci of llCr, washed three times, resuspended in 
R·IO, and added to effector cells at 5 x W' cells per 
well in 96-well round-bottomed plates (Costar. 
Cambridge, UK). After a 5 h incubalion. supernatants 
were harvested (Skatron Harvester, Skat ron, Oslo, 
Norway), and the release of SICr was measured in a 
gamma counter. Maximum SlCr release was determined 
by detergent (5% Triton X-IDO) lysis of target cells. 
Spontaneous release was determined by incubation of 
target cells in R·IO alone. Spontaneous release was 
<30% of ma",imum release. 
Calculation or resulls 
The percentage of lysis of specific and control targets 
was calculated for duplicate or triplicate wells of bulk 
cultures and (or each well of limiting dilution cultures 
according to the formula: %Iysis = (experimental 
release ~spontaneous release)!(maximum release 
~spontaneous release)] x 100, Individual wells of 
limiting dilution cultures were considered positive 
when lysis of specific targets exceeded by 10% that of 
control targets if the laller was < 10%, or by 20% if 
the latter was > 10%. In all positive wells the experi· 
mental release exceeded the spontaneous release by at 
least three standard deviations (S.D.). CfLp frequen-
cies were estimated by the maximum likelihood 
method using the statistical software packat;e descrihed 
by Strijbosch el 01. 19, wp.ich included a 1. goodncss-
of·fit test statistic. Frequencies were normalized to the 
number of CfLp per IO~ PBMC. Rates of change! 
month of follow-up (slopes), and correlation coeffi-
cients (r) of virus load, CfLp frequencies and CD4+ 
cell percentages were calculated by linear regression 
analysis. 
RESULTS 
Measurement of SIV Gag·speclfic CfL in bulk assays 
SIV Gag-specific CfL responses were studied in 
eight cynomolgus macaques during the first 4 months 
of infection with SIVmac32H(J5). Four monkeys (indi-
cated by an asterisk) had been immunized before infec-
tion with an SIV Env-Iscoms, Gag·Iscoms and 
Nef-lipopetides subunit vaccine\ whereas the other 
four animals were naive at time of virus inoculation. 
To establish optimal conditions for CfL measurement, 
we first compared in bulk assays the direct SIV 
Gag-specific CfL responses of unstimulated POMC 
with those mediated by the same PBMC following 
either mitogenic or antigenic ill ~'ilro restimuiation, A5 
shown in the examples of Figure lA, no significant CfL 
responses against SIV Gag were mediated by unstimu-
lated PBMC in E:T ratios up to 200;1. After mitogenic 
expansion with ConA (Figure 1B), effector cells 
specifically reactive against SIV Gag were detected in 
monkey K71. whereas relatively high levels of 
non·specific background lysis hindered reliable CfL 
measurement in monkey K8S·. In parallel, the specific 
lysis of SIV Gag rVV-infected targets was markedly 
enhanced by two I-week C)'CIcs of antigenic stimula· 
tion, using as APC autologous pfa-fixed B-LCL 
infected with SIV Gag rVV (Figure IC). 
Previously we'~ and others~' have shown that after 
pfa·fixation, Epstein-Barr virus-transformed B·LCL 
retain their ability to induce CfL activation, but lose 
their release of helper·like soluble factors. These 
factors are known to stimulate the growth of both 
MHC restricted and unrestricted cytotoxic cells reac· 
tive against the B·LCLJ3.20'. Extending these observa· 
tions to Herpes papio·transformed B-LCL, we 
observed that stimulation of PBMC from monkey K8S· 
with pfa-fixed SIV Gag APC elicited SIV Gag-specific 
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FIgure 1 In Vitro lestimutation Is lequ'led to detect SlY 
Gag-specific Cll in PBMC 01 immunized and non-immunized 
cynomolgus macaques infected \'lith SIYmac32H(J5}. Data are 
shown for two monkeys. Monkey Ksa* had been immunized with 
an SlY Env·rscoms, Gag-tscoms and Nef-lipopeptfdes subunit 
vaccine befole Infection. Monkey K71 was naive at the time of 
\'irus Inoculation. Effector cells were: (A) unstimulated PBMC 
Isolated either 12weeks (monkey K71) or four monlhs (monkey 
KSS*) after Infection; (SJ the same PBMC expanded by mitogenic 
stimulation with CorIA, and assayed twice, either on days 10 ( ... ) 
and 14 (~) 01 cuHure (monkey K71). 01 on days 7 ( ... ) and 10 
(-) 01 cu1!Ule (monkey KSS'); (e) the same PSMe expanded by 
two 1-week cycles of antigenio stimulation, using as APC 
autologous pla·fixed B·lel Infected with SN Gag iW. Targels 
wele autologous B-lel either Infected with SN Gag IW 01 with 
vaccinia virus (w) control, Of uninfected (medium contlOl). Results 
are expressed as mean specific lysis ±SD from triplicate (A and 
B) or duplicate (e) well estimations 
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Figure 2 Stimulation efficlency of StY Gag APe. Effector cells 
were generated by stimulation 01 PBMC from monkey K6S" with 
either pla·fixed (Al or irradiated (B and C) SN Gag APe. Targets 
wefe autologous 8·lCL either infected with SiV Gag rW or with 
vaccinIa virus (w) control, Of unlnfected (medium control). For 
cold target inhibition (C). non-labelled uninfecled B-lCL wele 
mixed with the $'Cr-Iabelled targets al a ratio 015:1 belore the GTl 
assay was Initialed. Results are expressed as mean specific lysis 
with S.D. from duplicate well estimations al an E:T ratio of 40;1 
CfL without significant expansion of cytotoxic cells 
reactive against control targets (Figure 2A). In contrast, 
after stimulation of the same PBMC with irradiated 
SIV Gag APC (Figllre 2B and C), relatively high 
numbers of cold (non-~'Cr-Iabelled) uninfected targets 
were required to inhibit non-specific background lysis 
and measure SlY Gag-specific CfL. 
In monkey K71, effector cells gcnerated by stimula-
tion with either SIV Gag (Figllre 3A) or Tat (Figllre 
313) APC mediated significant lysis of targets infected 
with the inducing rYV, but not of targets infected with 
either the discordant rVY or with vaccinia virus 
c~mtroL This finding confirmed that antigenic stimula-
!Ion induces selective CfL activation. Furthermore, 
Immunofluorescence analyses indicated an expansion 
of CD8+ cells at the end of the two cycles of SlY 
Gag-specific stimulation (data not shown). Depletion 
~tudies confirmed that SIV Gag-specific CfL were 
Indeed CD8+ cells: as shown in Figure 4 for monkey 
K71, SlY Gag-specific CfL responses mediated by 
total effector cells were preserved in positively isolated 
CD8· cells, but were abolished by CD8-depletion, In 
addition, these responses were restricted to autologous 
targets, whereas allogenic MHC class-I mismatched 
targets infected with SlY Gag rVV were not 
reco~nized. 
40 K71 A • T"-'l)<ts: 
'''G''APi' SIVTalAPC ___ --G~rVV ~30 -It.-Ta!('N ~ 
-o-.vronttol 
t 'G 
-----' 
~ 
, 
~ .~ 10 t:===o--. .-----0 __ ° 0-----
8 15 40 15 30 
E:T 
Figure 3 Se!octive expansion of antigen-speclfic eTL Effector 
cells were generated by stimu!ation of PBMe from monkey K71 
with elther SlY Gag (A) or Tal (B) APe. Targets were autologous 
8-lCl infected with either SIV Gag or Tat rW or with vaccinia virus 
(w) control. Results are expressed as mean specffic lysis with S.D. 
from duplicate well estimations 
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Figure 4 CDS' cel~mediated and MHC-restricted cytotoxic 
responses against SIV Gag. Effector cells generated by stTmulation 
of PBMC from monkey K71 with SlY Gag APC wele assayed as 
total eell population, positively isolated CDS' cells (:>99% CDS'), 
and CDS-depleted cell population «2% CDS'). Targets were 
autologous B·lCl infected with either S!V Gag rW or with vaccinia 
virus (w) control, and al!ogenic SlY Gag rW·lnlected B·lCl from 
three MHC class·[ mismatched monkeys 
Measurement of SlY Gag-specific CTL and CI'Lp In 
limiting dilution assays 
The frequencies of SlY Gag-specific CfL and CfLp 
were estimated by limiting dilution assays of unstimu-
lated and restimulated PBMC. respectively. The 
optimal assay parameters (Le. numbers and ranges of 
dilutions and numbers of replicate wells) yielding 'f 
goodness-of-fit test statistic < 10 were predetermined 
in a pilot experiment for each monkeys. Single-well 
cytotoxic responses of restimulated PBMC from 
monkey K71 are shown in Figure 5. In agreement with 
the results of bulk CfL assays {Figure IC}, after two 
I-week cycles of SlY Gag-specific stimulation, effector 
cells in most wells mediated killing of SlY Gag 
rVV-infccted targets (Figllre 5A), with negligible killing 
of control targets (Figure 5B). The relationship 
between the percentage of negative wells and the initial 
cell number was consistent with the single-hit Poisson 
model and. indicated a CfLp frequency of 58 (95% 
confidence mterval: 44-72; /:1) per to' PBMC (Figllre 
5C, filled circles). In contrast, in the absence of PBMC 
restimulation, SIV Gag-specific CfL were detected at 
a frcquency of only two (0.3-3; /:1) per 10' PBl'.'IC 
(Figure 5C, filled triangles). Similarly, 4 months after 
infection, the frequency of SlY Gag-specific crL in 
unstimulated PBMC of monkey K88* was only 2 
(0.4-4; 1.1:4) per 10' PBMC, whereas no CfL could be 
detected in unstimulated PBMC of other monkeys 
(data not shown). These findings confirmed that ill ~'i(ro 
restimulation greatly amplifies SlY Gag-specific CfL 
responses. 
Cell culture under limiting dilution conditions 
further increased the sensiti\'ity of CfL measurement. 
E\'en after SlY Gag-specific PBMC restimulation, 
monkeys with low, but still measurable CfLp frequen-
cies ( < 10 per 10' PBMC), showed no consistent CfL 
responses in standard bulk CfL assays, using E:T 
ratios up to 100:1. As an example, a comparison of 
bulk and limiting dilution assays of PBMC from 
monkey K66 is shown in Figllre 6. In bulk assays (Figure 
6A), no significant lysis of SlY Gag rVV-infected 
targets was mediated by PBMC that were unstimulated 
or restimulated with dthcr CunA or SlY-infected 
blasts. Lysis increased after SlY Gag-specific stimula-
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Figure 5 Umiting dilution analysIs of cytotoxlc responses agaInst SlY Gag. peMC Isolated from monkey K71 at week 12 after Infection 
were cultured In.six dilutions (range: 40000 to MIScalls per well), each Including 24 replicate wells. After two I-week cycles of SlY 
Gag-specifIC stimulation, Individual wells were tested against (A) autologous B-leL Inreelad with SlY Gag rW, and (8) autologous B·lel 
either In/ected with vae<:lnla virus (w) control Of linin/acted (medium control). and allogenIc SlY Gag tW·lnfected B·Lel from ona MHC 
class-j mismatched monkey. (el Frequency analys!s of SN Gag-specific CTt and cnp In unstimulated and restimulated PBMC, respec· 
wery. The relationship between the percentage of negawe wells and the Initial cell number was consistent with the sIngle-hit PoIsson 
model. FrequencIes were estimated by the maximum likelihood method and normal!zed to number 01 CTt or CTLp per 10~ PBMC. Dotted 
lines Indicate 95% confidence Imervals. The frequency of SlY Gag,specific CTl was 2 (0,3-3; I: 1) per lOs PBMC. The frequency of StY 
Gag-specific cnp was 58 (44-72; I: 1) per 10~ PBMC 
tion, but it was still < 10% after subtraction of 
non·specific background lysis. In limiting dilution 
assays, SIV Gag-specific CfLp were detected at a 
frequency of four (2-6; l.!: I) per W' PI3MC (Figure 
68). 
The reproducibility of CfLp frequency estimates 
was verified in 10 replicate assays of cl)'opreserved 
PBMC, which showed a mean coefficient of variation 
(as 100 x the S.D. of the residuals/mean CfLp 
frequency estimate) of 9.5% (data not shown). We also 
investigated the ability of SIV Gag APC to stimulate 
unprimed CfLp in naive PBMC isolated from the 
eight monkeys before exposure to either whole SIV or 
SIV antigens, These PBMC were assayed in paraliel 
with those obtained 4 months after infection, using 
identical culture and assay conditions. The individual 
wells of limiting dilution assays were never or rarely 
positive in naive PI3MC (CfLp frequencies < 1 per 10' 
PBMe slimulatroo 
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Figure 6 Bulk and limiting dilution assays of PBMC Isolated from 
monkey KeG al week 12 after Infection. In bulk assays (A). PBMC 
were unstimulated or restimulated with either CoM. or 
SIY-Inf~ted blasts, or SN Gag APC, and assayed In dupficate at 
an E:T ratio of 80;1. In limiting dilution assays (B), PBMC were 
restimulated with SN Gag APC. Target cells were autOlogous 
B-lel either infected with SlY Gag rW or with vacc!nla virus ('1'1) 
control (A and B) or uninfecled (medium control, B). The 
frequency of SlY Gag-specific CTlp was 4 (2-6; 1:1) per 10$ 
PBMC 
PBMC, data not shown), indicating that only primed 
CfLp were responsive to SlY Gag-specific stimulation. 
Kinetics of SIV Gag·specific CTLp 
In kinetic studies of the four monkeys that were 
naive at the time of virus inoculation, SIV Gag·specific 
CfLp were first detected between week 1 and 4 (K71, 
K73, K79) or 9 (K66) after infection (Table 1), CfLp 
detection in circulation coincided therefore with the 
containment of PI3MC·associated virus load and p26 
antigenemia which followed the initial virus burst 
observed at week 2 or 4 after infection·. The four 
vaccinated monkeys (K77', K80', K83· and K88*) had 
developed SIV Gag·specific CfLp upon immunization, 
at frequencies ranging from 2 to 13 per 11)' PBMC'. 
After infection, their CfLp frequencies were still 
similar to those found in the non·immunized animals 
(Table 1). In all eight monkeys, frequencies were gener-
ally maintained between week 12 and 4 months after 
infection, but a marked increase was observed in 
monkey K88*. Overall, no clear correlation emerged 
between CfLp frequencies and PBMC-associated virus 
load. In fact, 4 months after infection statistical analysis 
seemed to suggest a strong positive correlation 
between virus load and CfLp frequencies (r = 0.89, 
P = 0.003, not shown); however, this relationship was 
lost if monkey K88* was excluded from analysis. All 
eight monkeys remained asymptomatic during the first 
4 months of infection. Six animals showed a progressive 
decline' of CD4+ cell percentages. which was 
pronounced in monkeys K73 and K79 (Table J). 
DISCUSSION 
In the present study, we have studied the CfL 
responses of immunized and naive cynomolgus 
monkeys after infection with SIVmac32H(J5). We 
focused our attention on responses directed against the 
relatively conserved Gag protein, which has been 
described as a major target of CfL immunity against 
lentiviruses-',U.2I. Our findings demonstrate that anti-
genic stimulation of effector cells under limiting dilu· 
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Table 1 Evaluation 01 viro!oglca1 ",d Immunological parameters In vaccinated ",d naive cynomolgus macaques infected v.ith 
SIYmac32H(J5)' 
Monkey Virus !oad~ CTlp¢ CD4' cell slope· 
2-4 week (peak) 4 months 1-4weeksd 6-12weeks4 4 months 
K66 503 <1 0 4 (2-6; I) 5 (3-7; 3) -1.7±1 
K71 >1000 <1 27 (17-37: 4) 58 (44-72; 1) 55 (42-70; 3) +1±1.5 
K73 625 5 12 (8-17; 2) 9 (6-13; 1.5) 7 (5-9; 3) -4.3±O.5 (P<O.05) 
K7. >1000 6 14 (8-20; 1) II {IS-26; 2.5} 12 (8-15; 4) -3.2±O.8 (P<O.05) 
Kn' 2<>8 25 3 (1-5; 3) 7 (4-9; 2) 9 (6-12; 4) -O.S±O.S 
K80' 2<>8 3 8(4-12;2) 15 (10-21: 1) 12 (8-16; 2.5) -O.6±O.3 
K83' >1000 3 12 (9-16; 1) 13 (9-17; 1) 10 (7-14; 1) -1.3±O.9 
K88' >1000 156 N.D. 18 (12-24; 1) 121 (95-147; 1) -2.4±1 
'Data are presented for eight animals. Four monkeys (denoted by an asterisk) had been immunized with an SIV Env-Iscoms, Gag-Iscoms, 
Nef-lipopelides subunit vaccine before Infection, whereas the other four animals were naive at the time 01 virus inoculation 
~Cel1·associated virus load was measured in oo-cultures of PBMC with C8166 cells and normalized to the number of Infected cells per 10' 
PBMC 
'Effeclor cells were generated under limiting dilution culture conditions by stimulation with autologous pIa-fixed B-lCl infected with SIV Gag 
rW. Split·well"Cr·release assays were perfO/med on day 14 of culture. Frequenc!es were estimated by the ma;.;imum Hkehhood method 
and normalized to the number of CTlp per 10' PBMC; 95% confidence Intel"'.'als and / goodness-of-fit test statistics are gwen in 
parentheses 
~Resu1ts are presented from one of at least two experiments, with coeffic!ents of variation < 10% 
'Rates of change (slopes) in C04' celt percentages month-' were determined by linear regress!on analyses of longitudinal data obtained 
at minimum three time points (mean = 3.75) during 4 months of obsel"'.'ation. Positive ·slopes indicate increase, negative slopes correspond 
to a decrease 
tion conditions provides a sensitive and reproducible 
approach to characterize CTL responscs against SIV. 
With this approach we were able to detect SIV 
Gag-specific CTLp in PBMC of all animals studied, 
including those lacking significant CTL responses in 
standard bulk CTL assays (Fig/lre 6). 
III \';Iro restimulation was shown to be required to 
amplify SIV Gag-specific CTL responses to detectable 
levels (Figure 1). In contrast, Gag-specific CTL 
responses of asymptomatic HIV-I-infected adults have 
often been of sufficient magnitude to allow detection in 
primary assays. in the absence of ill I'i(ro restimula-
tion"·!!. In line with these observations, and in agrec-
ment with prcvious studics of SIVmac-infccted rhesus'·~ 
and cynomolgus!ll macaques, SIV Gag-specific CTLp 
were detected at frequencies generally lower than 
those measured in asymptomatic HIV-l-infecled 
adults l .U !. This discrepancy may reflect a relatively low 
degree of antigenic stimulation in macaques, due to 
rapid downregulation of SIV replication after infection. 
Our kinetic studies appear to support this hypothesis. 
Immediately after infection. we found that CTLp 
detection in the naivc macaques coincided with the 
initial decline of cell-associated virus load and p26 anti-
genemia. Subsequently, we found no significant differ-
ences in the CTLp frequencies of immunized and naive 
monkeys, whereas a posith'e correlation seemed to 
develop between virus load and the frequencies of SIV 
Gag-specific CTLp in the monkey showing relatively 
poor virus containment (Table I). Taken together, 
these observations support the hypothesis that the 
rapid development of CfL responses targeting certain 
critical viral proteins or epitopcs may indeed contribute 
towards the initial virus containmenf1..2.'. However, as 
also suggested by Ferbas et aU\ in cases of poor virus 
control, CTLp frequencies may become a reflection of 
persistently high levels of antigenic stimulation. 
To stimulate the growth of SIV Gag-specific CTLp 
we used autologous B·LCL infected with SIV Gag rVV 
and fixed in pfa. With a similar approach, we have 
been able to demonstrate Gag-specific CfLp in PBMC 
from HIV-I-infected persons, even after the onset of 
76 
overt disease'~. In the macaques, ill l'itro antigenic 
stimulation was shown to promote the selective e.xpan-
sion of SlY Gag-specific CTL of the CD8+ MHC class-
I restricted phenotype (Figllre 3Figllre 4Figllre 5). As a 
result, CTL detection was enhanced compared with 
results obtained after mitogenic stimulation with ConA 
(Figure I), a well·established method for CTL expan-
sion'·~. Other authors have also reported the use of 
rVV to expand CTL against HIV"< or SIV!" antigens. 
In the study by lubaki et aU·" the use of irradiated 
rVV-infected B-LCL as APC caused high levels of 
non-spedlie background lysis, and cold target inhibition 
was required to detect HIV-specifie CTL In our study, 
PBr-.·IC stimulation with irradiated SIV Gag APC also 
allowed crL detection in bulk assays when combined 
with cold target inhibition (Figllfe 2). However, this 
method did not allow a reproducible measurement of 
CTLp frequencies in limiting dilution assays (data not 
shown). Along the same line, Kent el aU" had to 
replace irradiated rVV-infected B-LCL with irradiated 
rVV-infected PBMC as APC to reduce the growth of 
non-specific cytotoxic cells and measure SIV-specific 
CTL The improved ratio of specific to non·specific 
lysis we obtained with pfa-fixed APC (Figllre 2). prob· 
ably resulted from an adequate preservation of their 
stimulation efficiency. together with a reduced rclease 
of T-heJper likc soluble factors that may stimulate the 
growth of non-SIV-spccific cytotoxic cclls'~~', 
Interestingly, a prcvious study by Venct e( (11.~ 
described an earlier development of SIV-induced 
disease in those monkeys which lacked detectable CTL 
responses. All our monkeys remained asymptomatic 
during the first 6 months of observation, Among the six 
animals with relatively low CTLp frequencies, five 
showed a progressive decrease of CD4+ cell percent-
ages. which was pronounced in only two cases 
(Table 1). Nonetheless, a longer follow-up may clarify 
whether the generation of higher SIV Gag-specific 
CTlp frequencies may be associated with a better 
long·term control of the infection in some monkeys. 
Studics are in progress to address this hypothesis, 
which may contribute to the design of effective \'accina-
Chapter 3 
tion strategies for the prevention and control of lenti· 
viral infections. 
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CDS+ cytotoxic T lymphocytes of a cynomolgus macaque 
infected with simian immunodeficiency virus (SIV) mac32H-J5 
recognize a nine amino acid epitope in SIV Gag p26 
Anna-Maria Geretti,'t Ellen G. J, Hulskotte,' Marlinda E. M. Dings,' Carel A. van Baalen,' 
Geert van Amerongen 2 and Albert D. M. E. Osterhaus' 
'Institute of Virology, Erasmus University, 3000 DR Rotterdam, The Netherlands 
2 Central Animal laboratory, National Institute of Public Health and Environmental Protection, 3720 SA, B,flhoven, The Netherlands 
A detaifed analysis of simian Immunodeficiency 
virus (SIV}-speclfic cytotoxic T lymphocyte (CTl) 
responses and the Identification of the proteins and 
epltopes they target may Improve the design of 
immunotherapeutic Interventions and provide in-
sights Into AIDS pathogenesis. Here, we Identified a 
newCTL epitope In the SIV Gag protein, recognized 
by COS+ and MHC class I-restricted CTL clones from 
a long-term asymptomatic cynomolgus macaque 
(Mococa fasclculor/s) Infected with SIVmac32H-J5. 
Using overlapping synthetic peptldes, the optimal 
minimal epitope was characterized as a nine amino 
acid peptide representing amino acids 242-250 of 
p26 (SVOEQIQWM). CTL recognItion waS shown to 
be abolished by amino acid substitutions observed 
wIthin homologous human Immunodeficiency virus 
(HIV)-1 and HIV-2 sequences. 
Infedion of macaques with several strains or clones of 
simian immunodeficiency virus (SIV) shows remarkable siml-
larities-with human immunodeficiency virus (HIV) infedion of 
humans and provides a valuable model for investigating the 
role of cytoloxic T lymphocyte (en) immunity in the host 
defence against lentiviruses (Desrosiers, 1990; lelvin (I al., 
1994). A number of studies have shown that detailed analysis 
of SlY-specific crL responses and the identification of the 
proteins and epitopes they target may help the design of 
immunotherapeulic interventions and provide insights into 
AIDS pathogenesis (Chen tI al., 1992; Yasutoml el al., 1995; 
Hulskolte eI aI., 1995). Extending our previous studies ofHIY-
I.infeded humans (Van Baalen tf al., 1996), we present here a 
Author for correspondeMe: Albert D. M. E. Osterhaus. 
Fax + 31 10 4365145. e-mail ostemaus$viro,fg9,eur.n.I 
t Department of Vir(/.ogy. Royal Free Hospital5chool 01 Medicine, 
RoWand Hill Street, london NW3 2PF, UK. 
minimally defined crl epitope in SIV Gag. recognized by CIl 
of the CDa+ and MHC class I-restrided phenotype. The 
epitope was identified using CTl clones and bulk cultures 
of peripheral blood mononuclear cells (PBMC) isolated from 
a cynomolgus macaque (designated K7I) during the first 
4 months of infedion with the pathogenic molecular clone 
SlVmad2H·J5 (Rud ef aL 1994). Following the initial virus 
burst at week 2 after infedion, the monkey showed effedive 
virus containment (Hullskotte tI al., 199.5), and remained 
asymptomatic with stable CD4+ cell counts during the 
subsequent 22 months of observation (not sho·wn). 
Effector cells were generated from PBMC under limiting 
dilution conditions. Cells in R-1O medium (RPMI 1640 
containing 10% FCS) were cultured with autologous 
paraformaldehyde-fixed B.lymphoblastoid cell lines (B-lel) 
(101 per wel!) infeded with a recombinant vaccinia virus (rVV) 
expressing Gag p.5.5 of SIVmad2H, and with autologous 
irradiated (2500 rad) feeder PBMC (101 per well), as described 
(Geretli eI al., 1996). Cultures received recombinant interleukin-
2 (r1l-2, 10 V/ml) from day 3, and were restimulated on day 7. 
On day 14, Ihey were tested in split-well assays against 
autologous ~lCr-labelIed B-lCl either infeded with SlY Gag 
rW, or infeded with a vaccinia virus control (I86-poly, 
containing a polydonal site without inser!; Transgene), or 
incubated with medium alone. Individual positive cultures of 
dilutions showing < 33 % positive wells tmderwent a third 
cycle of SIV Gag-specific stimulation and were subsequently 
subcloned by non-specific stimulation with PHA-L (1 jlg/mi), 
irradiated (2500 rad) allogenic PBMC (IDS per weU), irradiated 
(3500 rad) allogenic human B-lCl (lot per weU) (Van de 
Griend, 1984) and rll+2 (50 V/ml). These CTL are opera-
tionally referred 10 as lines. Eleven CTL lines were established 
and maintained in culture for at least 3 months by alternate 
(every 14-21 days) cycles of specific and non-specific stimu-
lalion. The crl lines' surface phenotype was CD2+ CDS+ 
CD4- (nol shown). Their fine specificities were detennined 
with three sets of la-mer synthetic peptides, O\'eriapping by 
10 amino acids, together spanning the p26 (ADP714/1-22), 
p17 (ADP77S/1-13) and pIS (ADP776/1+14) sequences of 
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FIg. 1, fine mapping of an MHC class I-restricted epitope In SiV Gag p26. CTl line K71JE26 was tested against: (a) 
autologous target B-lel either pulsed \'lith 30 j.lt.l synthetic peptides (20 residues 10119. w:th a 10 amino acid overlap) 
cO',eling the p26 (peptides 1-22), pl7 (peptides 1-13) and piS (peptides 1-14) sequellCes of SiVmac251 ; (b) auto!ogous 
target B-lQ sensitized with 30 J.ll>1 synthetic peptides (9--20 residues long) spanning amino adds 236-255 of p26; (e) 
auto'ogous, MHC class I mismatched and partially matched target B-LCL pu!sed with 30 lJ.~j peptide p26A5. Resu:ts are 
expressed as mean percentage speci& lysis with standa/d errOfS from du~icate we~1 estimations at an E:T ratio of either 5: 1 
(0)01"10:1 (b,c). 
Table 1. C08+ cytotoxk T lymphocytes expanded by 
stimulation with peptide p26A.5 
Effector ceUs generated by stirnulalion wllh autologous. peplide 
p26As.sensItized B·LCL were separated inlo posilinly Isolated CDS+ 
(CDS', > 99% cost cells) and CDS.depleted ((DS-, < 2% cost 
cells) fradions immediately before testing for cytoloxidly at different 
E; T Talios. Target cells were aUlologous B·LCL either sensItized I,·ith 
30 11M of peptide p26AS, or infected with SlY Gag rW or vacdnia 
virus (vv) control or incubaled wlth medium alone. Results are 
expressed as mean percentage specific lysis from duplicate well 
eslimalions with standard error < 10%. 
"!t> Specific lysis 
SIVGag 
effector cells E:T p26A5 ,w w Medium 
Total 50; 1 n OJ 13 13 
25; 1 ., 
" 
10 II 
12:1 
" " • 
7 
CDS' 50: 1 76 59 10 9 
25:1 61 53 , 
12:1 
" 
J5 7 , 
(DS- 50:1 • 
, 
• 25:1 , , 4 
12:1 , , 0 
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SIVmac25 I. As shown in Fig. 1 «(I) for the CTL line deSignated 
K7IjE26, of the 49 pepUdes tested, only peptide p26.11, 
covering amino adds 236-255 (IAGTISSVDEQIQWMYR) 
of p26, sensitized targets for lysis by Ihe CTL lines. The two 
contiguous peplides p26.10 and p26.12 were not recognized, 
indicating that the CTL epitope was contained in the central 
region of peptide p26.IL To define the minimal epitope within 
peptide p26.I1. the CTL lines were tested for recognition of 
synthetic peptides spanning amino adds 236-255 of p26 and 
varying in length from 20 to 9 residues (European Veterinary 
laboratory, Woerden. The Netherlands). As shown in Fig. I (b) 
for CTL line K71jE26, the 9·mer peptide p26A5, representing 
amino acids 242-250 (SVDEQIQWM) of p26. optimally 
sensitized targets for lysis by the CTL lines. Two truncated 
peptides lacking either the N·tenninal S residue (p26A.4: 
VDEQIQWMY) or the C-Ienninal M residue (p26A.6: 
SSVDEQIQW) were considerably less efficient. Further lrunc-
ation .at either terminus abolished recognition, probably by 
destroying MHC anchor residues. To sludy MHC class I 
reslriclion, the CTL lines were tested against MHC class I 
mismatched and partially matched B·LCL pulsed with peptide 
p26A5. As shown in Fig. l(c} for CTL line KnjE26, lysis was 
restcicled to targets sharing the Mafa-A2 allele. indicating 
recognition in the context of this macaque MHC class I 
molecule. It should be noted, however, that MHC class I alleles 
were defined by serological techniques, and one-dimensional 
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isoeledrk focusing may be required to confinn the restriction 
elemenl (Watkins, 1994). 
In reciprocal experiments, PBMC (2 x lOt per we!!) were 
cultured for 10 days with autologous irradiated (5000 rad) B-
LCL (lot per well) sensitized with 30 ~M of peptide p26A5, 
autologous irradiated feeder PBMC (Wi per well) and rJl-2 
(10 V/ml) from day 4. As a control, PBMC were stimulated 
with B-LCL sensitized with peplides p26.4, p26.6 orp17.6. No 
cytotoxic responses were mediated by these control cultures 
(data nol shown), whereas effeelor cells expanded by peptide 
p26A.5 recognized autologous targets sensitized with the 
inducing peptide, as well as targets expressing endogenously 
processed antigen afler infedion with SIV Gag rW (Table I). 
The C08+ phenotype of peptide p26A.5-specific en was 
confirmed by depletion studies (fable 1), using anti-C08 
antibody-coated magnetic beads (Dynabeads M-450, OynalJ 
as described (Gerelli dill., 1993). 
The amino add region 242-250 of p26 partially overlaps 
with C04+ T helper epilopes previously identified in im-
munized cynomolgus macaques (Mills & Jones, 1994). In 
addition, the homologous consensus sequences of the HIV -1 A 
and B clades fulfil the requirements for binding Ihe human 
HLA-A2.I molecule (Brander d al., 1995). The region is 
conserved among several strains of Ihe HIV-2/SIV 0 clade, 
including SIVrnac25I, SIVrnac32H, SIVrnaclAll and 
SIVmac239. The consensus sequence of Ihe HIV-2/SIV 0 and 
C clades shows one amino add substitution at position 242 
(S --J. T), whereas Ihe consensus sequence of the HIV-2/SIV A 
and B clades shows Iwo amino acid subslllutions, at positions 
242 (S -+ nand 244 (0 --J. E) (Myers d a/., 1994). The 
homologous sequence is highly conserved among most HIV-
1 clades (A-H). However, comparison of the SIVmac251 and 
HIV-1sn sequences reveals four amino add subslilutions at 
positions 242 {S --J. n 243 (V --J. r.), 244 (0 -+ Q) and 248 
(Q --J. G) (Myers (/ al., 1994). As shown in Fig. 2(a), targets 
that were either pulsed with peptide p24.11 (AOP 788/11), 
covering amino adds 235-254 of HIV-1sn p24 
(GSDIAGlTSTLQEQIGWMTN), or infeded with an rW 
expressing HIV-h.u Gag (TG1144; Transgene), were no! 
recognized by CTr. line K71/E26. These effeclor ce!ls also 
failed to recognize largets infeded l'Iilh an rW expressing 
HIV-2ROD Gag (TG2112; Transgene), suggesting either lack 
of generalion of the epitope, or that the two amino add 
substitutions at positions 242 (S --J. nand 244 (0 --J. E) of HI V-
2noD p26 were sufficient 10 abolish recognition. 
These observations suggest that variations in the p26A5 
epilope may generate virus variants able to escape or 
antagonize the CTr. response of monkey K71, thereby 
potentially affeding virus containment (Franco el aL 1995). 
Longitudinal studies are in progress 10 address this hypothesis, 
providing an additional basis for investigating the role of CTr. 
immunity in the control of !entiviral infedions. 
We [hank Professor A. McMichael (Institute of Molerular Medicine. 
Oxford. UK) for providing the SIVmacJ2H Gag p55 rVV, Dr H. C. 
Holmes (MRC AIDS Directed Programme, Potters Bar, South Mills, UK) 
for providing the ADP pepJides, Dr E. W. Rud (Health Canada, Ollawa, 
Ontario, Canada) and Dr M. P. Cranage (Centre for Applied Micro-
biology Jnd Research. Porion Down. Salisbury. UK) for providing 
SIVmacJ2H·J5, and Dr R. Bontrop (Biomedical Primale Research Centre, 
RijS\~iJk, Netherlands) for MHC typing. 
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Chapter 4 
Human Immunodeficiency Virus Type 1 (HIV-l)- and Epstein-Barr Virus-
Specific Cytotoxic T Lymphocyte Precursors Exhibit Different Kinetics in 
HIV-I-Infected Persons 
Anna l\I. Gerelti, Marl10da E. 1\1. Dings, 
C~cile A. C. M. van Els, Carel A. van Daalen. 
Folko J, Wljnholds, Jan C. C. Bodell!, 
and Albert D. M. E. Osterhaus 
IflStilli/e of nrology, ErrumUf University Rotterdam, Rotterdam: 
lilwralOry oj Vaccine Dewfopment and imnUl1It Mec},OIlUms, NatiOrlol 
1M/flute of Public Heolth WId E''m"'anmtnlal ProJection, BlllhoWTl; (lJIJ 
DepaTtme1Jf of Immunology Qlld illfrrno/ Medicine, 
Utudtl Unin:rsfty HOJpf/a/, Ulredll, Nether/o1Uu 
The frequencies of human immunodeficiency virus type 1 (HIV-l) Gag- and Epsteln·Barr virus 
(EBV)-speciflc cytotoxk T lymphocyte pr«ursors (CTLp) were studied longitudinally In peripheral 
blood mononuclear cells from 9 HIY·I-Infecled pefsons. By antlgen.specific stimulation, mV·1 
Gag-spe<:lfic CTLp were detected In vitro throughout tbc course of HN.l Infecllon, ncn after the 
onset of onrt disease. In 4 patients, howel'cr, HIY-l Gag-spedflc CTLp frequencies declined over 
time In the presence of maintained BOY·spedfic C11.p. This decline was correlated with decreasing 
cm (r '" .38; P < .05) and CD8 (r = .75; P < .001) celi numbers. The maintenance of BBY-
specific CTLp In patients with low cm cell numbers Indicated that EBY.specific CTL-medJated 
Immunity may remain longer unaffected by HIV·l-lnduud Immune dysfunction. Consistent with 
this observation, the growth of EBY·specific CTL could be supported In vilro by EBV·lnfecled 
Iyrnphoblastold B ceUlints, Independent of bolh em cells and eXGgeJlOus C)1okines. 
Human immunodeficiency virus type I (HIV-l)-specificcy-
totoxic T lymphocytes (CTL) are generated in most HIY-I-
infected persons and are generally believed to playa role in 
the containment of virus spread [1-4). The relatively conse!Ved 
HlY·1 Gag protein is a well·described target of the crL re-
sponse against mY-I: Gag-specific crL of the CDS and major 
histocompatibility complex (~iHC) class I-restricted pheno-
type have been detected in most asynlptomatic HIV-I-infected 
persons, e\'en without in vitro restimulation [5J. In addition. 
limiting dilution analyses have shown that the frequencies of 
Gag-specific CIL precursors (CTLp), although varying among 
HIY·J-infected persons, can be remarkably high in peripheral 
blood mononuclear cells (PBMC) from some asymptomatic 
persons (6-9J. Even though this strong response appears even· 
tually incapable of controlling HIY·) infection and preventing 
progression to AIDS, its decline as disease advances may sug-
gestthat significant, albeit temporary, antiviral effects are pro-
vided by HIV-l-specific CTL {9-12}. The mechanisms of 
CIL decline. however. have not been fully elucidated and it 
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Pr=ted in part: 12th European Immunology Meeting, Bucelona, Spain. 
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cannot be ruled out that this decline is a consequence rather 
than the cause of the progression of HIY-1 infection. 
Like HIV-l. Epstein.Barr virus (EBV) causes a life-long 
infection and induces strong and long-lasting C1L immunity 
[13}. Unlike HIY-l {14J, EBYestablisbes a slate of true latency 
in its host, interrupted by intennittent cycles of replication {IS). 
Substantial evidence indicates that virus-specific CIL playa 
part in controlling EBV infection of B lymphocytes and in 
preventing the outgrowth ofEBV-induced Iymphoprolifecative 
disorders [l6-JS}. Lymphoproliferalive disorders occur with 
increased incidence in patients with primary or acquired immu-
nodeficiency, including transplant recipients undergoing inunu· 
nosuppressive therapy and patients with AIDS. Interestingly, 
EDV sequences have been detected in virtually all transplant-
related but in only 25%-50010 of AIDS·related lymphoprolifer-
ative disorders {l9, 20J. II is also noteworthy that in HIV·I-
infected persons, the majority of ED V -induced Iymphoprolifer· 
alive disorders occur in the central ne!VollS system, where they 
may escape inununosurveillance. These observations suggest 
that HIV-I-infected persons may retain sufficient immuno-
competence to control EBV infection in advanced stages of 
disease, Consistent with this hypothesis, a cross-sectional study 
has suggested that the frequendes of EBV.specific CILp de-
lectable in H1V-I-Inf«:ted persons can be similar 10 those 
measurable in HlY.I-seronegative healthy persons [9}. In con· 
trast, an earlier cross-sectional study showed that the levels of 
EBV-specific C1L immunity are low in HlY-I-infecled pa-
Hents and decline further during disease progression [21). The 
occurrence of a sel«:tive dysfunction ofHIV-l~specific CIL 
in the presence of maintained C1L activity against EBV and 
the possible underlying mechanisms remain a matter of debate. 
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Here we present the results of a longitudinal study aimed at 
gaining further insight into the kinetics of HIV-l Gag~ and 
EBV-specific CTLp, and their relationship with circulating 
CD4 and CDS cells, during progression afHIY-l infection. 
Materials and Methods 
Stud), Group 
The study included 9 HIV-l-infe<:ted adults recruited from a 
cohort monitored at Utrecht University Hospital. HIV-! infection 
was related to intravenous drug use in I case, to high-risk hetero-
sexual contacts in 2 cases, and to high-risk homosexual or bisexual 
contacts in 6 cases. Six patients (Ew03, Fw19, Fw07, Ow21, 
Ow38, Ow39) remained asymptomatic throughout the study, 
whereas 3 patients (Ow43, Hw39, and Lw40) had dinical manifes-
tations of AIDS (CDC stages IV-A and IV-D) at the baseline 
visit. TOlalleukocyte counts were delennined at Utrecht Uniwrsity 
Hospital by standard methods. The patients' MHC phenotypes 
were detennined according to established National Institutes of 
Health procedures. 
PB:\IC PrEparation 
Blood samples were obtained from each patient at the baseline 
visit and at two or three consecutive time points. PBMC were 
separated from heparinized blood by density gradient centrifuga-
tion on ficoll-hypaque (Lymphoprep; Nycomed, Oslo), then 
washed three limes in RPMI 1640 containing penicillin (100 VI 
mL), streptomycin (100 pg/mL), IO-s M p·mercaptoethanol, and 
2 mML-glutamine (complete medium), andcryopreserved in liquid 
nitrogen until use. Cell viability (as assessed by trypan blue exclu· 
sion) exceeded 95% after thawing. 
Immunomagnetlc Cell Fractionation 
Magnetic beads coated with anti·CDS or anti-CD4 monoclonal 
antibodies (MAbs) (Dyuabeads M-450; Dynal, Oslo) were used for 
cell separation as described [22]. Briefly, cells were resuspended in 
complete medium supplemented with 2% fetal calf serum (FCS) 
and mixed with magnetic beads at a 10:1 target cell-Io-bead ratio. 
After incubation for 60 min at 4°C on a Rock-n-Roller (Snijders 
Scientific, Tilburg, Netherlands), rosetted cells were isolated on a 
magnetic separation device (MPC-6; Dyual)_ Immediately after 
fractionation, posith'ely selected cells were detached from mag-
netic beads using a goat anti-mouse Fab polyclonal antiserum (DE-
TACHaBEAD; Dynal) as described [22). 
Generation or B Lymphoblastold Cell Lines 
EBV-transfonned B Iymphoblastoid cell lines (il-LCL) were 
established by incubation ofPBMC with cell-free supernatant from 
the EBV-producing mannoset cell line B95-8 (American Type 
Culture Collection, Rockville, MD), in the presence of 3 Jlgfml 
cyclosporin A (Sandoz Phanna, Basel, Switzerland). B-LCl were 
86 
maintained in complete medium supplemented with 10% FCS 
(R-IO). 
Preparation of 111"·1 Gag Antlgen-Preuntlng Cells (APC) 
APC expressing the p55 protein of HIV-1LAt were prepared as 
described [23]. Briefly, autologous B-LCl were infected overnight 
with the recombinant vaccinia virus (rVV) TGIl44 (Transgene, 
Strasbourg, France) [24] at an MOI of 10 and then fixed in 1.5% 
parafonnaldehyde. Antigen expression was confinned by immuno· 
fluorescent analysis using a polycJonal bovine anti-vaccinia serum 
(RIVM, Bilthoven, Netherlands) and the murine anti-p24 MAb 
CLBl4 (CLB, Amsterdam) as described [23]. 
m"~1 Gag-Specific CIL 
LimUing diflilion Cllltrm.'s. At least four PBMC dilutions in R· 
10 were seeded in 96·well round-bottomed plates, and each dilu-
tion was done in at least 24 replicate wells. Appropriate numbers 
and ranges of dilutions and numbers of replicate wells were prede-
tennined for each patient with baseline PBMC samples. Cells were 
cultured with HIV-I Gag APC (104/well), autologous irradiated 
(2500 rad) feeder PBMC (104/well), and recombinant interleukin-
2 (rIL-2) at \0 VlmL (final concentration) from day 3. To Sludy 
CTLp activation requirements, PBMC and positively isolated CDS 
cells were cultured in limiting dilution with HIV_I Gag APC (lOl! 
well), with or without rIL-2 (10 UlmL), as indicated. After 14 days, 
m'O 50.pL aliquots from each well were screened for cytotoxicity 
against autologous B-LCL infected overnight with either HIV-I 
Gag rVV TOII44 or vaccinia control IS6 poly (10 MOl). To 
analyze MIIC restriction, HIV-I Gag-infected B-LCl from MHC 
class I-mismatched donors were used as targets in additional ex-
periments. 
Bttlk cultures. Positively selected CDS or CD4 cells (2 X lOt/ 
well) in R-IO were seeded in 96-well round-bottomed plates, in the 
presence ofHIV·] Gag APC (lOt/well), with or without autologous 
irradiated (2000 rad) CD4 cells (2 X IOllwell), and with or without 
rJL-2 (20 U/mL) from day 3, as indicated. After 14 days, cultures 
were screened for cytotoxicity against autologous B-LCl infected 
with either HIV-I Gag rVV or vaccinia control, at indicated ef-
fector-to-target cell (E:T) ratios. 
EBV-SPHific CTL 
Limiting dilution cultures. Parallel cultures were sel up as de· 
scribed abo\'e using PBMC from the same cell sample. Autologous 
irradiated (5000 rad) B-LCL infected overnight with EBV were 
used as stimulator cells at I01_1041well (stimulator-(o-effector 
cell ratio, < I: I), in the presence of autologous irradiated feeder 
PBMC (l04/well) and rJL-2 (10 UlmL) from day 5. To study 
CTLp activation requirements, positi\'ely isolated CDS cells were 
cultured with irradiated stimulator B-LCL alone. After 14 days, 
two 50-pl aliquots from each well were screened for cytotoxicity 
against autologous and MHC class I-mismatched EBV·infecled 
B-LCt. 
Chapter 4 
BIII!,-culfllres. PBMC (I0~/mL) were cultured in 24-w.::11 plates 
with autologous irradiated stimulator 8-LeL (I(l'i/mL), autologous 
irradiated feeder PBMC (Ifr'1/mL), and rIL-2 (10 UlmL) from day 
5. Alternatively, positively selected CDS Of CD-t cells (IO~/mL) 
wefC cultured with or without irradiated (2000 cad) CD4 cells (IO~I 
ruL), and with or without rJL-l (10 UfmL), in the preseoce of 
autologous imdiated stimulator B·LeL at indicated stimulator-
to-effector cell ratios. In additional experiments, autologous fi-
LeL were Created with parafonnaldehyde as described [23] before 
use as stimulator cells at IOsImL After 10 days, cultures were 
scrc<!ned for cytotoxicity against autologous and MHC class 1-
mismatched or partially matched B·LeL, al indicated E:T ratios. 
EBV-specific CTL lines were established by periodic restimulation 
(ewry 14-20 days) with irrndiated stimulator B-LCL, in the pres-
ence of autologous irrndiated feeder POMC and rIL-2 (20 UlmL). 
Immunofluorescence Analysis 
Circulating CD3, CD..\, and CD8 cells, cell fractions after immu-
nomagnetic separation, and e;"pandcd HIV-I Gag- and EBV-spe-
cific CIL were analyzed in double-color immunofluorescence 
analysis using fluorescein isolhiocyanate- or phycoerythrin·conju. 
gated anti-CD3, anti·CD4, and anti-CDS MAbs (Becton Dickin-
son, Etten-Leur, Netherlands). 
C)totol[dty Assay 
Cytotoxicity was measured in standard ~ICr release assays. Tar-
gets were labeled for I h with 100 pCi ofslCr al37eC in 7% COz, 
washed threl! times, resuspended in R-IO at 1O~/mL, then added 
to effector cells at 50 pL (5000 cells)!wel1 in 96-well round-
botlomed plates (Costar, Cambridge, UK). After a 5-h incubation at 
37'C in 7% COz, supernatants were harvested (Skatron harvester, 
Skalron, Oslo), and the release ofHCr was measured in a gamma 
counter. Maximum slCr release was determined by detergent (5% 
Triton X-tOO) lysis of targets. Spontaneous release was detemlined 
by incubation of target cells in R·IO alone. Spontaneous release 
was <25% of maximum release in all reported assays. 
Calculation or Results 
Percentages of lysis were calculated as follows: % lysis = [(ex-
perimental release - spontaneous releaseY(maximum release -
spontaneous release)] x 100. Individual wells of limiting dilution 
culiulX's were considered positive when lysis of specific targets 
exceeded by 10% that of control targets irthe Jauer was < 10% 
or by 20% if the latter was> 10"10. The reliability of these thresh· 
olds was tested by pilot experiments in which, after split-well CTL 
assays, residual cells oflimiting dilution cultures were restimulated 
to generate short·term CTL lines (data not shov.'ll). CTlp frequen-
cies were estimated by the maximum likelihood method using the 
statistical software package described by Strijbosch el al. [25]. All 
frequencies were normalized to the number of CTlplIO~ PBMe. 
Rates of change (slopes) and correlation coefficients (r) were cal· 
culated by linear regression analysis. 
Results 
KlneH~s or 111\'-1 Gag- and EBV.Speclfi~ CTI-p 
The frequencies of HlV·1 Gag- and EBV-specific CTLp 
were measured longitudinally in 9 HIV-I-infccted subjects. 
Of these, 3 (EwOJ, Fwl9, Gw21) remained asymptomatic and 
maintained CD .. cell numbers above 200lpL throughout the 
study, 3 (Fw07, G\\'38, and Ow39) remained asymptomatic but 
theirCD4 cell numbers declined to bclow 200/pL, and 3 others 
(Hw39, Lw40, and Ow43) had clinical manifcstations of AIDS 
(CDC stages IV-A and IV-D; figure I). Essentially two re-
sponse pattems could be distinguishcd: HIV-l Gag-specific 
CTLp were maintained or increased in 5 patients (figure IA), 
whereas they declined in thc remaining 4 patients (figure 18). 
In contrast, the frequencies of EBV-specific CTLp were main-
tained or even incrcased OYer time in all 9 patients. Figure 2 
summarizes the rates of change (slopes) of CTlp frequencies, 
as calculated by linear regression analysis of the longitudinal 
data. 
Reproducibility of CTLp Frequency Estimates 
Precautions were taken to reduce the influence of variations 
in experimental conditions on the outcome of CTLp measure· 
ments. First, to allow comparison, HIV-I Gag- and EI3V-
specific CTLp were measured in parallel in the same PBMC 
sample. Second, to improve the goodness of fit of limiting 
dilution analysis lines, pilot limiting dilution assays were caT-
ried out with baseline P8MC samples, prOYiding optimal num-
bers and ranges of dilutions and numbers of replicate wells fOT 
each subject [25]. Subsequently, PBMC from three or four time 
points were tested simultaneously using identical culture and 
assay conditions. The reproducibility of CTLp measurements 
was verified in 22 replicate experiments, which showed a mean 
cocfficient of variation (as lOOx SDs of the residuals/mean 
CTLp frequency estimate) of 7.4% ± 3.8% (data not shown). 
CorrelatIon or HIV-l Gag-specific CTLp Frequencies nlth 
CD4 and CD8 Cell Numbers 
The patterns of response in the 9 subjects appeared to be 
independent of the clinical status at baseline, as shown by thc 
presence of symptomatic patients (i.c" Gw43, Lw40, and 
Hw39) in each group. A clear relationship was detected be· 
tween thc kinetics of HJV-I Gag-specific CrLp and those of 
circulating CDS and, to a lesser extent, CD4 cell numbers 
(figure I). A cumulative analysis of this relationship is shown 
in figure 3. The frequencies of mV-1 Gag~specific CTLp 
showed a significant correlation (r = .38; P < .05) with the 
absolute numbers ofCD4 cells. A stronger and more significant 
correlation (r = .75; P < .001) was found bet\veen HlV·1 
Gag-specific CfLp frequencies and the absolute numbers of 
CD8 cells. A significant correlation was also observed between 
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t'igure 4. Single-well analysis of cytotoxic responses against mV-1 Gag. Baseline peripheral blood mononuclear cells (PBMC) from patient 
F .... 1>7 were seeded in 6 dilulions (range: 20,000-1000 cells/weil), each including 24 replicate wells. After 14 d3YS, 3 aliquot, from each well 
were screened for C}1010xicity against autologous (A) and major histocompatibility complex (MHC) class I-mismatched (8) B lymphoblastoid 
cell lines (S-L-eL) infected with HIV-I Gag recombinant vacdnia vilUs (rVV) and against autologous 8-LCL infected v.ith vacdnia control 
(C). D, % of negath'e wells plotted against initial cell no. Linearity of relationship is consistent with single+hit Poisson mode\. Frequency of 
HIV·' Gag-specific CHp (1110,100, or 99/1O~ PBMe) was estimated by maximum likelihood method (solid line interpolated at 37% negative 
wells). Dotted lines indicate 95% confidence intervals (74-1241106 PBMe). 
the patients' CD4 and CDS cell numbers (r = .43; P < .05; 
data not shown), where.as the frequencies of EBY -specific 
CTLp were not correlated with either CD4 (r = ~.097; P = 
.62) or COg (r = ~.057; P '" .77) cell numbers. 
Phenotype ot HlY-1 Gag-!pec[fic CTLp 
We have previously shown that in vitro stimulation ofPBMC 
from HlY·I-infected subjects with HIY·J Gag APC promotes 
the expansion of HlY-l Gag-specific CTL of the CDS and 
MHC class I-restricted phenotype [23}. In agreement with our 
previous observations, immunofluorescence analyses done on 
day 14 or 15 of limiting dilution cultures showed that cell 
populations in wells containing HIY·l Gag-specific CTLp 
were predominantly (>85%) of the CD3CDg phenotype and 
<1% were of the CD3CD4 phenotype (data not shown). Fur-
thennore, as shown in figure 4 for patient Fw07, additional 
limiting dilution analyses confmned that cytotoxic responses 
to mY·I Gag were directed predominantly against autologous 
rather than MHC class I-mismatched targets. 
Actlnllon Requirements or lilY-I Gag-specific CTL 
Limiting dilrllion assays. We studied the effects of CD4 
cell depletion on the expansion ofHIY·1 Gag-specific CTLp 
in patients Gw43 (baseline) and Hw39 (at 2 months). Limiting 
90 
dilution analyses were done with PBMC and highly pure 
(>99%) positively isolated CD8 ceUs in the presence ofHIY· 
1 Gag APC and rlL·2. As shown in table 1. the frequencies of 
HIY-l Gag-specific CTLp estimated in the positively isolated 
CDS cell fractions were only slightly lower than those mea· 
sured in PBMC. This indicated that the absence of CD4 cells 
did not have adverse effects on CTLp activation and expansion. 
To study the requirement for exogenous rIL.2, PBMC and the 
positively selected CDS cell fraction from patient Gw43 \"'ere 
Table I. FrequencyofHIY·1 Gag-spedficc)1otoxic T lymphoc}1e 
prtXursors (CTlp) determined by paralle1limiting dilution analyses 
of peripheral blood mononuclear cells (PBMe) and positively isolated 
CDS cells (CDS' fraction) from 2 HIY·I-infected patients. 
HIV-I-infeded patients 
Effecror cells rIL.2" GwH Hw39 
PBMC + 259 (197-321) 33 (23_4-1) 
CDS' fraction + 213 (164-262) 21 (10-31) 
PBMC 114 (91-13S) NT 
CDS' flaction )1 (10-52) NT 
NOTE. NT, not te.;led be.::3use of limited supply of PBMC ~mples. To 
faeilita!e comparison, all frequendes wue normalized to no. of CTLpllO' 
PBMC (95% confidence intervals). 
• Recombinant inurleukin·2 (rlL·2) was added to cultures on days ), 7, 
and 9. 
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cultured in limiting dilution with HlV-1 Gag APe alone. The 
expansion of HlV-1 Gag-specific CTLp was reduced in the 
PBMC and, to a greater extent, in the positively isolated CDS 
cell fraction (table I). This indicated that, particularly in the 
absence ofCD4 cells, exogenous r1L-2 was required to promote 
CTLp gro\vth. 
Bulk assays. The results of limiting dilution assays were 
confirmed in bulk assays of highly pure (>99%) posilh'eiy 
isolated CDS and CD4 cell fraclions from patient 0 ..... 43. As 
shown in figure 5 (line A), HlV-1 Gag-specific CTL were 
expanded from CDS cells cultured with HIV-I Gag APC, autol-
ogous irradiated CD4 cells, and rIL-2. The positively selected 
CD4 cell fraclion cultured in the same fashion showed a cyto-
toxic response mostly directed against control targets (figure 
5, line B). Consistent with the results obtained in limiting 
dilution, HlV-1 Gag-specific CTL were expanded from CDS 
cells cultured with HIV-I Gag APC and rIL-2 in the absence 
ofCD4 cells (figure 5,line C). Finally, no CTL were detected 
in CDS cells cultured with the same APC in the absence of 
both CD4 cells and rIL-2, 
Effects or CD4 Cell Enrichment on the Elpanslon or HIV-I 
Gag-specific CTLp 
Patient Hw39 showed a marked decrease of both HIY-I 
Gag-specific CTLp and CD4 cell numbers, while maintaining 
stable CDS cell numbers, between the second (2 months) and 
third (10 months) assessment (figure IB). To study whether 
CTLp detection at 10 months could be enhanced by CD4 cell 
enrichment, the positively isolated CDS cell fraction from time 
point 10 months (>99010 CDS ceils) was reconstituted with the 
CDS cell-depleted fraction from time point 2 months (31% 
CD4 cells, <2% CDS cells) before stimulation in limiting 
C03 CD4 APe rlL·2 
D • 
Hgure S. Activation requirements 
of lilY-I Gag-specific cytotoxic T 
'>mphocytes. Effector cells were 
positiyely selected CDS cells from 
patient Gw43 cultured with HIY·J 
Gag antigen'presenting cells (APC), 
autologous irradiated CD4 celis, and 
recombinant IL·2 (r1L-2) from day 3 
(line A); CD4 or CD8 cells cu1tu~d 
"'ith HIY-I Gag APC and rlL·2 
from day 3 (lines B, C); CD8 cells 
cultured with HIV-l Gag APC alone 
(line D). After 14 days, cytotoxicity 
was measured against autologous B 
lymphoblastoid cells infected with 
either HIV·J Gag recombinant \'3C-
cinia virus (rVY) or vaccinia control. 
Results are expressed as mean spe-
cific lysis with SE from duplicate 
well estimations at effector·!o-target 
cell ratio of 40: I. 
c 
B 
A 
dilutions. The reconstituted population contained 57% CDS 
cells from lime point to months and 13% CD4 cells from time 
point 2 months. In parallel, limiting dilution cultures were set 
up with PBMC from time points 2 months (14% CD4 cells, 
57% CDS cells) and 10 months (5% CD4 cells, 59% CDS 
cells). Despite CD4 cell reconstitution, the frequency ofHIY-
I Gag~specific CILp in the reconstituted population (figure 
6, bottom) was similar to that measured in POhlC from time 
point 10 months (figure 6, center) and still considerably lower 
than that measured in PBMC from time point 2 months (figure 
6, top). 
Phenotype of EBY.speclllc CTLp 
As also observed with HIY-I Gag-specific CTLp, immuno· 
fluorescence analyses done on day 14 or 15 of limiting dilution 
cultures showed that cell populations in wells containing EBV-
specific CILp were predominantly of the CD3CDS phenotype 
(data not shown). This observation suggested that EDV-specific 
CIL were indeed CDS cells and was consistent with the delee-
tion of cytotoxic responses restricted predominantly to autolo· 
gous targets. However, in both limiting dilution (data not 
shown) and bulk cultures of positively isolated CDS cell frac· 
tions (figure 7), the phenotype of cytotoxic cells against EBV 
was influenced by the ratio of stimulator to effector cells: Ratios 
below I: 1 were required to favor the gro .... 1h of MHC class 1-
restricted CIL over that of unrestricted cytotoxic cells. 
Characterization or EBV-spedlk CTL in Patient Gw43 
To analyze further the phenotype ofEBV-specific CIL, bulk 
PBMC cultures were done with stimulator B·LCL at I: 10 stirn· 
ulator·to·effector cell ratios and separated into positively iso-
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Figure 6. Frequency analysis of mv-' Gag-specific cytotoxic T 
lymphocyte precursors (CTLp) in patient Hw39. Effector cells were 
peripheral blood mononuclear cells (PBMC) from time points 2 and 
10 months (PBMC1• PBMC lo• respectively) and positi\'ely seltxted 
CDS cells from time point 10 months (CDS· (0) reconstituted with 
CDS.depleted fraclion from lime point 2 months (CDS' l ). Parallel 
cultures were set up in presence of HlV-' Gag antigen-presenting 
cells and recombinant interleukin_2 from day 3. Aner 14 days, cyto-
toxicity was measured against autologous B Iymphoblasloid cell lines 
infe~!ed with either HIV-I Gag recombinant vaccinia virus or ,'acdnia 
control. CTLp frequencies were 33 (23-44), 7 (3-11), and 6 (2-9)1 
105 PBMC, res~cli,·ely. 
92 
Targets: 
60 l1li Autologous 8-lCl 
D MHC class I mIsmatched B-lCl 
50 
w 
~ 40 
0 
!E 
0 30 
'" 0. W 
'$. 20 
10 
0 
10: 1 1 : 1 1 : 10 
Stimulator to effector cell ratio 
Figure 7. ElT~ts of stimulator-to-effector cell ratios on C)1otoxicity 
against EBV. Positively isolated CDS cdls from patient G\\'43 were 
cultured \\ith irradiated stimulator B lymphob1l5loid cell lines (B-LCL). 
autologous irradiated CI).j cells, and recombinmt interleukin-2 from day 
5. After JO days, cytotoxicity was measured a£ainsl autologous and 
major histocompatibility romplex (MHC) class I-mismatched B·LCL 
Results are expressed as mean sp..-xilic lysis \\ith SE from triplicate well 
estimations at effector·to-targ~1 cell ratio of 30: I. 
lated CD8 cell (>99% CDS cells) and CDS cell-depleted 
«2% CDS cells) fractions before use in CTL assays. As sho\\TI 
in figure 8 for patient G\\'43, the EBY-specific CTL response 
detected in the total effector cell population was entirely pre-
served in the positively isolated CD8 cell fraction. Conversely, 
the response was abolished by CDS cell depletion. In line with 
these observations, EBY-specific CTL lines established from 
PBMC ofpatien! Gw43 all showed a CDS and MHC class I~ 
restricted phenotype. The restriction of CTL line Gw43/004 
by MHC class I allele B62(15), detennined with panels of 
autologous, MHC class I~mismatched and partially matched 
targets, is illustrated as an example in table 2. 
Acth'alion Requirements of EBV-speclfk CTL 
Limiting dill/lio/l assays. To study the dependence ofEBY· 
specific CTLp on CD4 cells and exogenous rIL·2, limiting 
dilution analyses were done with the positively isolated CDS 
cell fraction from patient Gw43 (baseline), in the presence of 
irradiated stimulator B-LCL alone. As illustrated in figure 9, 
the frequency ofEBV·specific CTLp estimated in the positively 
isolated CD8 cell fraction (2241106 cultured CDS cells, equal 
to 141/106 PBMC) (figure 9, bottom) was similar to that mea· 
sured in parallel in the PBMC (154/106 PBMC) (figure 9, top). 
These results indicated that the activation and expansion of 
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EBV -specific CTLp was independent of both. CD4 cells and 
exogenous rIL-2. 
Bulk assays. Bulk cuHures of highly pure (99%) positively 
isolated CDS and CD4 cell fraclians from patient Ow43 con· 
firmed and extended the observations made in limiting dilution. 
As shown in figure 10, the presence of CD4 cells and rIL·2 
(figure 10, line A) was not required to promote the growth. of 
EBV -specific CTL, since this could be entirely supported by 
irradiated stimulator B·LeL (figure 10, line B), No crL were 
detected in the CD4 cell fraction cultured in the same fashion 
(figure 10, line C). Similarly, no CIL were detected in the 
CDS cell fraction cultured with rlL·2 alone, indicating that the 
presence of stimulator B·LCL was required for CIL activation 
(figure 10, line D). 
Eff«ts of B·LeL Fbailon In Pararormaldehyde 
As also shown previously by Fishwild et al. [26], the ability 
of stimulator B·LCL to support the gro\\llh of EBY -specific 
crL was abolished by fixation with parafonnaldehyde (figure 
10, line E). This inhibition was not corrected by the presence 
Table 2. Major histocompatibility complex (MHC) class i-reo 
stricted cytotoxicity against EBV. 
Targets' MHCdass I' % lysis 
Gw43 AIO, A24 (9), 835, B62 (15) 31 
611 A2, All, BH, B62 (IS) 21 
RV AJ, AIO(25), 818, B51 • 2JJ A), A24 (9). 035, B60 
067 A!Q (26), A2S, B1, B51 
GwJ8 A), AJI (19). B44 (12), 81l 
• Autologous and pMtia!ly matcbW EBV-inf~tecl B Iympoob!astoid c~U 
line$ a115:1 effector·lo-larget cell ratio. 
'Stured ]T.rnc class I andes are underlined. 
of autologous irradiated CD4 cells but could be partially over· 
come by the addition of exogenous rIL-2 at the beginning of 
culture (figure 10, line F). The latter finding indicated that 
parafonnaldehyde-treated B-LCL had retained their ability to 
activate EBV.specific CIL but lost their ability to promote 
CIL expansion, probably because of reduced release of soluble 
factors. 
DIscussion 
We report a longitudinal study showing that HIY-I-infected 
persons may retain EBY-specific CIL responses while losing 
both their CD4 cells and their CIL responses against the Gag 
protein of illY·!. 
For crLp deteclion we used an antigen-specific stimulation 
protocol that proved highly efficient in inducing selective 
expansion of MHC class I-restricted CD8 CIL against HIV-
I Gag [23} (figure 4). As also observed by Lubaki et a!. (27), 
antigen-specific stimulation allowed the detection of HlY·1 
Gag-specific CIL responses even in patients with advanced 
disease (figure 1)_ The frequencyofHlY-J Gag-specific CTLp 
differed considerably among patients, ranging from 5 to 3061 
106 PBMC, This is consistent with results obtained in cross· 
sectional studies of HlY-I-infected persons [6-9}: Frequen-
cies ranging from 5810 5881106 PBMC were reported by Koup 
et a!. [7], whereas Cannichael el a!. [9} measured HIY-I Gag-
specific CILp al frequencies ranging from 0 to ~488/106 
PBMC, Similarly, the frequency of EBY-spedfic CTLp dif· 
fered considerably from patienllo patient, ranging from 18 10 
3551106 PBMC (figure I), which is also in agreement with 
observations made by others {9. 13}. We studied extensively 
the reliability and reproducibility oflhe limiting dilution analy-
ses in assessing changes in crL immunity OVer lime, Optimal 
assay parameters were first detennined for each patient with 
baseline samples, and subsequently PBMC from all time points 
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Figure 9. Expansion ofEBV-spedflc cytotoxic T lymphocyte pre-
cursors (CfLp) in absence of CD4 cells and e;o;ogenous recombinant 
interleukin-2 (rIL-2). Limiting dilution cultures of peripheral blood 
mononuclear cells (pBMe, composed of 63% CDS cells) from patient 
Ow43 we[e done with irradiated stimulator 8 Iymphoblastoid cell 
lines (B·LeL). irradiated autologous feeder PBMe, and rlL-2 from 
day 5. In parallel, posith-ely isolated CDS cells (CD8\ >99% CDS 
cells) were cultured in presence of stimulator H·LeL alone. After 
14 days, cytotoxicity was measured against autologous and major 
histocompatibility complex class I-mismatched H-Lel. EBV-spe-
cific CTLp frequencies were 154 (1I7-19IYI06 PBMe and 224 
(171-278).11O~ cultured CDS cells, respectively. 
were tested simultaneously using identical culture and assay 
conditions. This resulted in a high reproducibility of CTLp 
measurements, with mean coefficient of variation among repli-
cate experiments of 7.4%. 
fn tv.·o earlier cross-sectional studies, the EBV-specific CIL 
responses of AIDS patients were compared with those of 
asymptomatic HIV-I~seropositive and healthy seronegative 
persons: The relatively high numbers of EBV -specific CTLp 
detected in some HIV-I-infe<:ted persons by Cannichael et a!. 
[9J are in agreement with our observations but seem to contra-
94 
dict the low levels of EBV -specific CTL immunity observed 
in HlV-I-infected persons by Blumberg et a\. [21].11 should 
be pointed out, however, that the study by Blumberg et a\. 
compared the results of bulk CTL assays rather than those 
of limiting dilution analyses. The latter approach may indeed 
increase CTL detection in HIV-I-infected persons (81. Our 
longitudinal study extends these initial cross-sectional observa-
tions by providing data on individual patients followed for up 
to 25 months (figure 2), together with evidence of a significant 
relationship between the kinetics ofHIV-l Gag CTLp frequen-
cies and those of circulating CD4 and CDS cell numbers (fig-
ures I, 3). Furthennore, we attempted to investigate possible 
mechanisms underlying EBV-specific CILp maintenance in 
otherwise immunocompromised patients. 
Several mechanisms have been proposed to explain mv-
I-specific CIL decline during disease progression, includ-
ing impairment of APC function [28I, infection ofCD8 celIs 
(291, emergence of CTL suppression pO, 31 J, and antigenic 
variation in HlV-i Gag leading to escape from CIL surveil· 
lance (32J. Ihe hypothesis that persistently high levels of 
antigenic stimulation may first lead to clonal expansion and 
subsequently to clonal exhaustion of virus-specific CD8 CTL 
has also been postulated [33, 34). CD4 T helper cell dysfunc-
tion is likely to play an important part in the decline of HIV-
I specific CTL immunity (35-37). In support of this view, 
we detected a significant correlation between the numbers 
of HI V-I Gag-specific CTLp and those of circulating CD4 
cells (figure 3, top left). Previous cross-sectional studies have 
either denied [38J or confirmed [39] this association, a dis-
cordance probably due to different methods ofCIL measure-
ment as well as different compositions of the groups of pa-
tients studied. 
CIL differentiation in vivo is a complex multistep process, 
which obviously can only be partially explored through in vitro 
studies. In particular, the degree of dependence on CD4 cell-
mediated help is likely to vary in relation to the stage of CTL 
differentiation and may become less stringent during in vitro 
recall. In an attempt to study this dependence, we found that 
the expansion of HIV-l Gag~specific CD8 CTLp, although 
requiring the addition of exogenous rIL.2, was not significantly 
influenced by removal (table I, figure 5) or enrichment (figure 
6) of CD4 cells. 
These findings imply that mY-I ~induced CD4 cell dysfunc-
tion may affect HIV-i-specific CIL responses at an early stage 
ofCTL differentiation. As a consequence, HIV-I-specific CTL 
may lose their responsiveness in vitro [12) and eventually dis· 
appear [40-42J. Indeed, a progressive disappearance of HIY-
i-specific CTL was suggested by the finding that the decline 
ofHlV·1 Gag-specific CTLp was strongly correlated with the 
decline of circulating CD8 cells (figure 3, bottom left). This 
strong correlation seems to confiml the view that in the course 
of HIV-I infe<:tion, the kinetics of circulating CD8 cells are 
mostly a reflection of the host response against HIV-I [38,39J. 
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In contrast with the frequency arHlY -I Gag~specific CTLp, 
the frequency of EBV-specific CILp was not correlated with 
either CD4 or CD8 cell numbers. Indeed, the most evident 
differences between the kinetics of HI V-I Gag-specific CTLp 
and those of EBV -specific CTLp were seen in the presence 
of marked CD4 cell decline (figure IB, figure 3 (top]), This 
observation indicates that EBV -specific CIL immunity may 
remain longer unaffected by mY-i-induced CD4 cell and 
cytokine dysfunction. Results of in vitro studies seem to support 
Ihis view. We found that EBV-transfonned B-LeL were able 
to finely regulate (figure 7) and support the growth of EBV-
specific CDS CTL (figure 8) in the absence of both CD4 cells 
and exogenous cytokines (figures 9, 10). as also reported in 
HlV-seronegative persons (26J. This ability of EBV-trans-
fonned D-LCL efficiently to activate EBV-specific CTL may 
reside in their high expression ofMHC antigens and accessory 
molecules. Support for CTL expansion may derive from their 
rich production ofsolub!e factors (figure 10) (26. 43J, including 
IL-12, a cytokine that by itself can induce differentiation of 
CTLp into mature CTL [44]. Therefore, EBY infection of B 
lymphocytes in vivo may result in the induction of high-affinity 
CTL [45], displaying a low degree of dependence from CD4 
cell-mediated help from the early stages of their differentiation. 
In summary, our data indicate that HlV-1 Gag-specific 
CTLp can be detected in vitro even after the onset of symptom-
atic disease, although, in some persons, their numbers decline in 
correlation with declining CD4 and CDS cells. The prolonged 
maintenance of EBY-specific CTLp in these persons may re-
flect the relative independence of EDY-specific CrL function 
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Figure 10. Activation require-
ments of EBV-specific cytotoxic T 
lymphoc)1es. Effector cells were 
positi~·ely selected CDS cells from 
patient Gw43 cultured with irradi-
ated stimulator B Iymphoblastoid 
cell lines (H.lCl), autologous irra· 
diated CD4 cells, and roxombinant 
inter!eukin·2 (IL-2) from day 5 (line 
A); CDS or CD4 cells cultured with 
autologous irradiated stimulator B-
lCL alone (lines B, C); CDS cens 
cultured with rIL-2 alone from day 
I (line D); CDS cells cultured with 
autologous paraforma!dehyde (pfa)· 
treated B-LCL and either autologous 
irradiated CD4 cells or r1L-2 from 
day 1 (lines E, F). After 10 days, 
cytotoxicity was measured against 
autologous and major histocompati. 
bility complex (MilC) class I-mis-
matched B·LCL. Results are ex-
pressed as mean spedfic lysis \\ith 
SE from triplicate well estimations 
at effector-to·target cell ratio of 
50;1. 
from HIV-I-induced CD4 cell and cytokine dysfunction, pos-
sibly providing one explanation for the relatively low incidence 
of EBY-related lyrnphoproliferative disorders in patients with 
AIDS. 
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SUMMARY 
The evolution of simian immunodeficiency virus (SIV)-specific cytotoxic T 
lymphocyte (CTL) responses, and their relationship with the kinetics of virus replication, were 
studied in peripheral blood mononuclear cells (PBMC) and lymphoid organs of cynomolgus 
macaques infected intravenously with the molecular clone SIYmac32H-JS. In the early stage 
of infection, CTL precursor (CTLp) frequencies in PBMC were higher than those in lymph 
nodes. In a latcr stage, a dissociation emerged between PBMC and secondary lymphoid 
organs: virus load was higher in both spleen and lymph nodes than in PBMC and CTLp 
frequencies reflected virus distribution. During up to 22 months of observation, effective virus 
containment in three animals was indicated by the absence of both culturable virus and PCR-
detectable provirus in PEMe. These findings were associated with a progressive decline of 
circulating SlY-specific CTLp, with the presence of relatively low-level virus reservoirs in 
lymphoid organs, and with at least partial susceptibility to homologous re-challenge. In one 
of these three animals, the detection of functionally immunodominant Gag-specific CTL, 
targeting amino acids 242-250 of p26 (SVDEQIQWM), coincided with the emergence of a 
variant virus carrying an aspartic acid to glutamic acid substitution at position 244. The 
mutated sequence was recognized poorly by CTL specific for the prototype epitope. However, 
CTL specific for the variant epitope were induced, which, like the variant virus itself, localized 
preferentially in the spleen. The observed compartmentalization of antiviral CTL to sites of 
virus distribution is consistent with their pivotal role in the containment of SlY infection. 
INTRODUCTION 
Even though the role of CTL in the host defence against lentiviruses has not as yet 
been firmly established, several observations indirectly support the view that CTL may indeed 
be effective against human immunodeficiency virus (HlV). CTL responses against HIV 
antigens have been detected in persons exposed to the virus but lacking evidence of infection 
(32). Furthermore, the detection of HIV -specific CTL ill infected persons may be correlated 
with the length of the asymptomatic period, whereas CTL decline is usually associated with 
more advanced disease (6, 15,22). A temporal association has also been described between 
the development of antiviral CTL and the containment of the acute phase of HIV replication 
(4,24). However, studies of the relationship between CTL responses and virus burden during 
the subsequent course of infection have yielded conflicting results (II, 22). 
The host and viral factors that facilitate virus persistence in the face of relatively 
strong antiviral C1L responses are still largely unknown. The high degree of variability shown 
by the HIV genome suggests that emergence of mutations within CTL epitopes may result in 
the selection of virus variants which escape recognition. In line with this hypothesis, single 
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amino acid substitutions have been shown to abrogate CTL recognition in vitro by affecting 
either MHC binding or TCR interaction (31). In addition, CTL escape variant viruses have 
been generated in vitro under selective CTL pressure (25), Virus variants containing mutations 
within CTL epilopes have also been demonstrated in vivo during infection with a number of 
viruses including HIV (5, 18,23). However, the biological relevance of these variants remains 
somewhat controversial (8, 27). The observation that chronically infected persons generally 
mount a polyclonal and multi specific CTL response against several HIV antigens (6), 
indicates that complete evasion from immune surveillance may be a rare occurrence. 
Nevertheless, even reduced efficiency of C1L recognition may affect virus containment in 
vivo. At the same time, rapid virus evolution may favour immune evasion by causing CTL 
exhaustion, as a result of persistently high levels of antigenic stimulation (38). 
Simian immunodeficiency virus of macaques (SIVmac) establishes a persistent 
infection in macaques which resembles HIV infection of humans (10). As iu humans, the 
course of infection varies considerably: some animals rapidly develop an AIDS-like disease 
and die within few weeks or months, whereas others may remain asymptomatic for a few years. 
Infection of macaques with a molecular clone of SIVmac offers a unique opportunity to 
explore the contribution of host antiviral immune responses to the containment of lentiviral 
infections. We have previously demonstrated that vaccine-induced Env-, Gag- or Nef-specific 
CTL did not prevent infection of cynomolgus macaques upon intravenous challenge with the 
molecular clone SIVmac32H-J5, nor were they associated with significantly reduced virus load 
immediately after infection (20). A number of earlier studies have also addressed the 
contribution of CTL responses to the control of acute SIV infection (12, 21, 29). Here, we 
investigated the relationship between SlY replication and antiviral CTL responses in 
chronically infected animals. As the analysis of peripheral blood may not adequately reflect 
events in secondary lymphoid organs, virological and immunological data from peripheral 
blood were compared to those from spleen and lymph node samples. 
MATERIALS AND METHODS 
Animals. Eight colony-bred juvenile cynomolgus macaques were infected intravenously with 
either 50 (primary challenge) or 200 (re-challenge) monkey median infectious doses of cell-free 
SIVmac32H-J5 (33). Four monkeys (K77*, K80*, K83*, and K88*) had been previously vaccinated with 
an SlY Bnv-, Gag-, and Net':.. subunit vaccine but became infected upon challenge (20). Observation 
lasted minimum t3 months (monkeys K73 and K79) and up to 22 months (monkey K66. K71. K77*. 
K80* and K88*). Monkey K83 was euthanized 18 months after infection upon development of 
symptomatic disease with diarrhoea and weight loss. 
Preparation of peripheral blood, lymph node and splenic mononuclear ceJls (PBMC, 
LNMC and SPMC). Animals were anaesthetized with kctamine for periodic blood sampling and lymph 
node biopsies. Spleens were removed at the end of observation. Lymph node and spleen biopsies in 
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complete culture medium (RPMI 1640 with 100 Ulml penicillin, 100 ~g/ml streptomycin, 10" M p-
mercaplo ethanol, and 2 mM L-glutarnine) containing 10% FCS were tcased with forceps to place cells 
in suspension and filtered through 112-)1m-pore-size nylon mesh. Mononuclear cells were separated by 
density gradient centrifugation (20), and either used immediately or cryopreserved. Herpes virus papia-
transformed B-LCL were established by incubation of PBMC with cell-free supernatant from cell line 
S594 (20). 
Flow cytometry analysis. Cells in PBS with 0.1 % BSA were incubated for 30' at room 
temperature with anti-CD2 (Leu-5b-FITC, Beckton Dickinson, Montan View, CA) and anti-CDS (Leu-
2a-PE, Beckton Dickinson) or anti-CD4 (OKT4-P1TC, Ortho Diagnostic System, Raritan, NJ) 
monoclonal antibodies (mAb), washed twicc. fixed in 1.5% paraformaldheide, and analysed with a 
FACscan (Beckton Dickinson). 
Virus detection. I. Cell-associated virus load was determined in serial dilutions of freshly 
isolated PBMC, LNMC and SPMC, and in their CD8·depleted fractions, by co-culture with the human 
T cell line C8166; the lowest dilution contained 10" cells (20). Cell separation was performed with 
antibody-coated magnetic beads (Dynabeads M-450, Dynal, Oslo, Norway) as described (14). II. SIV 
p26 core antigenemia was assayed by antigen-capture ELISA (Coulter SIV Core Antigen Assay, Coulter 
Electronics, Mijdrecht, Netherlands). Ill. A 500-bp tragment of SIV Gag was amplified by nested PCR, 
modified from Chen ct al. (8). Brieny. high molecular weight DNA was extracted with silica particles 
(3) from 106 freshly isolated PBMC, LNMC, SPMC, their CD4-enriched fractions, and the same cells 
after co-culture with C8166 cells. After heparinase treatment, IO.u1 of a 100,£.11 solution were 
resuspended in a tlnal volume of 100 .ul containing I X PCR buffer (50 roM KCI, I OmM Tris-HCI pH 
9.0,0.1% Triton X-IDO), MgCI,(1.5mM), dNTP (0.2mM), Taq polymerase (I U), and primers (31 pM). 
Two sets of primcrs were used, for outer (5'- CATTCACGCAGAAGAGAAAG; 3'-
GCATTTTGAATCAGCAGTG) and inner (5'-ACAAGTAGACCAACAGCACC; 3'-
TGAAATGGCTCTITTGGCC) amplification respectively. PCR conditions were: 1'10" at 94 'c, 1'30" 
at 50 D C and I' at 72°C for 25 and 30 cycles, with a 10' final extension. Amplified DNA was analysed 
on 2% agarose gel. Sequence analyses were conducted both directly and after cloning in a peR2 cloning 
vector with the TA cloning kit (In Vitrogen, Mountain View, CA). Automated sequencing was 
pertormed with the Dye Deoxy Terminator sequencing system (Applied Biosystems, Foster City, CA) 
with inner primers or T7 and SP6 primers. All clones were sequenced on both strands. Data were 
analysed with the Geneworks program (Intelligenetics, Mountain View, CA). 
Antibody detection. Anti-Env antibodies were measured by indirect ELISA (20). Virus 
neutralising antibodies were measured in a yield reduction assay. Briefly, I :50 serum dilutions (20 
J.tl/well) were incubated for 30' at 37°C with 20 J.tl of serially diluted SlVmac32H in eight replicates per 
dilution. C8166 cells (1.33X104/mi) were added to each well in 150 Jll. After 7 days, cells were 
transferred to paly-L-Iysine coated plates, fixed in methanol and analyzed by immunoperoxidase staining 
(20). 111e yield reduction was calculated as the ratio of vims titre (TCID50/mi) in the absence of serum 
to the titre in the presence of the sample serum. 
Recombinant vaccinia viruses. Recombinant vacinia vectors (rVV) were used to express: Env 
(20) and Gag p55 (provided by Prof. A. McMichael, Institute of Molecular Medicine, Oxford, UK) of 
SIVnmc32H; Nef of SIVmac32H-J5 (20); Pol of SIVmac-BK28 (ADP263, provided by Dr. H.C. Holmes 
through the MRC AIDS Directed Programme (Potters Bar, South Mills, UK); and Tat of SIVmac25I 
(TG4174, Transgene, Strasbourg, France). The vector 186-poly, provided by Dr M. P. Kieny 
(Transgene) and containing a polycloning site without insert, was used as control. 
Synthetic peptides. Three sets of peptides (20 residues long with a 10 amino acid overlap) 
covering p26 (ADP71411-22), pI7 (ADP77511-13), and piS (ADP77611-14) of SIVmac251 were 
provided by Dr. H.C. Holmes through the MRC AIDS Directed Programme. A 9-mer peptide designated 
p26A.5, covering amino acids 242-250 of p26 (SVDEQIQWM), and a 9-mer variant peptide containing 
an aspartic acid to glutamic acid substitution (D .... E) at position 244 (SVEEQIQWM), were synthesized 
at the European Veterinary Laboratory (Woerden, The Netherlands). 
Generation of effector cells. The optimal conditions for the detection of SlY -specific CTL 
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and CTLp were established as described (17). Effector cells were expanded by two I-week cycles of 
antigenic stimulation with 104/weil autologous paraformaldheide-fixed B-LeL infected with rVV 
expressing SlY antigens. In bulk assays effector cells were cultured at 2.5X I 04/well. In limiting dilution 
assays (LOA) the appropriate numbers and ranges of dilutions and numbers of replicate wells were pre-
determined for each monkey in a pilot experiment: cultures included at least four and up to eight 
dilutions, each dilution in at least 24 and up to 48 replicate wells. Both bulk and LDA cultures also 
contained autologous irradiated (2500 rad) feeder PBMC (lOt/well), recombinant interleukin-2 (rIL-2, 
10 U/m!) from day 3, and 10% supematant from ConA~stimulated blasts frorn day 7. For peptide~specific 
stimulation, effector cells (2XIO~/well) were expanded for to to 14 days with autologous irradiated 
(5000 rad) B~LCL sensitized with synthetic peptides (lO~/well), autologous irradiated feeder PBMC 
(to4/well), and r1L-2 (10 U/m!) from day 4. For mitogenic stimulation, effector cells (10 Iml) were 
cultured with ConA (5 ~glml) for three days and further expanded with r1L-2 (20 U/ml) for 4 to II days. 
Gag-specific CTL clones were derived frorn PBMC and characterized as described (16). 
Cytotoxicity assay. Cytotoxicity was measured in standard 5 hour .'iICr-releasc assays (17). 
Autologous B-LCL incubated overnight with either SlY rYY, vaccinia vims control, synthetic peptides, 
or medium alone were used as targets. For anti-CD8 blocking, effector cells were incubated for I hour 
with ascitic fluid of the anti-CD8 mAb PKI8 (37) at a 1:300 dilution, before adding the targets. 
Maximum .'iICr release was deterrnined by detergent (5% Triton X-I 00) lysis of target cells. Spontaneous 
release, determined by incubation of target cells in medium alone, was always <30% of maximum 
release. TIle percentage of lysis of specific and control targets was calculated for duplicate wells of bulk 
cultures and for each well of LDA according to the formula: % lysis = [(experimental release -
spontaneous release)/(rnaximull1 release-spontaneous releasc)]x I 00. Individual LDA wells were 
considered positive when lysis of specific targets exceeded by 10% that of control targets if the latter was 
below 10%, or by 20% if the latter was above 10%. In all positive wells the experimental release 
exceeded the spontaneous release by at least three standard deviations. CfLp frequencies were estimated 
by the maximum likelihood (17) and normalized to the number of CTLp/lO" mononuclear cells. 
Estirnates were accepted when their X2 goodness-of-fit lest statistics were < I O. Rates of change (slopes) 
of CTLp frequencies and CD4+ cell percentages were calculated by linear regression analysis. 
RESULTS 
Virological and clinical status of SIV-infecled macaques, As described previously 
(20), eight cynomolgus macaques were infected intravenously with SIVmac32H-J5, a 
pathogenic molecular clone derived from SIVmac32H. In monkey K71, PBMC-associated 
virus load and p26 antigenemia showed a peak between week one and two after infection 
(>1000 infected cellsllO' PBMC and 1.10 ng/ml respectively) followed by a rapid decline. 
Repeated aUempts to isolate virus from PBMC were unsuccessful between week 12 and five 
months after infection (Table I). However, during this time proviral DNA was detected in 
PBMC by nested Gag-PCR. Between 12 to 20 months after infection, virus isolation remained 
unsuccessful in both whole PBMC and their CD8-depleted fractions. In addition, repeated 
aUempts failed to detect proviral DNA by PCR in PBMC, their CD4-enriehed fractions, and 
the same cells after co-culture with C8166 cells. Similar results were obtained between 12 and 
22 months after infection with monkeys K77* and K80*, In contrast, virus was detected in 
PBMC of other five monkeys (K66, K73, K79, K83*, and K88*) for the entire length of 
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TABLE 1. Virological status and CD4+ cell slopes of SlY-infected macaques 
Monkey Virus detection" CD4+ cell slope" 
Peak load weeks months 
1~9 12 4-6 12 IS~20 
K66 503 + + ~ + ~ + ~ + ~ + ~ O_S ± 0.2 (0.004) 
K71 >1000 + ~ + ~ + 0 
K73 625 + + + + + ND -I.J±OA (0.04) 
K79 >1000 + + + + + ND - 0.7 ± 0.3 (0.04) 
K77~ 20S + ~ + + 0 
KSO' 20S + + + 0 
K83* >1000 + + + + + ~ O.S ± 0.2 (0_01) 
K88* >1000 + + + + 1+) + - 0.3 + 0.1 (0.04) 
"Vims isolation was performed in serial dilutions ofPBMC and their CD8-depleted fractions. Vims load 
(number of infected cells/106 PBMC) peaked at week two or four (monkey K73) after infection. Nested-
Gag-PeR was used to amplify provims DNA from PBMC, their CD4-enriched fractions, and the same 
cells after co-culture with C8166 cells. + + represents virus isolation positive, peR positive; (+) + virus 
isolation intermittently positive, peR positive; - + virus isolation negative, peR positive; - - virus 
isolation negative, PCR negative. ND, not done. 
"Rate of change with standard error (and P values) in CD4 + cell percentages/month calculated from a 
minimum of six measurements for each monkey (mean 8.1, range 6-9). 
observation (minimum 13 months) (Table 1). Seven of the eight monkeys remained 
asymptomatic during their respective observation periods. Monkey K83* developed 
symptomatic disease 18 months after infection. The percentages of circulating CD4 t cells were 
stable over lime in monkeys K71, K77* and KSO*, but declined significanlly in the other five 
monkeys (Table I). 
Frequencies of SlV·specific CTLp. The frequencies of Env~, Gag~, Pol~, Tal~ and Nef~ 
specific CfLp were determined in PBMe that were isolated from each monkey at three or four 
lime points after infection and tested in parallel under identical culture and assay conditions 
(Table 2)_ Before infeclion, monkeys K77*, KSO*, KS3* and KSS* had developed vaccine~ 
induced Env~, Gag~, or Nef~specific CTLp at frequencies up to 105110' PBMC (20). CTLp 
frequencies in naive PBMe isolated before exposure to either SlY or SlV antigens were 
always <2110' PBMC (nol shown). Multi specific CTL responses were detected between four 
and six months after infection: all animals had CTLp against Gag and Tat (7 of 7), and most 
had also CTLp againsl Env (6 of7), Nef (5 of7), or Pol (4 of7). Frequencies were in mosl 
cases < 15/10" PBMC, but higher eslimates (up to 121/10" PBMC) were obtained in monkeys 
K71, KSO*, and KS8*_ Over time, li-equencies appeared stable or increasing in monkeys K66, 
K79, and K88*, and stable or decreasing in monkeys K83*, K71, K77* and KSO*. After 20 
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TABLE 2. Frequencies of circulating SIV.specific CfLp 
SIV Month crLp/lO~ PBMC (with 95% confidence intervals) 
protein K66 K71 K79 K77* K80* K83*' K88*' 
Em' 4 0 I (0-3) 2 (1-5) 8 (5-11) 84 (64- 105) 7 (3-11) 99 (74-1231 
6 0 2 (03-41 2 (0.4-4) 5 (1-9) 36 (24-48) 7 (3-10) 51 04-68) 
12 6 (4-11) 2 (0-4) 4 (1-8) 6 (2-9) 30 (21-38) 0 46 (31-61) 
18-20 9 (4-14) 0 NO 6 (2-10) II (5-18) NO 61 (46-76) 
Gag 4 5 0-7) 56 (42-70) 12 (8-15) 9 (6-12) 12 (8-16) 10(7-14) 121 (95-174) 
6 15 (8-21) 60 (45-74) 12 (7-17) 8 (3-14) 12 (5-18) 4 (1-6) III (70-1521 
12 22 (13-31) 20 (13-26) 12 (6-18) 2 (03-3) 8 (4-12) 8 (4-13) 106 (66-1461 
18-20 26 (14-38) 3 (0.4-6) NO 2 (0-4) 4 (1-7) II (6-16) 118 (85-1511 
Pol 4 2 (1-4) 0 3 (1-5) 0 22 (16-29) 2 (1-4) 0 
6 7 (3-12) I (0-2) 4 (1-7) 2 (0-4) 17 (9-26) 2 (0.3-4) 0 
12 3 (0-6) 2 (0-4) 3 (0·6) I (0-3) 13 (8-19) 5 (1-10) 0 
18-20 4 (03-7) 0 NO 2 (0-4) 9 (4-15) NO I (0-2) 
Tat 4 0 23 (16-30) 9 (5-14) 5 (2-7) 6 0-9) 10 (5-141 III (84-138) 
6 4 (1-8) 21 (14-29) 70-11) 4 (0.5-7) 4 (1-7) 10 (5-141 83 (50-1151 
12 II (6-17) 10 (4-15) II (5-18) I (0-2) 0 0 94 (58-1291 
18-20 31 (20-42) 7 (4-11) ND 3 (0-5) 0 NO 99 (72-127) 
Ner 4 2 (1-3) 0 8 (4-12) 7 (4-10) 31 (22-41) II (6-13) 0 
6 2 (0-5) I (0-3) 13 (7-18) 8 (3-13) 14 (7-21) 10 (4-151 0 
12 3 (0-7) 2 (0-4) 15 (7-22) 5 (2-8) 15 (9-20) 0 3 (0.4-51 
18-20 2 <0-41 0 ND I <0-31 4 (1-71 NO 3 II-51 
months of infection, overall CTLp frequencies in the latter three monkeys waned to levels 
significantly (P <0.05) lower Ihan Ihose measured at four months. Monkey KS3* loslthe CTL 
response against Env, Tat, and Ncf one year after infection, but maintained the CTL response 
against Gag 18 months after infection, the time of onset of symptomatic disease. 
Data from peripheral blood were compared with those from axillary and inguinal lymph 
node biopsies obtained during the first five months of infeclion. As shown in Fig. I for 
monkeys K66 and K71, CTLp detection in PBMC coincided with the initial decline of virus 
replication and the development of virus neutralizing antibodies. The kinetics of cell-
associated virus load and Gag-specific CTLp in LNMC mirrored those of PBMC. However, 
from a quantitative perspective, CTLp frequencies in PBMC became over time higher than 
those measured in LNMC. The laller observation was confirmed afler adjustment of CTLp 
frequencies to the initial input of CDS' cells in the LDA, despite the finding that CD4': CDS' 
cell ratios were consistently higher in LNMC (1.9 to 2.6) than in PBMC (0.5 to 0.7). 
Kinetics of Gag- and p26A,S epitope-specific CTL in monkey K71. Eleven CD2' CD8' 
CD4- CTL clones were derived by Gag-specific stimulation of PBMC collecled Ii-Ofn monkey 
K71 at three and four months after infection. The fine specificity of all clones was mapped to 
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FIG. 1. Kinetics of ccll-
associated virus load 1000 
(number of infected 
cells/IO' mononuclear 
cells), virus neutralizing 100 
antibody (VN Ab) titres 
(yield reduction values) 
and Gag-specific CTLp 
10 frequencies (number of 
CTLp/l05 mononuclear 
cells) during the first 23 
weeks of infection with <1 . 
SICmac32H-J5. Data 
from PBMC were 
compared to those from 1000 
axillary (Ax) and 
inguinal (In) lymph 
node mononuclear cells 100 (LNMC). Error bars 
indicate 95% 
confidence intervals. 
10 
<1 
K66 PBMC K66 LNMC 
q -A-CTLp/l06 PBMC £ CTlp 110
6 lNMC 
-D· Virus load/tOG PBMe 
'. -*-VNAbtilres 
D Virus load 1106 LNMC 
C]" 
..., 
D~ .. /:; Ax 
In In 
.lA-f t ~ . .l n 
K71 PBMC K71 LNMC 
~- ~~ In Ax 
I" 
! ~ 
. '. 
: o· .'. 0 0 , , , , , , , 
5 9 13 17 21 25 1 5 9 13 17 21 25 
weeks 
a 9-mer peptide designated p26A.5, representing amino acids 242-250 (SVDEQIQWM) of 
p26 (16). Using synthetic peptides spanning the entire sequence of SIV Gag, it was shown that 
the same amino acid region was also the only target of Gag-specific effector cells expanded 
by mitogenic stimulation with ConA (Fig. 2). These findings were suggestive of a Gag-specific 
CTL response narrowly focused against the p26A.5 epitope. However, comparison of the 
frequencies of Gag- and p26A.5-specific CTLp suggested that CTL with other epitope 
specificities were present between 4 and 10 months after infection (Table 3). P26A.5-specific 
CTLp represented 77% of Gag-specific CTLp early after infection, but only 31 % to 49% 
between four and ten months after infection. The frequencies of GagHspecific CTLp, after 
reaching a plateau, declined more rapidly than those of p26A.5-specific CTLp. The rates of 
decline from four months after infection were - 4.2 ± 0.6/month (P ~ 0.003) and -I.I ± 
0.3/month (P ~ 0.01), for Gag- and p26A.5-specific CTLp respectively. As a result, between 
12 and 20 months after infection p26A.5-specific CTLp constituted 92% to 100% of Gag-
specific CTLp. To ensure comparability, Gag- and p26A.5-specific CTLp frequencies were 
measured simultaneously in the same cultures expanded by stimulation with SlY Gag rVV. 
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FIG. 2. Gag-specific CTL of monkey K71 recognize a nine-mer peptide in SlY p26. Effector cells 
derived from PBMC by stimulation with either SlY Gag rVV (solid bars) or ConA (open bars) 
recognized targets eilher pulsed with 30 ~M of peptide p26A.5 (SVDEQIQWM) or with peptide p26.11 
(IAGTTSSYOEOIOWMYRQQN). or expressing endogenously processed antigen after infection with 
SlY Gag rVV. Control targets were either infected with vaccinia virus (vv) control or incubated with 
medium alone. Results are expressed as mean specific lysis from duplicate well estimations at an E:T 
ratio of either 5: I (solid bars) or 20: I (open bars), 
TABLE 3. Kinetics of circulating Gag- and p26A5-specific CTLp of monkey K71" 
Month 
t.4 
4 
6 
7 
to 
12 
15 
20 
Expll 
30 (21-29) 
58 (44-73) 
62 (45-79) 
64 (48-80) 
41 (30-53) 
17 (10-23) 
t3 (9-16) 
3 (1-6\ 
Gag-specific CTLp 
Gag-stimulation 
Expt II 
NO 
56 (42-70) 
60 (45-74) 
NO 
NO 
20 (t 3-26) 
NO 
3 (0.4·6) 
p26A.s.specific CTLp 
Gag-stimulation p26A.5-stimulation 
23 (16·30) 24 (16-32) 
t8 (12-25) NO 
21 (15-28) NO 
25 (17-33) 23 (17-29) 
20 (13-27) 17 (11-23) 
t6 (9-22) 18 (12-24) 
12 (9-16) NO 
3 (1-6) 3 (0.4-6\ 
"After two one-week cycles of stimulation with either SlY Gag rVV or peptide p26A.5, fOllr aliquots 
from each well of limiting dilution cultures were tested for cytotoxicity against autologous B-LCL either 
infected with SIV Gag rVV or with vaccinia virus control, sensitized with peptide p26A.5, or incubated 
with medium alone. Frequencies (with 95% confidence intervals) were normalized to the Humber of 
CTLp/l O' PBMC. 
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CTLp frequencies were reproduced in independent replicate experiments (Table 3). 
In addition, the frequencies of p26A.5-specific CTLp measured after stimulation with SIV Gag 
rVV were reproduced in cultures expanded by stimulation with peptide p26A.5 (Table 
3).Inhibition studies were conducted with anti-CDS mAb using as effector cells i) the p26A.5-
speeitic CTL clone designated K71E/26 (16), and ii) positively selected CDS' cells expanded 
by stimulation with peptide p26A.5. In bulk assays, neither type of effector cells was 
susceptible to anti-CDS blockade (inhibition <10%, not shown), suggesting that the 
inununodominance of p26A.5-specific CTL may be related to high affinity effector cell-target 
cell interactions (I). Consistent with these data, anti-CDS blocking in LDA reduced the 
frequency of Gag-specific CTLp but not that of p26A.5-specific CTLp (Fig. 3). 
Homologous re~challenge. Twenty months after primary infection, monkeys K66 
and K71 were re-challenged intravenously with SIVmac32H-J5. Two naive monkeys were 
challenged at the same time to serve as controls. Consistent with previous findings (Table I), 
a burst of virus replication (up to 313 infected cells/lO' PBMC) was observed in the two naive 
monkeys between two and five weeks after infection (not shown). In monkey K71, a transient 
increase in virus burden was observed at week six after fe-challenge, in parallel with a 
transient decrease in circulating CD4+ cells (Fig. 4). An increase was detected in both the 
numbers and percentages of circulating CD8+ cells. 
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FIG. 3. P26A.5-specific CTL responses of monkey K71 are not inhibited by anti-CDS mAb. Effector 
cells were generated from PBMC by Gag-specific stimulation. Autologous 8-LCL either infected with 
SIV Gag rVV or with vaccinia virus control, sensitized with 30 I-tM of peptide p26A5, or incubated with 
medium alone were lIsed as targets. In the absence of anti-CD8 mAb, CfLp frequencies were 64 (range: 
48·80; X' = I) and 25 (17-33: X' = 5) for Gag- and p26A.5-specific CTLp respectively. In the presence 
of anti-CD8 mAb CTLp frequencies were 40 (29-51; X' = I) and 25 (17-33; X = I) for Gag- and 
p26A.5-specific CTLp respectively. Dotted lines indicate 95% confidence intervals. 
106 
Chapter 4 
FIG. 4. Re-challenge of 
monkey K71. Cell~associated 
virus load (number of infected 
cclls/l Olt PBMC) was measured 
in whole PBMC and their CDS-
depleted fractions. Nested-Gag 
peR was lIsed to amplify 
provirus DNA from PBMC, 
their CD4-enriched fractions, 
and the same cells after co-
culture with C8166 cells. Open 
boxes: peR negative; solid 
box: peR positive. Gag- and 
p26A.5-specific CTLp 
frequencies (number of 
CTLp/lO' PBMC) were 
determined in cultures 
expanded by Gag-specific 
stimulation and tested against 
autologous B-LCL either 
infected with SlY Gag rVV or 
with vaccinia virus control, 
sensitized with peptide p26A.5, 
or incubated with medium 
alone. Error bars indicate 95% 
confidence intervals, 
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Parallel LDA of PBMC samples isolated during the ten weeks of observation showed 
a progressive increase in Gag-specific CTLp: by week four after re-challenge their frequency 
(2211 0" PBMC; range: 15-2S; X'= I) was similar to that measured at week four after primary 
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infection (27/10' PBMC; range: 17-37; X = 4). In the same LDA, p26A.5-specific CTLp 
showed also a rapid but less pronounced increase: by week ten they represented 50% of 
circulating Gag-specific CTLp. These kinetics were confirmed in cultures expanded by 
stimulation with peptide p26A.5 (not shown). The frequencies of Tat- and Pol-specific CTLp 
also increased after fe-challenge, whereas, as seen before re-challengc. no CTLp were detected 
against Env or Nef (Table 4). In monkey K66, provirus DNA was repeatedly detected by PCR 
in PBMC, but virus isolation was sliccessful only at week four after fe-challenge. and only 
from CDS-depleted cells (virus load < 0.4 infected cells/lO' PBMC). The numbers and 
percentages of circulating CD4+ and CD8t- cells remained stable, whereas virus neutralizing 
and anti-Buy antibody titres showed a moderate increase (from 19 to 58 and from 128 to 267 
respectively, not shown). CTLp frequencies in PBMC showed also a moderate increase (Table 
4). 
Comparison of peripheral blood and lymphoid tissues 22 months after primary 
infection. After 22 months of infection, virus isolation and peR data from peripheral blood 
were compared to those from lymph nodes and spleen (Table 4). Overall virus burden was 
higher in LNMC and SPMC than in PBMC. Virus was recovered from both LNMC and SPMC 
of monkeys KSS* and K66; the highest virus load Was measured in SPMC of the latter 
monkey. Provirus DNA was detected by PCR in LNMC and SPMC from all five monkeys, 
including those lacking detectable virus in PBMC (K71, K77* and K80*). However, virus load 
in LNMC and SPMC of the latter three monkeys was below or barely above detection levels. 
CTLp frequencies were determined in parallel LDA of mononuclear cells from all three 
compartments, and compared after adjustment to the initial input of CDS' cells (Table 4). In 
the re-challenged monkey K66, and in monkeys K77* and KSO*, CTLp frequencies were 
higher in SPMC and LNMC than in PBMC. In the re-challenged monkey K71, CTLp 
frequencies in LNMC were lower than those in PBMC and SPMC, whereas those in SPMC 
werc similar to (Gag- and Tat-specific CTLp) or higher than (Pol-specific CTLp) those in 
PBMC. In monkey K8S* CTLp frequencies in PBMC were lower than those in LNMC but 
similar to those in SPMC. The three compartments contained CTLp of similar protein-
specificities, with the exception of Pol-specific CTLp, found in both PBMC and SPMC but 
not in LNMC of monkey K71, and Tat-specific CTLp, found in SPMC and LNMC, but not 
in PBMC of monkey KSO*. 
Prospective analysis of the p26,AS epitope sequence in monkey K71, The p26A.5 
epitope region of SIV Gag is conserved among several strains of the HIV-2/SIV D clade, 
including SIVmac251, SIVmac32H, SIVmaclAl1 and SIVmac239. The homologous 
sequence is also highly conserved among most HIV-l clades (A to H) (26). As amino acid 
substitutions in the homologous HIVR lsF2 and HIV-2RoD epitope sequences were shown to 
abolish recognition by CTL clone K71fE26 (16), we tested the hypothesis that variation in the 
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TABLE 4. Comparison of peripheral. lymph node and splenic mononuclear cells 22 months after primary infection 
Monkey cen Virus detection CTLp/l0(' mononuclear cells (with 95% confidence interval) CD8+% 
type (with load)' 
Env Gag Pol Tat Nef 
K66 
PBMC (+) + « 0.4) 9 (6- 13) 27 (19-35) 14 (10-19) 30 (21-39) 3 (1-5) 38 
LNMC + + (25) 17 (14-20) 35 (30-40) 16 (10-22) 35 (23-47) 3 (1 -5) 36 
SPMC + + (>3125) 31 (20-42) 47 (34-60) 18 (13-23) 47 (31-62) 3 (1-4) 40 
K71 
PBMC 0 34 (21-47) 12 (7-16) 16 (11-21) 0 50 
LNMC 
- + 0 7 (3-11) 0 5 (3-7) 0 36 
SPMC + + (1) 2 (0.3-4) 30 (23-37) 27 (20-34) 18 (12-25) 2 (0.3-4) 47 
K77* 
PBMC 0 2(1-4) 1 (0-3) 4 (2-6) 2 (0-4) 52 
LNMC 
- + 1 (0-2) 0 0 13 (6-20) 11 (7-16) 40 
SPMC - + 0 0 2 (0.4-4) 36 (23-47) 23 (16-30) 58 
KSO* 
PBMC 6 (2-10) 5 (2-8) 4 (2-7) 0 4 (1-7) 48 
LNMC + + (1) 11 (5-18) 13 (8-18) 9 (4-15) 7 (3- 10) 14 (12-17) 48 
SPMC + + (1) 15 (9-21) 22 (15-30) 8 (3- 13) 6 (2-9) 18 (14-22) 44 
KSS* 
PBMC ++ (5) 61 (46-76) 118 (85-151) 1 (0-2) 99 (72-127) 3 (1-5) 54 
LNMC + + (63) 69 (51-87) 89 (73-105) ND 75 (60-91) 3 (0.4-5) 36 
SPMC + + (25) 51 (40-62) III (99-123) ND 89 (71-107) 4 (2-6\ 49 
~.-.---.---
UVirus isolation was perfonned in serial dilutions of PBMe. LNMC. SPMC and their CDS·deplered fractions. Nested-Gag-PCR was used to amplify 
provirus DNA from PBMe, LNMC, SPMC, their CD4-enriched fractions, and the same cells after co-culture with CS166 cells. + + represents virus 
isolation positive, PCR positive; (+) + virus isolation intennittently positive, peR positive; - + virus isolation negative, PCR positive; - - virus isolation 
negative, PCR negative. Virus load was nonnalized to the number of infected cells/J 06 mononuclear cells. 
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FIG. 5. Genetic variation within the p26A.5 epitope. DNA samples were analysed by nested-PeR 
amplification of a 500 bp fragment of SlY Gag. Results of direct sequencing were contlrmed with 4 to 
10 independent clones from each sample. Sequencing was confirmed for both sense and antisense 
strands. Deduced amino acid sequences between positions 242 and 250 are shown in the single letter 
code. Dashes indicate amino acid identity with the SIVrnac32H-J5 sequence. 
p26A.5 epitope may generate CTL escape mutants. Sequence analyses of the p26A.5 epitope 
and its flanking regions were conducted by PCR amplification of a 500-bp fragment of SlY 
Gag derived from PBMC, LNMC, SPMC, their CD4-enriched fractions, and the same cells 
after co-culture with C8166 cells (Fig. 5). Four months after primary infection, the last time 
point at which provirus DNA was detected by PCR, PBMC were still harbouring the sequence 
of the JS molecular clone used for challenge. Ten weeks after re-challenge, a homogenous 
prototype virus population was detected in both PBMC and LNMC. In contrast, a single point 
aspartic acid to glutamic acid (D-t E) substitution at amino acid position 244 was detected in 
all spleen-derived sequences, including those derived from cultured samples. Outside the 
epitope. a second mutated region (N-->S) was identified in all spleen-derived sequences at 
amino acid position 143 (not shown). 
To study the effect of sequence variation on CTL reactivity, seven p26A.5-specific 
CTL clones were tested for recognition of a 9-mer variant peptide carrying the amino acid 
substitution D-E (SYEEQIQWM). Individual clones showed different patterns of reactivity 
(Fig. 6): three (e.g. K71 El26) did not recognize the variant peptide even at the highest peptide 
concentration tested (I 00 ~M), two (e.g. K71 El27) recognized the variant peptide with a lower 
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FIG. 6. Recognition of the prototype (SVDEQIQWM) and variant (SVEEQIQWM) p26A.5 epitope 
by CTL clones generated from PBMe of monkey K71 at three and four months after primary infection. 
Results are expressed as mean specific lysis from duplicate well estimations at an E:T ratio of 5: I. 
TABLE S. Recognition of prototype and variant p26A.5 epitope by CTL lines of monkey K7 I 
Months Peptide recognition" 
Prototype Prototype Prototype Variant 
only and > > 
Variant Variant Prototype 
1.4 17 (65) J (12) 5 (19) 1(4) 
10 10 (71) I (7) 2 (14) 1(7) 
22 II (69) 3 (19) I (6) I (6) 
+Short-term CTL lines were generated by p26A.5-specific stimulation of PBMe under limiting dilution 
conditions and tested in spliHvcll assays against autologous target B-LCL sensitized with 30 pM of 
either the prototype p25A.5 peptide (SVDEQIQWM) or a variant peptide carrying a single point 
mutation (SVEEQIQWM). Results are presented as numbers (and percentages) of CTL lines recognizing 
either the prototype peptide alone or both the prototype and the variant peptides with either similar 
(<10% difference in spednc lysis), higher or lower (14% to 55% difference in specific lysis) eftidency. 
efficiency Ihan the prototype peptide, whereas two olhers (e.g. K71 FJ 14) recognized both Ihc 
variant and the prototype peptides with a similar efficiency. These observations were extended 
using a large panel of short-term CTL lines (Table 5). These were derived by p26A.5-specific 
stimulation of PBMC isolated both before and after re-challenge. The majority (65% to 71 %) 
of CTL lines did not recognize the variant peptide, whereas the remaining recognized the 
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variant peptide with various degrees of efficiency. 
The effect of sequence variation on CTL induction was studied by investigating the 
ability of the variant peptide to stimulate ClL expansion in PBMC and LNMC isolated before 
and after fe-challenge, and in SPMC isolated at the end of observation. In bulk assays, the 
variant peptide was effective in inducing CTL expansion from SPMC, but was poorly 
immunogenic for PBMC and LNMC (Fig. 7a). Consistently, the frequencies ofCILp able to 
recognize the variant peptide were higher in SPMC than in PBMC or LNMC (Fig. 7b). These 
observations suggested the existence of three different CIL populations: one recognizing only 
the prototype peptide found predominantly in PBMC and LNMC; a second recognizing only 
the variant peptide found predominantly in SPMC; and a third smaller population recognizing 
both the prototype and the variant peptide found in all compartments studied. 
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FIG. 7. Bulk (top) and limiting dilution (bottom) assays of CfL responses against prototype 
(SVDEQIQWM) and variant (SVEEQIQWM) p26A.5 epilope. PBMC, axillary (Ax) and mesenteric 
(Mes) LNMC, and SPMC were isolated from monkey K7t both before and after re-challenge. Effector 
cells were generated by stimulation with either the prototype (left) or the variant (right) p26A.5 peptide. 
Results of bulk assays are expressed as mean specific lysis from duplicate well estimations at an E:T 
ratio of 10: I. CfLp frequencies were normalized to the number of crLp/lO~ mononuclear cells; error 
bars indicate 95% confidence intervals. 
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DISCUSSION 
In this study we followed the evolution of SlY-specific CTL responses of macaques 
infected intravenously with the molecular clone SIYmac32H-J5. We showed that effective 
virus containment, as indicated by the absence of detectable virus in PBMC, was associated 
with declining CTLp frequencies in circulation and with at least partial susceptibility to re-
infection. We showed also that the presence of functionally immunodominant Gag-specific 
CTL coincided with the emergence of a virus variant carrying a mutated epitope sequence. 
This was recognized poorly by CTL primed by the prototype sequence, but induced new CTL 
specificities. Finally, we showed that both SlY protein- and epitope-specific CTL of 
chronically infected animals localized preferentially in the sites of virus distribution. 
We have previously reported that antigenic stimulation of effector cells under LDA 
conditions allows a sensitive and reproducible assessment of SIV -specific CTL imlllUnity over 
time (17). With a similar approach, we have demonstrated CD8+ MHC class I-restricted CTL 
in HlY-1 infected humans even after the onset of overt disease (15). CTLp frequencies of SlV-
infected monkeys were lower than those often found in HIY -I infected humans (Table 2), as 
also shown in previous studies of SIV-infccted rhesus and cynomolgus macaques (12, 21), 
Besides the influence of host genetic factors, relatively low CTLp frequencies may reflect a 
low degree of antigenic stimulation in vivo, due to rapid downRregulation of SIV replication 
after infection. In support of this view, high frequencies of circulating CTLp were found in the 
monkey with the highest PBMC-associated virus load (i.e., K88*, Table 2 and reference 17). 
No evidence was found in the other monkeys of an inverse relationship between virus load and 
frequencies of circulating CTLp (17, 20). 
As a consequence ofrapid virus containment. CTL may eventually disappear or home 
to potential sites of active virus replication, such as lymph nodes (19) and spleen (9). To 
address this hypothesis. CTL responses and virus load were analyzed prospectively in 
peripheral blood and secondary lymphoid organs. Immediately after infection, CTL detection 
in circulation coil1cided with the initial dowl1~regulation of virus load and SIV p26 antigenemia 
(Fig. I). Similar observations have been made with both HlV-I-infected humans (4, 24) and 
SlY -infected macaques (12, 29). In contrast with previous findings (12), but in agreement with 
others (2), the initial virus containment also coincided with the detection of virus neutralizing 
antibodies (Fig. I). During the early phase of infection, cell-associated virus load and SIY-
specific CTLp frequencies showed similar kinetics in PBMC and LNMC, but, from a 
quantitative perspective, CTLp frequencies became rapidly higher in PBMC than in LNMC 
(Fig. I). Although kinetic data obtained from different lymph nodes should be interpreted with 
caution, our conclusions are supported by the finding that in the early phase after intravenolls 
SLY infection virus load and histopathological changes are similar in different (axillary and 
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inguinal) lymph nodes of the same animal (7). Parallel do\Vn~reglllation of virus replication in 
both peripheral blood and lymph nodes following the initial burst of SlY replication (Fig. I ) 
has also been reported (7, 29). 
In a later stage of infection a dissociation emerged between peripheral blood and 
secondary lymphoid organs (Table 4). Overall virus burden was higher in both LNMC and 
SPMC than in PBMC, which is consistent with observations made during chronic infection 
with HIY-I (9) or SlY (7). Our data extend these previous studies by demonstrating that 
during the chronic phase of infection SlY-specific CTLp frequencies mirrored virus 
distribution. These observations are consistent with CTL being the effector cells of the in vivo 
immune response against SlY. 
Additional support for a role of CTL immunity in virus containment comes from the 
observation that CTLp frequencies declined before the onset of symptoms in the monkey 
which developed overt disease (i.e., K83*, Table 2). Longitudinal evaluation also led to the 
identification of three monkeys (e.i., K71, K77* and K80*) showing remarkable control of 
virus replication in peripheral blood (Table I), It should be noted however, that low~level virus 
reservoirs were detected in their lymphoid organs (Table 4), This is an important finding, as 
lack of virus detection in PBMC has been regarded as an indicator of viral clearance (30). 
A remarkable observation was that the lack of detectable virus in PBMC coincided 
with a progressive decline in the frequencies of circulating CTLp (Tables 2 and 3), As antiviral 
T cell memory in vivo is believed to be correlated with CTLp detected by LDA in vitro (28), 
our data suggest that SlY-specific memory CTL decline in the periphery under conditions of 
limited antigenic stimulation. This may have direct implications for the evaluation of vaccines 
aimed at inducing long-lasting protective CTL responses. A decline of SlY-specific CTLp over 
time may also be explained by a progressive state of SlY-induced immune dysfunction. 
However, the three animals showed no signs of disease progression during 22 months of 
observation (Table I). Their T cell function, as defined by the ability to respond to allogenic 
cells in mixed-lymphocyte reactions, was also preserved over time (not shown). Finally, the 
rapid increase in CTLp frequencies observed after fe-challenge in one of the animals (Fig. 4) 
argues against a compromized CTL function. Transient cell-associated viraemia and rising 
levels of SlY-specific antibodies and CTLp frequencies suggested that chronic infected 
animals were at least partially susceptible to re-infection (Fig. 4). Virus replication was limited 
in comparison with the virus burst observed upon infection of naive monkeys. This seems in 
line with the observation that infection with non-pathogenic HIV-2 or Nef-deleted SlY mac 
confers resistance to subsequent challenge with pathogenic SlY (34). Although the 
mechanisms underlying resistance to superinfection are still largely unclear, they are likely to 
include host antiviral immune responses. 
In previous studies, CTL responses against a dominant T cell epitope were induced 
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by lower antigenic doses and lasted for a considerably longer time than CTL responses against 
minor epitopes (28). It was suggested that the affinity of effector cell-target cell interactions 
may be a determinant of T cell memory. We found that CTL responses against an 
immunodominant epitope in p26 designated p26A.5 (Fig. 2) developed more rapidly and 
lasted longer in circulation than those directed against putative minor Gag epitopes (Table 3). 
Resistance to anti-CD8 blocking (Fig. 3) suggested that p26A.5-specific CTLp had indeed 
high affinity for their targets. These CTL may require lower levels of antigenic stimulation 
(28), be triggered by infected cells displaying very low epitope density (35), be relatively 
independent ofT cell help (13), and ultimately be more effective in virus containment (36). 
It is conceivable that, under certain stringent circumstances, functionally 
immunodominant CTL may favour the negative selection of elL escape mutants which may 
then replace the prototype virus, as observed in the spleen of monkey K71 (Fig. 5). It is not 
surprising that the mutation in the p26A.5 epitope was detected only in spleen-derived 
sequences, as co-existence of viral expression and en expansion in splenic white pulp may 
create a highly favourable microenvironment for immunological pressure (9), As a molecular 
clone was used for infection, the epitope mutation must have originated during the course of 
either primary or secondary infection. The absence of epitope mutations in monkey K66, 
which lacked p26A.5-specific CTL (not shown) and showed high virus burden in the spleen 
(Table 4), favours CTL pressure over sole growth advantage as the cause of virus mutation. 
Overall, the variant virus was recognized poorly by CTL that had been primed by the 
prototype sequence (Table 5 and Figs. 5 and 6). However, the existence of multiple p26A.5-
specific CTL populations, probably using different TCR gene rearrangements (39), was 
indicated by the recognition of the variant peptide by at least some of the CTL clones and 
short-term CTL lines tested. The redundancy of CTL responses targeting the same viral 
epitope may result in a more effective control of virus replication and represent a first-line 
safeguard mechanism against emerging virus variants. Lack of complete escape from CTL was 
also indicated by the finding that the variant virus was able to induce CTL of new specificities. 
These also appeared to localize preferentially in the spleen (Fig. 7). The low virus burden 
measured in this compartment (Table 4) suggests that the new CTL were effective in 
containing virus replication. However, the possibility exists that a virus variant with even a 
slight advantage would have eventually replaced the prototype virus in other compartments. 
In conclusion, our findings add to understanding of the host-virus interactions taking 
place during the course of l~ntiviral infections, indicate a role for SlY-specific CTL in the 
containment of virus replication, and support the concept that the quality of antiviral CTL is 
as important as their quantity in determining the course of virus infections. However, the 
factors that ultimately lead to virus persistence and disease progression require further 
investigation. 
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Chapter 5 
Increasing evidence indicates a protective role of antiviral cytotoxic T lymphocytes 
(CTL) in the host defence against human immunodeficiency virus (HIV). CTL reactive against 
HIV antigens have been detected in persons exposed to the virus but lacking evidence of 
infection. These include a small number of female prostitutes in Africa, sexual partners of 
infected persons, children born to infected mothers, and health care workers exposed to 
infectious body fluids (reviewed by Rowland-lones ef al., 1995). Based upon the assumption 
that CTL induction requires endogenous synthesis of viral proteins, these findings suggest that 
transient HIV infection and virus clearance by CTL are indeed possible. During acute HIV 
infection, the detection in circulation of specific CTL coincides with the fall in viraemia that 
follows the initial virus burst (Borrow ef al., 1994; Koup ef al., 1994). In the subsequent 
stages, persistence of antiviral CfL may be associated with a prolonged asymptomatic period, 
whereas their decline is usually coincident with disease progression (Klein ef al., 1995). The 
relatively strong CTL response often detected during the asymptomatic stage of HIV infection 
is associated with increased numbers of circulating CD8+ T-cells, whereas ClL decline is 
usually associated with marked CD4+ T-cell depletion, with values well below 2001 ~L (Oeretti 
ef al., 1996). To explain the progressive decline of HIV-specific CTL, either exhaustion due 
to prolonged high-level antigenic exposure, progressive loss of helper function (Om'eUi ef al. 
1996), or both may be advocated. Nevertheless, it is of note that a few patients may maintain 
relatively strong CTL responses against HIV Oag during the late stages of the disease (Oereui 
et al., 1996). This seems consistent with data showing that persons with the most benign 
disease course not necessarily have the highest levels of elL activity. 
Studies on the relationship between virus load and CTL responses in chronically 
infected patients have also yielded conflicting results, as both direct (Ferbas et aI., 1995) and 
inverse (Klein et aI., 1995) correlations have been reported. While further work is needed to 
clarify such discrepancies, it is clear that antiviral CTL responses can only be interpreted in 
the framework of the dynamics of virus replication, recognition and clearance of infected cells, 
and virus attempts to evade immune surveillance. It is also likely that qualitative factors, such 
as affinity of target cell-effector cells interaction, playa crucial role in determining the 
effectiveness of CTL response, thus explaining, at least in part, why the presence of high levels 
of CTL does not necessarily prevent development of disease. In fact, at least in some cases, 
high CTL frequencies may simply reflect either persistently high level of virus replication or 
a continuously diversifying genome. 
Infection of macaques with simian immunodeficiency virus (SlY) orters a valuable 
model for studying the complex interaction between lentiviruses and host immune system. One 
aim of this discussion is to outline how this model has contributed to Ollr understanding of the 
role of CIL in the control of lentiviral infections, and how its full potential may be exploited 
in the future. 
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General aspects of SIV infection of macaques. SIV of macaques (SIVmac) was tirst 
isolated in 1985 from animals held in captivity in the United States. Macaques, however, are 
not natural hosts of the virus. It is believed that cross-species transmission from sooty 
mangabeys, which are healthy natural carriers of SIV (SIVsm), was the source of infection. 
Fighting and biting among animals co-housed in outdoor corrals was the most likely route of 
horizontal transmission (Gardner, 1996). SIVmac shares with HIV many biological and 
structural features, including its tropism for the CD4 receptor and CCR5 co-receptor, a similar 
genomic organization and extensive genetic homology. The virus establishes persistent 
infection in macaques and causes an immunodeficiency syndrome closely resembling human 
AIDS. As in humans, prominent features of the disease include CD4+ cell loss, constitutional 
symptoms, lymphadenopathy, skin and neurological disorders, opportunistic infections and 
neoplasias. Although the average time to disease is 1-2 years, the course of infection varies 
considerably among macaques. Even after infection with the same viral molecular clone, some 
animals rapidly develop disease and die within months, whereas others may remain 
asymptomatic for a few years, thus resembling long-term non-progressors with HIV 
infection.This variability, combined with the opportunity to define parameters of infection 
such as strain, dose, and route of virus inoculation, may prove valuable for clarifying the role 
of CTL immunity in lentivirus contaimnent. 
Early vaccination studies in macaques aimed primarily at preventing infection through 
the induction of virus neutralizing antibodies. As a result, a protective role of CTL in some of 
the successful vaccination strategies reported, such as those based upon live attenuated SIV 
vaccines (reviewed by Ruprecht ef al., 1996), can only be hypothesised. More recently, the 
prevailing view that it Illay be desirable for a vaccine to prevent disease if not infection, and 
the appreciation that SIV infection of macaques provides a valuable model for studying HIV 
pathogenesis, coupled with the development of reliable means of detecting SIV -specific CTL, 
have drawn considerable attention to antiviral cell-mediated immunity. 
Deteelion of virus-specific CTL (i) Target cells. HIV - or SIV -specific CTL 
responses are currently measured against autologous B Iymphoblastoid cell lines (B-LCL) 
immortalized either Epstein Barr virus or by Herpes virus papio respectively. After infection 
with recombinant vaccinia vectors (rVV) encoding HIV or SlY proteins, these cells express 
endogenously processed antigen in the context of MHC class I molecules. The use of rVV 
expressing different regions of the HIV or SIV genome has shown that antiviral CTL target 
both structural and regulatory viral proteins. In macaques, as also in humans, the strength and 
magnitude of the response vary among animals (Venet ef al. 1992; Gereui ef al., 1997a). 
Alternatively, B-LCL can be sensitized for lysis by incubation with short synthetic viral 
peptides that bind directly to MHC class I molecules on the cell surface, thus allowing the 
definition of epitope specificities (Gereui ef al., 1997b). 
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(ii) Effector cells. In contrast with data from HIV-I-infected asymptomatic adults. 
in vitro restimulation has almost universally been required to amplify SlY-specific CTL 
responses to detectable levels. As an interesting exception, direct cytotoxicity against the 
envelope protein (Env), Gag, and the regulatory protein Nef has been recently observed with 
intestinal intraepitheliallymphocytes of two macaques infected with SIVmac251 (CoudeJ et al., 
1997). One of the animals showed signs of advanced disease, including a marked colitis. 
Although a high proportion of intestinal intraepitheliallymphocytes express the CD8 marker, 
the exact nature and function of the activated intestinal effector cells, and their contribution 
to host defence or immunopathogcnesis t remain to be determined. The same authors found 
little or no evidence of direct cytotoxicity in peripheral blood, spleen and lymph nodes. This 
is in line with the observation that the frequencies of circulating CTL precursors (CTLp) 
detected in SlY-infected or vaccinated macaques are in general lower than those measured in . 
asymptomatic HIY-infected adults (Geretti ef al., I 997a). While the requirement for 
appropriate methods of CTLp restimulation may explain the apparent lack of CTL induction 
in some vaccine studies, it also highlights the need for standardised assays which would 
facilitate comparison of different experiments, often including only small numbers of animals. 
One successful method for the expansion in vitro ofHIY- or SIV-specific CTLp is 
based on stimulation with paraformaldehyde-fixed autologous B-LCL infected with rVV 
expressing HlV or SlY antigens (Van Baalen ef al" 1993; Geretti ef al., 1996). Compared with 
non-specific methods of stimulation, this approach enhances eTL detection by inducing 
selective CTL expansion, with reduced interference from background lysis. Cell culture under 
limiting dilution conditions appears to increase further the sensitivity of CTL measurement, 
as it allows CTLp detection, albeit at low frequencies, in macaques lacking significant 
responses in standard bulk CTL assays (Geretti ef al., I 997a). Autologous blasts infected with 
SIV have also been used successfully as stimulator cells (Gallimore ef al" 1996). 
Alternatively, synthetic peptides spanning defined regions of the HIV or SlY genome can be 
used to stimulate the growth of epitope-specific CTL. 
Should vaccine-induced CTL prevent or limit virus replication? SIV Env-, Gag-
or Ncf-specific CTL have been induced in macaques through several immunization strategies, 
including live attenuated viruses (Cranage ef al., 1997), proteins either expressed by live 
vectors such as recombinant vaccinia virus (Gallimore et al., 1995; Kent et al., 1996), 
incorporated into iscoms (Hulskotte e/ al" 1995) or adjuvanted by QS-21 saponin (Newlllan 
ef al" 1994), non-infectious virus-like particles (Klavinskis ef al., 1997), peptides in various 
formulations (Bourgault ef al., 1994, Huslkotte ef al., 1995, Yasutomi ef al., 1995), and DNA 
plasmids (Lu ef al., 1996). In those studies that have tested the outcome of subsequent 
challenge, the detection of vaccine-induced CTL has usually failed to predict complete 
resistance to infection. In one early report, vaccine-induced CTL against pCII, a well-defined 
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epitope in Gag, failed to protect macaques from intravenous challenge with SIV macaca 
nemestrina (SIVmne)(Yasutomi ef al., 1995). The induction of relatively low frequencies of 
CTLp of limited specificity, and the absence of antibodies, were believed to have contributed 
to the lack of protection. However, in a subsequent report, weshowed that immunisation with 
Env- and Gag-iscoms and three Nef lipopeptides induced both virus neutralizing antibodies 
and relatively high frequencies of Env-, Gag, or Nef-specific CTLp, but similarly failed to 
protect macaques Irom intravenous challenge with SIVmacJ2H." (Hulskotte ef al" 1995). 
Recently, intravenous, intramuscular and gene gun inoculations of SlY DNA plasmids have 
produced similar results: despite the induction of virus neutralizing antibodies and 
Env-specific CTL, 110 protection was induced against intravenous challenge with SIVmac251 
(Lu ef al" 1996). 
Although disappointing, these findings are consistent with the view that CTL may not 
be able to prevent or control HIV or SlY infection, unless stringent qualitative and quantitative 
requirements are met. This finds indirect support in the observation that macaques immunised 
with whole inactivated SIVmac and protected from intravenous challenge with cell-associated 
SIVmac-,m, share the Mamu-A26 MHC class I allele with the donor of the infected cells 
(Osterhaus ef al., 1992; Heeney ef al., 1994). Mamu-A26 positive animals also behave as long 
time survivors (Bontrop ef al., 1996), suggesting that gene products of this allele may be 
correlated with the ability to mount protective CTL responses against SlY. In addition, certain 
human MHC genotypes have been found to influence the degree of susceptibility to HIV-
infection. In particular, the B35 or the AI-B8-DR3 haplotypes have been associated with rapid 
disease progression; whereas other haplotypes such as B27-A24-DRI have been found in long-
term nonprogressors (Kaslow et al., 1996). These data strengthen the case for a geneti cally 
determined ability of the immune system in controlling lentiviral infections. 
More direct evidence of a protective role of defined CTL sUbpopulations is provided 
by a study of macaques immunised with SIV Nef rVV (Gallimore ef al., 1995). Although six 
of seven animals became infected upon intravenous challenge with SIYmac:nH_j5, the 
frequencies of vaccine-induced Nef-specific CTLp measured before challenge were inversely 
correlated with the levels of viral load measured after infection. In addition, the animal with 
the highest CTLp frequency was protected from infection. Recent findings also support the 
concept that protective CTL may limit rather than completely prevent virus replication. 
Vaccinated macaques lacking both detectable virus and antibody responses after either 
intravenous or intrarectal challenge with SIVmne showed CTL responses against SIV proteins 
present in the challenge virus but not in the vaccine (Kent ef al., 1996). Similarly, macaques 
immunised with Env-iscoms lacked both detectable virus and anamnestic antibody responses 
after intravenous challenge with a chimeric simian-human immunodeficiency virus (SHIV), 
but had CTLp against antigens other than Env, including the non-virionic regulatory proteins 
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Rev and Tat (Hulskotte et al., 1997). These data indicate that CTL responses provide a highly 
sensitive marker of transient or low~level virus replication. It is tempting to speculate that 
similar silent or abortive infections may have remained undetected in some of the early vaccine 
studies. 
What is the role of antiviral CTL in mucosal immunity? As most HIV infections 
are acquired by mucosal routes, current efforts are directed at inducing immune responses that 
may prevent or limit virus spread after mucosal exposure. The SIV model offers the 
opportunity to explore issues related to mucosal immunity and infection that are difficult to 
address in humans. Indeed, evidence that protection from sexually transmitted SIV and, by 
inference, HIV may be induced by effectively stimulating genital and systemic antiviral CTL 
is increasing. In female macaques inoculated intravaginally with SIVmacm , at least some (I 
in 2425 to I in 26686) of the CD8' cells recovered from the vaginal epithelium arc 
SlY-specific CTLp directed against Env or Gag. In line with the view that progressive CTL 
compartmentalization occurs during persistent infection, the frequencies of genital ClLp are 
higher in chronically infected monkeys than in animals with recent infection (Lohman et at .. 
1995). SlY-specific CTL have also been detected in both peripheral blood and gut-associated 
lymph nodes of macaques infected intravenously with live attenuated SIVmacn:, and resistant 
to inlrarectal challenge with either SIVmacJ2H.j5 or SHIV (Cranage et al .. 1997). Furthermore, 
inoculation of macaques with SIV p27:Ty virus-like particles by either the rectal-oral and 
vagi no-oral route, or subcutaneous immunisation targeting the iliac lymph nodes, have induced 
specific CTL in the rectal and cervico-vaginal mucosa, as well as in regional lymph nodes, 
spleen and peripheral blood (Klavinskis el al., 1997). Finally, intra-vaginal inoculations with 
attenuated SHIV have induced at least partial resistance to intravaginal challenge with 
pathogenic SIVmacm (Miller el at., 1997). Although the presence of SlY-specific CTL in the 
genital tract was not determined in this study, protected animals had circulating Gag-specific 
CTL at the time of challenge, with or without specific antibodies in genital secretions.To 
explain the generation of local and systemic primary immune responses upon vaccine delivery 
to mucosal sites, antigen up-take by resident dendritic cells is hypothesised, followed by their 
migration to regional lymph nodes where naive T lymphocytes are stimulated. These would 
then enter the circulation and migrate to the genital site, where they may be restimulated upon 
re-exposure to the antigen, thus providing a first line of defence against sexually transmitted 
viruses. 
What is the relationship between virus-specific CTL and virus replication? In 
analogy with observations made in humans, kinetics studies have shown that the detection of 
Gag- or Nef-specific CTL by week I or 2 after intravenous SN infection is coincident with 
the decrease in virus load and p26 antigenemia that follows the initial virus burst (reviewed 
by Letvin el aI., 1994). In the early phase of infection, virus load and SN-specific CTL 
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responses show similar kinetics in peripheral blood and lymph nodes. In contrast, during 
chronic infection, virus sequestration within lymphoid organs (Chackrabarti ef al., 1994) is 
mirrored by CIL compartmentalization to the sites of infection (Geretti ef al., 1997 c). These 
observations are consistent with CTL being the effector cells of the in vivo immune response 
against SlV. Further support for a protective role of antiviral CTL comes from the observation 
that macaques with strong CTL responses against multiple SlY antigens. including the 
regulatory proteins Nef, Rev and Tat, remained free of disease for at least two years after 
intravenous infection with SIVmac251 • In contrast either absent, transient, or weak CTL 
responses were observed in animals rapidly progressing to overt disease (Venet ef al., 1992). 
Preliminary findings also indicate that the detection of strong CTL responses against Rev and 
Tat in the early phase of infection may be associated with effective virus containment and lack 
of disease progression in both HIY-infected humans (Van Baalen ef al., 1997) and 
SIV -infected macaques (Geretti, unpublished). 
The relatively low frequencies of SlY-specific CTLp usually detected in SlY-infected 
macaques seem in contrast with the strong ClL responses often detected in asymptomatic 
HIY-infected persons. Besides the influence of host genetic factors, or the effects of 
progressive immunodeficiency, relatively low CTLp frequencies may reflect a low degree of 
antigenic stimulation in vivo, due to rapid down-regulation of SLY replication after infection. 
Consistent with this view, high CTLp frequencies can be occasionally detected in animals with 
high viral load in their peripheral blood mononuclear cells (PBMC) (Geretti ef al., 1997a). 
Conversely, the frequencies of circulating SIV-specific CTLp may decline significantly over 
time in asymptomatic SLY-infected macaques lacking detectable virus in PBMC and showing 
low-level virus reservoirs in lymphoid organs (Fig. I and Geretti ef al., 1997c). In light of 
these findings, it is not surprising that the degree of protection conferred by live attenuated 
SlY vaccines, and the strength of the Env- and Gag-specific CTL responses they induce, are 
inversely correlated with the level of virus attenuation (Lohman ef al., 1994). These 
observations bear direct implications for vaccine designs aimed at inducing long-lasting 
protective CTL responses: a successful vaccine will need to achieve a difficult balance 
between safety, which is dependent upon a high degree of attenuation, and efficacy, which 
appears directly related to the ability of the virus to replicate. 
Are virus-specific CTL deleterious to the host? It has been suggested that in a 
physiological attempt to eradicate persistent infection, CTL may also induce pathological 
changes deleterious to the host. This is supported by the finding that HIV-specific CTL are 
present in both the bronchoalveolar lavage of AIDS patients with lymphocytic alveolitis and 
in the cerebrospinal fluid (CSF) of patients with AIDS dementia complex (reviewed by 
Zinkernagel, 1995). The detection of SlY-specific CTL in the skin rash of SlY-infected 
macaques (Yamamoto el al .. 1992) also suggests a role for ClL in mediating tissue damage. 
126 
Chapter 5 
() 200 
:;; 
ro 
D.. 100 w 
0 
x 
>-
" <:: 
" 
" 0-~ 
0-
--' i- 10 () 
~ A B C .0 
A-A ~ m------'m 0······0" D····· .. ' \ 0" ~A m 
- .. d 
, , , , , , , , , 
4 6 12 20 4 6 12 204 6 12 20 
Months of infection 
FIG. 1. Kinetics of circulating SlY -specitk CT1.. precursors (CfLp) in macaques infected intravenously 
with SIVmac32H_J5 . After the initial burst of virus replication, three monkeys lost evidence of either 
culturablc virus or PeR-detectable provirus in peripheral blood, while maintaining low-level virus 
reservoirs in spleen and lymph nodes; they remained asymptomatic with stable CD4-l- cell counts during 
22 months of observation. llucc other monkeys had persistent virus in peripheral blood and high viral 
load in lymphoid organs; two remained asymptomatic but showed a progressive CD4+ cell loss, whereas 
the third one developed AIDS 18 months aller infection. TIle cumulative frequencies of circlIhning SIY-
specific CfLp, after reaching a plateau, declined significantly in the three macaques lacking detectable 
virus in peripheral blood (A) and in the animal which progressed to overt disease (8), but not in the two 
asymptomatiC macaques with persistent infection in peripheral blood (C). 
SIV -specific elL have been also detected in the CSF and brain of infected macaques as early 
as I week after infection and concomitant with the detection of virus (Von Herrath et at .. 
1995). Interestingly, different SlY proteins were targeted by CTL recovered from the brain, 
CSF and peripheral blood, suggesting that these can be separated compartments in SlY 
infection. As these promising data indicate, the SlV model provides an excellent system to 
explore further the role ofCTL in HIV-associated neurological disorders. 
Can HIV or SIV variants eSC3}le CTL recognition? Selection of mutant viruses 
resistant to specific CTL may be proposed as one mechanism whereby highly variable viruses 
escape from immune recognition. Single amino acid substitutions within CTL epitopes can 
abrogate recognition by affecting either MHC binding or T cell receptor (TCR) interaction 
(Roth barth ef al., 1989), whereas mutations within epitope flanking regions may reduce 
presentation by affecting peptide processing and transport (Eisenlohr ef al., 1992). Recent 
studies also suggest that mutated epitopes may arise, which still interact with the TCR, but 
inhibit CIL function by inducing T cell anergy, or by showing partial agonistic or antagonistic 
activity (reviewed by Klenerman el al., 1996). In this case, even virus variants that do not 
become the predominant viral species may affect immune surveillance, as they can block CTL 
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recognition of viruses that do not contain mutated epitope sequences. Finally, there is evidence 
that rapid virus evolution and strong antigenic stimulation may also favour immune evasion 
by causing CTL exhaustion (Von Boehmer, 1993). 
Although mutant viruses which arc resistant to CTL have been detected in persons 
infected with HIV (reviewed by Koup, 1994; Koenig ef al .. 1995; Borrow ef al., 1997; 
Goulder ef al., 1997), and despite evidence that multiple mechanisms may be operative in HIV 
attempts to escape recognition (Couillin ef al., 1994), the biological relevance of these findings 
remains somewhat controversial. The fact that HIV-infected persons, or SIV-infected 
macaques, generally mount CTL responses against multiple viral antigens suggests that despite 
the loss of CTL recognition of one epitope, complete evasion from immune surveillance 
should be a rare occurrence. Nevertheless, qualitative aspects of antiviral CTL, such as the 
nature of the targeted epitope (Moskophidis ef al., 1995) and the affinity of effector cell-target 
cell interactions (Tsomides ef al., 1994) may be crucial determinants of effective CTL 
pressure. It is therefore conceivable that under stringent circumstances. strong CTL responses 
targeting key epitopes may promote selection of viral mutants which, at least temporarily. can 
evade immune recognition. The finding that pronounced HIV genetic heterogeneity is 
associated with strong CTL responses against Env (Wolinsky ef al .. 1996) appears to support 
this view. 
The effects of CTL pressure on SlY evolution have so far received limited attention. 
In a study of macaques infected with SIVmac2S1 • the presence of strong pllC-specific CTL 
responses was associated with the detection of amino acid mutations within the CTL epitope 
(Chen ef al .. 1992). Although two of four mutated epitope sequences were recognized less 
efficiently than the prototype sequence, statistical analysis failed to indicate a higher rate of 
mutations in the epitope compared with other regions of Gag. and selection of the mutated 
viruses could not be demonstrated. 
Infection of macaques with molecular clones of SIV may help to clarify these issues, 
as any mutation detected in the viral genome must have originated during the course of the 
infection. In a long~term non-progressor macaque infected wHh the molecular clone 
SIVmac.12H_J5• the detection of 'high affinity' immunodominant CTL targeting a nine-mer 
epitope in Gag designated p26A.5 (Geretti ef al., 1997b), coincided with the emergence of 
a variant virus carrying a mutated epitope sequence (Geretli, I 997c). Surprisingly. the mutated 
sequence was detected in the spleen, where it had uniformly replaced the challenge virus, but 
not in peripheral blood or lymph nodes. This probably reflects the fact that co-existence of 
viral expression and CTL expansion in splenic white pulp creates a highly favourable 
microenvironment for immunological pressure (Cheynier et ai., (994). The variant virus 
escaped recognition by most, but not all p26A.5-specific CTL (Fig. 2). The latter observation 
suggests a certain redundancy of CTL responses targeting the same epitope, also described 
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FIG. 2. Different patterns of epitope~specific CfL recognition. Short-term CfL lines were generated 
by stimulation of peripheral blood mononuclear cells with a nine-mer peptide representing the prototype 
p26A.5 epitope, and tested for their ability to lyse autologous targets pulsed with either the prototype 
peptide, or a variant peptide carrying an aspartic acid to glutamic acid substitution (D-·E). Four patterns 
of reactivity were identified: most (38 of 56) CTL lines (e.g. AOI) did not recognize the variant peptide 
even at the highest peptide concentration tested (100 11M), eight (e.g. C 12) recognized the prototype 
peptide with higher efficiency than the variant peptide, seven (e.g. A05) recognized both the prototype 
and the variant peptide with a similar efticiency, and three (e.g. F09) recognised the variant peptide with 
higher efficiency than the prototype peptide. 
for pCII-specific CfL (Shen ef al., 1994; Chen ef al., 1996), which may represent a first-line 
safeguard mechanism against emerging virus variants. Remarkably, CTL subpopulations able 
to recognise the variant sequence also localized preferentially in the spleen. The low virus load 
detected in this compartment suggests effective virus containment. However, the idea that a 
variant virus with even a slight advantage might have eventually replaced the challenge virus 
also in other compartments and gradually affected the control of the infection remains H valid 
hypothesis. 
CONCLUSIONS 
Over the past decade, the macaque model of SIV infection has provided signilicant 
new information on the host-virus interplay taking place during the course of lentivirnl 
infections. Increasing evidence indicates a role for antiviral CTL in the containment of SlY 
replication. and supports the view that the quality of antiviral CTL is as important as their 
quantity in determining both the outcome of infection and the course of the disease. It is now 
believed that the ability to induce antiviral CTL that would limit, if not completely prevent 
virus spread, particularly after mucosal exposure, is an important prerequisite of an effective 
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HIV vaccine. The concept that the design of such a vaccine will require improved 
understanding of what may constitute a protective CTL response is also now widely accepted. 
The SIV model offers valuable opportunities to better understand the mechanisms of 
lentivirus-induced disease and to clarify the basis for protective immunity. Hopefully. it will 
fullill its promise: - helping the development of a successful vaccination strategy against HIV. 
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Samenvatting 
AIDS werd voar het ccrst als ceo nieuw ziektcbecld onclerkend in 1981, toen cen 
ongewone clustering van Kaposi sarcomas en Pneumocystis carinii pneumonieen werd , 
waargcnomen in jOllge homosexuclc mannen. Epidemiologische studies wezen in de 
riehting van eeo infccticlis agcns dat overgebracht werd door sexuele contact en, door 
intravencus druggebruik, door bloed en blocdproduktcn, en oak van moeder op kind. De 
eerste isolatie van cen virus dat later human immunodeficiency virus type 1 (HIV-l) 
genoemd zou worden, geschicdde in 1983. In 1985 werd cell apen-equivalent van dil virus, 
het simian immunodeficiency virus (SlY mac), gei'soleerd uit Aziatische makaken in 
gevangenschap, die een ziektebeeld vertoonden dat sterk deed den ken aan AIDS bij de 
mens, Een tweede human immunodeficiency virus (HIY~2) werd in 1986 ge'iisoleerd uit 
West Afrikaanse palienten met een relatief milde vorm van immunodeficientie, Alhoewel 
zowel HIY~1 als HIY·2 AIDS veroorzakell, wordt bij HIY·2 gernfccteerde individuen cell 
relatief langere klinische lalcntielijd. en een lagere morbiditeit waargenomen. Vit 
verschillende Afrikaansc apcnsoortcn zoafs graene mcerkaHen, sooty mangabeys, 
mandrillen en sykes apcn, zijn later mcerdcre SlY stammen gci'soleerd, en in chimpansees 
werd het SIYcpz gevonden. Deze viru5sen, die natuurlijk voorkomen bij de genoemde 
apensoorten in Afrika, veraorzakcn geen ziektcsymplomen in hun natuurlijke gastheren. 
Opmerkelijk is dat bepaalde SlY stammen een hoge male van scquentiehomologie 
vertonen met HIV-2 isolaten uit West Afrika, terwijl HIY~l meer gclijkenis vertoont met 
HIVcpz. Of schoon op dit moment de oorsprang van HIV~1 en HIV~2 nag niet geheel 
duidelijk is, lijkt het op grand van fyloge~ctische analyses waarschijnlijk dat infccties met 
beide virussen het gevolg zijn van zoonotische transmissics vanuit niet humane primaten 
reservoirs. 
Het klinisch beloop van HIY~l infeclics is zeer variabcl. Cohortsludies tonen aan 
dat ongevccr 50% van de ge'infcclecrde individuen AIDS ontwikkelen Ita 10 jaar; sommige 
tonen een rclaticf snelle progrcssie (mindcr dan drie jaar, "snelle progressors"), tcrwijl 
andere zestien jaar of langer asymptomatisch blijvcn ("lange termijn non~progressors"), 
Inzicht in de virus~, gasthcer- en omgevingsfactoren die aan deze variabele 
progressiesnelheid ten grondslag Iiggell is cruciaal voor het ontwikkelen van cffectieve 
therapieen en vaccins tegen HIV infecties. SlY mac heeft vcle biologische en structurele 
karakteristiekcn alsmede de genoomorganisatie en nuclcotidcsequentics gemeen met HIY. 
Infectie met SIYmac leidt tot cen persistcntic van het virus in makaken die" resultcert in 
het syodroom dat sterke gelijkenis vertoont met AIDS. Alhoewel het gemiddeld ceo tot 
twee jaar duurt voordat zickle wordt waargcnomcn, varieert het bcloop van de infectie 
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aanzienlijk. Zelfs na infectie met dczcIrdc molcculairc kloon, onlwikkclcn bcpaalde dicren 
zeer snel ziektesymptomen waarcloor zc binnen enkclc maallden stervcn, tcrwijl andere cen 
aantal jaren asymptomatisch blijvcn. Deze variatic doct sterk den ken aan de "snclle 
progressors" en de "lange tCfmijn non-progrcssors" onder HIV gc'infeclcerde mensen. 
Vanwege deze stcrkc overeenkol11stcn met HIV infccties van de mens, biedt SlY infcctie 
van de makaak een zeer waardevol model Dill de rol van de gasthccr-immunitcit bij de 
controle van lentivirusinfecties tc bcstudcren. 
De studies in dit procfschriCt hcbbcn zich gcrichl op de bcstudcring van de rol die 
eytotoxisehe T Iymfoeyten (CfL) spelen bij het controleren van HIV en SlY infecties. Na 
een introductie in de bclangrijkste cigcnschappen van infectics met primaten ienlivirussen 
in hoofdstuk 1, beschrijft hoofdstuk 2 de resuhaten van ccn twectal vaccinaliestudies in 
makaken. Beide studies waren gcricht op de bcstudcring van het vermogen van vaccin-
gci'nduceerde humor ale en CfL rcsponsen om intravcneuze infectie van makaken te 
voorkomen met hetzij een l110lcculairc kloon van SIVmac, helzij een HIV-SIV hybride 
virus (SHIV). Ondanks de inductic van virlisllelilraiisercnde anlisloffen en CTLJ werd in de 
eerste stu die geen beschenning legcn infcctic gevondcn. Alhoewel deze bcvinding 
teleurstellend was, was hij wei in overcel1slclllming met de opvalling dat CTL niet in staat 
zijn om cen SIV of HIV infectie te controlcrcn, lenzij aan strikle kwalitatievc en 
kwantitatieve voorwaarden is voldaan. Dc opvalting dal SIV-spccifieke CTL imll1unitcit zou 
hebben bijgedragen aan het beperken van de virusreplicatie in lenminsle cnkele van de 
bestudeerde dieren blijft tegelijkertijd echler eCIl altractieve hypothese. De resullatcn van 
de twecde vaccinatiestudie tonen aan dat CTL responscll cell zcer gevoclige marker zijn 
voor een tijdelijke of op een laag nivcau verlopcndc virus replica lie en onderstcunen de 
hypothese dat beschermende CTL eerder de infectie bepcrken dan hem compleet 
vcrhinderen. In deze studie werden in apen die ge'il11muniscerd waren mel Env-iscomsJ 
geen virus en oak geen anamnostische antilichaamrcsponscn aantoonbaar na inlraveneuze 
challenge-infcctie met SHIV. \Vel waren elL precursor cellen legen andere anligenen dan 
Env, waaronder de niel viriongebonden regulatoire ciwilten Rev en Tat aanloonbaar. 
Aannemend dat voor CTL inductie endogene synthcsc van virale ciwittcn nodig iSJ tonen 
dcze bevindingen aan dat cell tijdelijke illfectic ell ook viruseradicatie door CTL inderdaad 
mogelijk zijn. 
]n hoofdstuk 3 wordt uitcengezct hoc de optimalc condities voor CTL expansicJ 
kwantitatieve analyses en fenoypische karaktcrisaties ill vitro voor deze studies werden 
opgczet. De isolatie van T eel subsets is cell bclangrijke slap in de karakterisatie van CTL 
responsen. Resultatcll in het eersle deel van het hoofdstuk tonell aan dat het mogclijk is 
am CD8+ CTL te scheiden van andere celfraclics, zonder dal hun fenotype en cytotoxische 
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eigenschappcn worden aallgetast. In het twccde decl van het hoofdstuk worden de 
verschillcndc methoden voor de ill \1/(1"0 expallsie van SIV~spccifieke CfL vergcleken. In 
tegenstelling tot gegevens verkregen met HIV -I gcinfecteerde asymptomatische volwassen 
pcrsoncll, bleck ill vitro reslimulatic bijna allijd no dig am in de apen SIV~specifieke CfL 
responsen tot dctcctcerbare niveaus te verhagen. Daardoor latcn SIV geinfecteerde of 
gevaccineerde makakcn doorgaans CTL precursor (CfLp) frcquenties zien die aanzienlijk 
lager zijn dan die in het algemeen in asymptomatische HIV gei'nfecteerde volwassenen 
worden gevondcn, hctgecn aangccft dat de daartoe gceigende methodcn van ill vitro 
rcslimulalie nodig zijn voor hun dclccLic. Ecn succcsvollc methode voor de ill vitro 
expansie vall antivirale CTL is gebaseerd op de stimulatie met formaldehyde geftxeerde 
autologe B cellijnen (B-LCL) die tevoren geinfecteerd zijn met recombinant 
vacciniavirussen die SIV anligenen tot expressie brengen, Deze benaderingswijze bleek de 
CTL detccticgrens tc verhogen door selectieve crL expansie te bewerkstelligen. Bovendien 
verhoogde het kweken van de cellen onder "limiting dilution" condities de gevoeligheid van 
de CfL mctingen en maakte het mogclijk Ont, zij het in lage frequenties, CTLp aan te 
tonen in makakcn die in stalldaard "bulk" CfL (esten geen significante CfL responsen 
lielen zien, Het hoofdstuk beschrijft bovcndicn de identilicalie van ecn minimaal epitoop 
van SIV Gag dat herkend wordl door antivirale CTL van cen SIV gci'nfccteerde makaak. 
Het bcpalcll van virale epitopen dic door spccifieke CTL worden herkend kan het 
ontwerpen van imlt1unotherapcutischc interventies verbelcren en tevens cen extra basis 
verschaffen voor hel vcrkrijgen van inzicht in de pathogcncsc van AIDS. Inderdaad bleek 
dat aminozuursubstituties in de sequenlie van het epi(oop, zoals die werden waargenomen 
bij het vergelijken van de homologc regia's van HIV-l en HIV-2, voldoende waren om de 
herkcl1ning door CTL gehecl tcnict le doen, Icidde tot de hypothese dat virusvarianten die 
aan de epitoop-spccilicke CTL respons kunncn ontsnappcn /IJ l'/lIO onder de bcstaande 
CTL druk kunnen ontstaan. Dc resullaten van een longitudinale studie die crop gericht is 
om deze hypothesc (c (esten wordcn in hoofdstuk 4 beschreven: Twee prospectieve studies 
die in de chronische fase van rcspcctievclijk HIV-l en SlY infecties werden uitgevoerd. De 
ecrstc sludie analyseerl de kinctiek van HIV-l Gag en Epstein-Barr virus (EBV) specifieke 
CTL en bcschrijft hun rcJatie met vcranderingcn in CD4+ en CD8+ celtellingen in de tijd. 
In HIV-l ge'infectecrde volwasscll individuen werd cen relatier stcrke CfL respons 
gevonden tijdens de asymptomatische fase, die geassocieerd was met verhoogde aaotallen 
CD8+ T cellen. Dcze respons nam veelal af bij ziekteprogressie, tegelijk met een duidelijke 
CD4 + T ccldeplctie, die tot aantallen ruilll onder 200 CD4 + cellen per 1'1 leidde. Op dit 
moment be staat cr gcen bevrcdigcnde vcrklaring voor deze daling, alhoewel een 
progrcssicf verlies van helpcr functie er deel van uit kan makeD, Tevens dient te worden 
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opgemerkt dat enkclc palienlcn cen relalicf stcrke CTL res pons legen HIV -1 Gag 
behielden gedurende de latc stadia van het zicktcverloop. Dit is in Qverecnslemming met 
de opvatting dat individucn met het meest gocdaardigc zicktcverloop niet 
noodzakclijkerwijs de hoogste niveaus van CTL activitcit hoc"cn tc hcbhcn. Omgekeerd 
hoeven zoals hicrhovcn gcstcld, hoge niveaus van CfL niet noodzakclijkcrwijs de 
ontwikkeling van het ziekteproces tc voorkomcn. Eeo andere interessante bevinding van 
deze stu die was, dat de frequentie van EBY-specilieke CfL niet gclijktijdig afnam met de 
afnemendc CD4+ cclfrcquenties, hetgccn waarschijnlijk direct samenhangt met de rclatieve 
onafhankelijkheid van deze EBV-specifleke CTL van CD4+ cel-gerelateerde T helper eel 
factoren. 
De twcede studie die in dit hoofdstuk wordt bcschrcven, bcstuclcert de cvolutic van 
SIV-specificke CTL in relatie tot de kine tick van virusrcplicatie en pogingcn van het virus 
om aan immuunsurveillance te ontsnappen. Het dctccleren van virus-spccil1ckc CTL direct 
na intravencuzc infcctie met SlY, ging gcpaard met het afncmen van de hoevcclhcid virus 
en p26 antigeen na de initHHe explosicvc tocnamc van het virus in circulatie. In dcze vroege 
fase van de infect ie, tDonden virushocveclhcid en virus-spccificke CTL responscn 
overccnkolllstige kinelickcn in het pcrifcre bloed en in de Iymfcklicren. Bij de meer 
chronische fasen van de infcctie daarenlcgcn, werd het "wegdrukkcn" van het virus naar de 
lymfoi'de organen weerspiegeld in het comparlimentaliseren van de CTL op de piaatsen 
waar de infcctic nog aanwczig was, Dcze bcvindingcn zouden de hypothese bevestigen dat 
CfL de effectorcellen zijn die de ill vil'o imllluunrespolls tegen SlY bep31en, De relatief 
lage frequenties van specifieke CfLp die in de bcstudeerdc makaken werden gevonden 
schijnen niet in overeenslemming le zijn mel de slerke CfL responsen die vaak in 
asymptomatische HIY ge'infecteerde individuen worden gcvonden. Naast de invloed van 
door de makaak zelf bepaalde genetische factoren of de effecten van de voortschrijdcnde 
immunodeficientie, kunnen de lage CfLp frequenties cell rcOectie zijn van een lage graad 
van antigene stimulatie ill vi~'o als gevolg van de snelle ondcrdrukking van SIV 
vermeerdering na infectie. Hiermee in overeellstemming is de opvalling dat hoge CfLp 
freql1enties soms werden gevonden in dieren met cen grate hocveclheid virus in hun in het 
bloed circulerendc monanucleaire cellen (PBMC). Omgckccrd namen de frequenties van 
circulerende SIV-specifieke CTlp significant af in de tijd in asymptamatische SIV 
gci'nfecteerde makaken die geen aantoonbaar virus in hun PBMC hadden en oak geringe 
hoeveelheden virus in hun Iymfoi'de orgallen aanloonbaar aanwezig hadden, Tn het Iicht van 
deze bevindingen is het niet verwondcrlijk dat de mate van bescherming die door levcnd 
geattcnueerde SlY vaccins wordt bewerkstelligd en de slcrkle van de Cfl responsen die ze 
induceren, omgekeerd evcnredig lijken le zijn met de mate van altellualie van het virus. 
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Deze gegevcns hcbbcn directc gevolgcn voor hel ontwerpen van vaccins die zich richlen op 
het induceren van langdurige beschcrmcnde CTL responsen en geven aan dat cell 
succesvol vacdn cell mocilijk te bcrcikcll evcnwicht dient te bewerkstclligen tussell 
veiligheid die afhankelijk is van cen hoge graad van attcnualie en cffcctivitcit, die direct 
gcrelateerd Iijkt te zijn aan de mate waarin het virus zich kan vcrmccrdcrcn. 
Sclcctie van gemuteerde virllssen die resistent zijn tegen spccificke CTL responsen 
kon worden voorgesteld als een van de mechanism en waardoor sterk varierendc virussen 
kunnen ontsnappen aan immuunhcrkcnning. ludien de kwaliteit van de antivirale CTL cell 
cruciale determinant zou zijn van immunologische druk, is het voor le stell en dat bcpaalde 
sterke CTL respOllsen, selcctic van mutaillvirlissen die tellminstc tijdelijk zoudcn kunllen 
ontsllappen aan hcrkcnning, in de hand zouden werkcn. In een "lange termijn non-
progressor" makaak ge'infecteerd mel een molcculaire kloon van SIVmac, ging de dctectic 
van "hoog affine" immunodominantc CTL die hCl p26A.5 epitoop van Gag herkendell, 
gepaard met het ontstaan van een variant virus met een mUlalie in de sequentie van dit 
epitoop. Opmerkclijk was dat de gemutcerde sequcntie wcrd aangetoond in de milt waar 
het het oorspronkcJijke challenge-virus gehcel had vcrdrongcn, tcrwijl dit Iliet het geval 
bleek in het perirere bloed of in dc lymfeklieren. Hel gelijktijdig aanwezig zjjn van 
virtlsexpressie en CfL expansic in de wille pulpa van de milt doct waarschijnlijk een 
micro-omgeving ontstaan dic immunologische druk in de hand werkt. Het variant virus 
olltsnapt daarap aan de hcrkcnning door de meesle maar niet door aile epitoop-specilickc 
CTL. Inleressant is dal CTL subpopulaties die de varianlscql1cntic konden herkennen, zich 
oak prefcrcntieel in de milt ophieldell. De lagc hoc"eelheid virus die in dit compartiment 
werd waargenomcl1 suggerecrt dat het virus cr cffcclicf onder controle werd gehouden. 
Echter, de speculalie ligt voar de hand dat cen virus-variant die oak maar een gering 
selectievoordcel hceft, het challenge-virus uitcindclijk zou hcbbcn verdrongen, oak buiten 
de milt, en dat dit dynamische proces geleidelijk de cant role van de infcctie zou 
ondcrmijllen. 
Tcnslolte bevat hoordsluk 5 een samenvatling en eell discussie van de experimentcn 
uit dit onderzoek, gcplaatsl legen de achlergrond van soorlgelijke studies dic door anderen 
in zowel mensen als niel-humanc primatcn zijll uitgevoerd. Dit laatste hoofdstuk iIIustreert 
hoe in de argelopen lien jaar makaak-SIV modellcll belangrijke nieuwe informatic hebben 
opgeleverd over de interactic tussen gaslheer en virus gcdurendc het beloop van 
lentivirusi nfectics. 
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